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Abstract 
Bipolar affective disorder has a strong genetic heritability. In the UCL laboratory, a 
locus on chromosome 1p36 was found to be linked to bipolar and related unipolar 
affective disorders with a log of the odds score above 3.00. This region was 
subjected to fine mapping using tests of allelic association in a case-control sample 
as part of this thesis in order to identify the genes involved in bipolar disorder. In 
addition, a GWAS was also employed to fine map other bipolar affective disorder 
susceptibility genes.  
The tests of allelic association found evidence for the involvement of the PRKCZ 
gene. Markers D1S243 and rs3128396 at the PRKCZ gene were significantly 
associated with bipolar disorder with empirical P = 0.037 and P = 0.040, 
respectively. Other loci encoding brain expressed proteins found to be associated in 
the UCL GWAS sample were the genes - GRM3 and GRM7. Therefore, these genes 
were sequenced using PCR-based genomic sequencing. A 3'-UTR base pair change 
(rs56173829) in the GRM7 gene was found to be significantly associated with the 
disorder, although the minor allele was more frequent in controls. 
A base pair mutation (rs148754219) was found in the GRM3 exon 1 two bases 
before the translation start codon (forming part of Kozak sequence) of a GRM3 
receptor isoform. The mutation was associated with bipolar disorder (P = 0.0046, 
odds ratio 4.2 (95% CI 1.42-12.37). Transcription factor binding assays and cloning 
experiments comparing the gene expression activity of wild-type and mutant alleles 
showed that the mutant allele strongly affected the reporter gene activity in SH-
SY5Y and HEK293 cells. If the GRM3 Kozak sequence mutation is confirmed as an 
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important mutation in the aetiology of bipolar disorder, then it could be used as a 
marker for personalised treatment for a genetic subtype of affective disorders.  
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1.1. Bipolar disorder 
1.1.1. Overview 
Bipolar disorder is a mood disorder characterized by impairing episodes of mania 
and depression. Although bipolar disorder has been described as a ‘cyclic’ illness, 
the manic episode is the defining feature of the disorder. A patient is diagnosed with 
bipolar disorder on the basis of having had a manic episode but they may not 
necessarily have had depressive episodes. Also, patients return to their normal state 
of well-being in the intervals between these episodes. Manic episodes are 
characterized by flight of ideas, pressure of speech, increased energy, decreased need 
for sleep, hyperactivity, grandiosity, increased sexual activity and impulsive 
behaviour. Predominantly, the mood of manic episodes is elevated or irritable. 
Psychotic symptoms such as delusions and hallucinations may or may not be present 
in a manic episode. Depressive episodes are characterised by depressed mood, loss 
of interest, decreased sexual interest, accompanied by reduced self-confidence, 
decreased energy and feelings of guilt and worthlessness. Severe forms of both 
mania and depression cause marked impairment in social and occupational 
functioning (WHO 1993; APA 2000). The morbidity and mortality associated with 
bipolar disorder is very high, with one study suggesting 20-fold greater risk for 
suicide compared to the general population (Perlis et al. 2010). 
The personal and societal costs of bipolar disorder are enormous with relapse being 
common in adequately-treated individuals, and the disorder can be profoundly 
disabling resulting in serious economic burden (Kessler et al. 2005). With some 
variability by diagnoses, numerous epidemiological studies on mental disorders 
throughout the world have shown that in each year about one-third of the adult 
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population suffers from a mental disorder (Wittchen et al. 2011). The Global Burden 
of Disease studies have found that disorders of the brain are increasingly 
contributing to the disease burden. A recent analysis estimated that 13% of the global 
disease is due to the disorders of brain, surpassing both cardiovascular diseases and 
cancer (Collins et al. 2011; Wittchen et al. 2011). Every year over 38.2% of the 
European Union population (Wittchen et al. 2011) suffer from mental disorders 
costing the economy €798 billion (Olesen et al. 2012). Recent research has 
highlighted ongoing cognitive difficulties and multiple domains of dysfunction in 
patients suffering from bipolar disorder (Burdick et al. 2007; Gutierrez-Rojas et al. 
2011). Furthermore, the rates of morbidity, mortality and suicide are higher in those 
with bipolar I disorder (BP I), a subtype of bipolar disorder (Yutzy et al. 2012). A 
recent World Mental Health Survey in seventeen countries conducted by World 
Health Organisation (WHO) (Kawakami et al. 2012) reported that early-onset mental 
disorders are associated with a significantly reduced household income in high and 
upper-middle income countries but not in low/lower-middle income countries, with 
associations consistently stronger among women than men. 
1.1.2. History of Bipolar disorder 
The ancient descriptions of the morbid states of depression and exaltation by the 
physicians and the philosophers in the pre-Hippocratic era make mania and 
melancholia two of the earliest described human diseases. Hippocrates (460 - 377 
BC) was the first to systematically formulate the classification of mental disorders 
into melancholia, mania and paranoia (Angst and Marneros 2001). Later, in the first 
or the second Century AD, Areteus of Cappadocia conceived mania and melancholia 
as two different facets of one single disease, thereby, explicitly linking the two states 
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for the first time (Yutzy et al. 2012). During the seventeenth and eighteenth 
centuries, psychiatrists continued to acknowledge the association between mania and 
melancholia but it was the nineteenth century that witnessed the birth of the modern 
concept of bipolar disorder. In 1845, a German psychiatrist, Wilhelm Griesinger, 
described the relation of mania and melancholy using the image of a circle although 
it was Falret, in 1854, who finally drew the conclusion that bipolar disorder was an 
entity on its own based on his long-term observations of patients. He defined the 
sequential change from mania to melancholia and the interval in between as an 
independent disease on its own, namely the 'folie circulaire' (Angst and Marneros 
2001). The foundation of psychiatric nosology and scientific psychiatry has its roots 
in the publications of Emil Kraeplin in 1899 that characterised psychoses into 
dementia praecox and manic-depressive insanity (Zivanovic and Nedic 2012). In 
1957, Leonhard coined the term 'bipolar' for the patients with depression who also 
experienced mania. Hypomania is another term used quite often to discriminate 
between BP I and bipolar II (BP II) disorder based on DSM-IV classification (APA 
1980). Accordingly, people with hypomania (BP II) have fewer and less severe 
symptoms that usually do not require hospitalization than those with mania (BP I). 
Erich Mendel described, conceptualized and coined the term 'hypomania' in 1881, 
although Dunner (1976) is credited for the creation of BP II category (Angst and 
Marneros 2001). 
A gradual refinement of the terminology has occurred during the development of the 
concept of bipolar disorder moving from a traditional and broader concept of mania 
and melancholia to a more modern concept of circular disease. In recent years, the 
concept has broadened to include schizoaffective bipolar disorder type, mixed states, 
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bipolar spectrum etc. to encompass the complexity of degree of severity and a 
combination of symptoms. 
1.1.3. Epidemiology of Bipolar disorder 
Epidemiology is the study of the distribution of diseases in human populations and 
the variation of these distributions among different population subgroups. Prevalence 
is an epidemiological measure of the proportion of individuals that have a disorder at 
a specified time or during a specified period. The early family studies conducted 
from 1929 to 1954 did not distinguish between major depression and bipolar 
disorder due to the use of the term ‘manic depression’ encompassing both the 
disorders. The prevalence estimate of manic depression from these early studies was 
14.6% among parents of probands and 10.9% among siblings of probands compared 
to the general population estimate of 0.7% (Smoller and Finn 2003). 
Lifetime prevalence is the proportion of those in the population who had a disorder 
at some time in their life up to their age at the time of interview. A lifetime 
prevalence of 0.8% and 1.6% for manic episodes was reported in the 
Epidemiological Catchment Study (ECA) and the National Comorbidity Study 
(NCS) respectively (Regier et al. 1990; Kessler et al. 1994). A cross-national 
epidemiology study involving BP I patients from 10 countries, including United 
States, Canada, Puerto Rico, France, West Germany, Italy, Lebanon, Taiwan, Korea 
and New Zealand, reported lifetime prevalence rates ranging from 0.3% to 1.5% 
(Weissman et al.1996). European studies have reported lifetime prevalence rates for 
bipolar disorder ranging from 0.2% to 1.1% (Wittchen et al. 2011). A few studies 
report the wider range of bipolar spectrum disorders as having prevalence rates of 
5.1% and 6% (Pini et al. 2005). Recent US and international studies have reported 
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the lifetime prevalence of bipolar I disorder ranging from 0.4% and 1.3% (Yutzy et 
al. 2012). Another review of the literature on the robust and replicable genetic 
findings reported in the last decade through genome-wide association studies 
(GWAS) and structural variation studies predicted the lifetime prevalence of bipolar 
disorder as 0.7% and the heritability as being 75% (Sullivan et al. 2012). 
Even though BP II has neither been a subject of large-scale studies internationally 
nor is listed in the International Classification of Diseases (ICD)-9 or ICD-10 
classification (WHO 1967; WHO 1993), a lifetime prevalence of 0.5% was reported 
for this disorder in the ECA study (Regier et al. 1990) and the Diagnostic and 
Statistical Manual of Mental Disorders (DSM) series (APA 1994; APA 2000). In a 
recent review, Merikangas and Lamers reported results from studies in adults across 
11 countries as part of the World Mental Health Survey showing that lifetime 
prevalence rate of BP II was 0.4% and is also substantially greater in adolescents 
with rates approaching 3-4% (Merikangas and Lamers 2012). 
Previous studies have also reported raised incidence of bipolar affective disorder 
(BPAD) and mania in African American, Asian Indian and many other immigrant 
groups (Leff et al. 1976; Lloyd et al. 2005). 
Age at onset 
Early-onset bipolar disorder has been associated with severe clinical symptoms, a 
stronger family history of affective disorder and poor clinical outcome. Previous 
studies on bipolar disorder have estimated the average age of onset between early-to-
mid 20s to early 30s (Kupfer et al. 2002). Baldessarini et al. (2010) reported the 
estimated age of onset in a pooled sample of 1566 DSM type I or II bipolar disorder 
from six international sites. The mean age of onset (±IQR) across all the sites and 
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bipolar disorder subtypes was 25.2 ± 15.1 years. However, the median onset was 
nearly six years younger among BP I patients than BP II patients. Additionally, there 
was little (<3 years) difference in age of onset between men and women with men 
tending to be somewhat younger at onset among BP I cases with psychotic or mixed 
initial episodes (Baldessarini et al. 2010). Juvenile-onset (≤ 20 years) and childhood-
onset (<13 years) bipolar disorder were more common in European samples than US 
samples (juvenile: 26.7% vs 15.9%; child: 3.33% vs 0%) (Baldessarini et al. 2010). 
A significant association between the age of onset of bipolar disorder in probands 
and an increased risk of bipolar disorder in family members has been reported in 
several studies (Althoff et al. 2005). Comorbid depression (Post et al. 2010) and 
mania/hypomania (Bauer et al. 2010) have also been observed to occur in excess 
with early-onset bipolar disorder. Recently, an overall median age of onset of 24.0 
years was reported in a study of 1665 BP I disorder patients from seven international 
centres along with an early age of onset being associated with the least favourable 
clinical outcomes and a greater familial risk (Baldessarini et al. 2012). 
Gender 
Existence of epidemiological and clinical differences between genders amongst 
patients with bipolar disorder has long been debated. Although compelling evidence 
from previous studies suggests that there is no major gender distinction in the 
lifetime prevalence of bipolar disorder, there are few studies that report higher 
prevalence rates in men (Diflorio and Jones 2010). According to the National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC), men were 
twice as likely as women to have a history of unipolar mania amongst individuals 
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with BP I (Grant et al. 2005). However, a higher prevalence of BP II and hypomania 
in women has been reported in some but not all studies (Diflorio and Jones 2010). 
Another controversial topic is the sex distribution of bipolar patients with rapid 
cycling. Two meta-analyses conducted between the years 1977 and 2002 reported 
that women with bipolar disorder showed greater rates of rapid cycling than men 
(Tondo and Baldessarini 1998; Kupka et al. 2003) whereas a recent prospective 
study reported an almost equal one year prevalence of rapid cycling in both the sexes 
(Schneck et al. 2008). 
According to the earlier studies of bipolar disorder in the US (Viguera et al. 2001) 
and Europe (Raymont et al. 2003), women reportedly have later age at onset 
compared to men. In a study based in Camberwell, England (Kennedy et al. 2005), a 
strong association between gender and age at onset of first-episode mania and 
bipolar disorder was observed with men having a mean age at onset of 5.1 years and 
4.4 years respectively earlier than women. In a childhood-onset bipolar sample, male 
gender was overrepresented in the group with an onset before 12 years (Biederman 
et al. 2004). In the NESARC study, men were reported to have a younger age of 
onset of manic and mixed but not depressive episodes in the BP I sample (Grant et 
al. 2005). Some studies have also indicated that women show a predominance of 
depressive polarity (Nivoli et al. 2010). Pregnancy and childbirth are considered to 
be predisposing factors to bipolar disorder. Women are suggested to have more than 
two-fold risk for bipolar disorder after childbirth (Altman et al. 2006). There is also 
consistent evidence of a gender effect for substance use disorders in bipolar patients 
with alcohol being more of a problem in men and eating disorders and Post 
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Traumatic Stress Disorder (PTSD) being more common in women (Diflorio and 
Jones 2010). 
1.1.4. Diagnosis of Bipolar disorder 
The two main modern systems of classification for the diagnosis of mental disorders 
are the DSM series published by the American Psychiatric Association (APA) and 
the ICD manual published by the WHO. The introduction of DSM-III in 1980 (APA 
1980) initiated the conceptualization of mania and the associated disorders along 
with the development of a valid and reliable criteria. In 1972, Feighner and 
colleagues (Feighner et al. 1972) at the Washington University identified a set of 
criteria for mania that later formed the basis of the Research Diagnostic Criteria 
(RDC) (Spitzer et al. 1975; Spitzer et al. 1978) and DSM-III. No substantive changes 
have been added to the subsequent iterations of the DSM series (DSM-III-R, DSM-
IV, DSM-IV-R) (Singerman 1981; APA 1987; APA 1994; APA 2000). DSM-IV 
classifies bipolar disorder into BP I and BP II whereas there is no such distinction in 
the ICD-10 classification. According to DSM-IV, at least one manic episode is 
required for the diagnosis of BP I disorder whereas at least one hypomanic episode 
and at least one major depressive episode are required for BP II diagnosis. The 
duration of a manic episode needs to be at least one week for a bipolar disorder 
diagnosis, while depressive episodes should last at least two weeks. Hypomania is a 
less severe form of mania where the patients are generally euphoric and very 
cheerful with an ‘infectious’ mood (APA 1980). For an ICD-10 diagnosis of bipolar 
disorder, a manic episode along with another mood disturbance should be 
experienced by the individual (WHO 1993). Patients with bipolar disorder may 
present with either a depressive or a manic episode but due to mania being the 
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important criteria for bipolar diagnosis, 40% of the patients are diagnosed initially 
with unipolar depression instead. Each episode may last from one week to several 
months varying across different patients. Also, a bipolar patient may suffer from 
many depressive episodes before having the first episode of mania (Akiskal 2005). 
While, the frequency of depressive episodes is usually higher than manic episodes, 
the course of illness is variable among individuals. A seasonal pattern has also been 
reported by some researchers with manic episodes more likely in the spring or early 
summer and depressive ones in the autumn or winter (APA 2000). 
Other variants of bipolar disorder such as cyclothymia, mixed episodes, rapid 
cycling, schizoaffective disorder and seasonal affective disorder are specified as 
Bipolar disorder not otherwise specified (BP-NOS). Cyclothymia is a chronic 
condition in which the patient experiences short periods of mild depression and 
hypomania lasting anywhere between a few days to a few weeks again separated by 
short periods of normal mood. Mixed episodes are conditions when a patient 
experiences both manic and depressive episodes nearly every day over at least one 
week. Additionally, psychotic features may be present during mixed episodes (APA 
1980). Schizoaffective disorder is a controversial subtype, which shows 
characteristics of both schizophrenia and bipolar disorder. In other words, it is a 
schizophrenia-bipolar boundary disorder. Rapid cycling is another condition in 
which the patient has at least four distinct episodes of mood disturbances in a single 
year separated by periods of remission. These individuals are usually resistant to 
many available treatments such as lithium therapy, and are thereby, clinically 
challenging to treat. 
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1.1.5. Treatment of Bipolar disorder 
The treatment of bipolar disorder is considered on the basis of the course of the 
illness, i.e., specific for manic/hypomanic, mixed or depressive episodes 
(Fountoulakis and Vieta 2008). Mood stabilizers are the most important 
pharmacological treatments that ameliorate manic symptoms and also sometimes 
those of depression (lithium and lamotrigine) (Fountoulakis and Vieta 2008; Malhi et 
al. 2009a; Malhi et al. 2009b). Medications developed for other indications, such as 
anticonvulsants for epilepsy and antipsychotics for schizophrenia, have also been 
approved for use in bipolar disorder. Although lithium was first used as a successful 
treatment for bipolar disorder in 1947 (Cade 1949), it gained the US Food and Drug 
Administration approval only in 1970. Lithium has many effects in the brain. 
According to one interesting theory among several, lithium has been proposed to 
have a robust neuroprotective and neurotropic action leading to the upregulation of 
synaptic plasticity. A recent study found that a 4-week administration of lithium 
magnified the long-term potentiation of CA1 pyramidal cells thus upregulating the 
synaptic plasticity in the hippocampus (Shim et al. 2012). Reports also suggest that 
lithium decreases suicide risk (Muller-Oerlinghausen and Lewitzka 2010). 
Unfortunately, lithium has a narrow therapeutic index and lithium toxicity can be 
fatal in some occasions. Some other common mood stabilizers used in clinical 
practice are valproate, carbamazepine, gabapentine and lamotrigine. 
It is well established that bipolar depression causes greater psychosocial impairment 
and disability in bipolar patients, who spend much more time being depressed than 
being manic (Fountoulakis et al. 2012). Almost every guideline on the treatment of 
bipolar depression reviewed by Fountoulakis et al. (2005) in 2005 suggested the use 
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of antidepressants only in combination with an antimanic agent to avoid manic 
switches. A number of antidepressants are in current use, including tricyclic 
antidepressants, Selective Serotonin Reuptake Inhibitors (SSRI), Monoamine 
Oxidase Inhibitors (MAOI), Noradrenaline Reuptake Inhibitors (NARI), Serotonin-
Noradrenaline Reuptake Inhibitors (SNRI) and atypical antidepressants (Palucha and 
Pilc 2007). Among atypical antipsychotics, quetiapine, olanzapine and fluoxetine are 
routinely used in monotherapy or in combination for the management of bipolar 
depression. In a recent review, the CANMAT (Canadian Network for Mood and 
Anxiety Treatments), ISBD (International Society for Bipolar Disorders) and the 
WFSBP (World Federation of Societies of Biological Psychiatry) guidelines 
generally suggest lithium, lamotrigine or quetiapine monotherapy as the first-line 
choice. These guidelines also recommend the use of antidepressant agents in 
combination with antimanic agents such as lithium and valproate, as well as the use 
of Olanzapine-Fluoxetine Combination (OFC). The NICE (National Institute for 
Health and Clinical Excellence) guidelines also suggest a similar treatment strategy 
and in the presence of psychotic symptoms recommend adding an antipsychotic drug 
such as olanzapine, quetiapine or risperidone to the combination of antidepressant 
and antimanic agents (Nivoli et al. 2011). 
Maintenance therapy in bipolar disorder is prophylactic, primarily to prevent 
relapses and improve residual symptoms. Atypical antipsychotics have been proven 
to be effective in maintenance treatment in addition to being effective against mania 
and bipolar depression. A placebo-controlled trial suggested that lamotrigine 
stabilized mood, which is useful in depressive-relapse prevention (Calabrese et al. 
2003). Mood stabilisers namely, valproate, carbamazepine and lithium are widely 
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used due to their prophylactic effect. Electroconvulsive therapy (ECT) is an 
alternative treatment used for severely affected patients who fail to respond to 
pharmacotherapy. However, ECT is not routinely used lately. 
In summary, treatment of bipolar disorder was very much improved when lithium 
was first introduced over 60 years ago. Lithium is only effective in a minority of 
cases. Mood stabilizers, antidepressants in combination with anti-manic agents, and 
antipsychotics are all currently used in the treatment of bipolar disorder. 
Monotherapy with antidepressants is contraindicated in mixed states, manic episodes 
and BP I. There is an urgent need for the development of novel drugs targeting 
bipolar disorder with greater efficacy, faster onset of action and with less 
burdensome adverse-effect profiles. 
1.1.6. Pathophysiology of Bipolar disorder 
Little is known about the specific pathophysiology of bipolar disorder. This limited 
understanding has prevented development of new treatments. Monoaminergic 
systems including serotonergic, noradrenergic and dopaminergic systems in the brain 
have been the most investigated in neurobiological studies of mood disorders making 
them valuable targets for the therapeutics. 
Brain imaging studies (Savitz and Drevets 2012), transgenic mouse models (Lesch 
and Mossner 2006), genetic studies (Serretti and Mandelli 2008; Craddock and Sklar 
2009) and gene expression studies (Elashoff et al. 2007) have all suggested that the 
monoaminergic and serotonergic systems are implicated in the pathophysiology of 
bipolar disorder. Studies investigating the effects of dopamine and serotonin 
antagonists on their respective neurotransmitter systems have also led to the 
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proposition that these systems are involved in the aetiology of bipolar disorder. 
Antipsychotics block dopamine D2 receptors and it is thought that some of the 
psychotic experiences in bipolar disorder are mediated through dopamine pathways 
(Brugue and Vieta 2007). Altered glutamate levels in the plasma, serum and 
cerebrospinal fluid (CSF) of individuals with bipolar disorder have also been well 
documented (Sanacora et al. 2008). Similarly, postmortem studies have also shown 
increased glutamate levels in diverse brain areas in individuals with mood disorders 
(Hashimoto et al. 2007). A recent study demonstrated altered expression of 
glutamate and dopamine transporters in postmortem frontal cortex from bipolar 
disorder patients (Rao et al. 2012). Elevated brain glutamate/glutamine ratio and 
reduced levels of N-methyl-D-aspartate (NMDA) receptor subunits have been 
reported in postmortem brains from bipolar disorder patients (Hashimoto et al. 2007; 
Rao et al. 2012). Inconsistent results have been documented regarding the levels of 
the Serotonin Reuptake Transporter (SERT) in the prefrontal cortex of bipolar 
disorder patients (Dean et al. 2001; Sun et al. 2001). Other neurotransmitter systems 
such as the γ-aminobutyric acid (GABA)-ergic (Fatemi et al. 2011; Luscher et al. 
2011) and cholinergic systems (Machado-Vieira and Zarate 2011) may also be 
involved in the pathophysiology of bipolar disorder. 
Atrophic changes in the brains of bipolar disorder patients have been reported since 
1983 when Reider et al. (1983) first found a correlation between age and ventricle-
to-brain ratios in a group of bipolar disorder patients. A recent meta-analysis found 
an inverse correlation between illness duration and total cerebral volume (Hallahan 
et al. 2011). The same study found increased hippocampal and amygdala volume in 
lithium treated bipolar disorder patients compared to lithium untreated patients and 
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normal subjects. Structural and functional imaging (fMRI) evidence and behavioural 
and cognitive deficits associated with bipolar disorder have implicated specific 
regions of the brain in the pathophysiology of the disorder. The ventral prefrontal 
cortex and the anterior cingulate cortex are the two regions with the most significant 
evidence for the involvement in bipolar disorder, although other regions have also 
been reported. Decreases in prefrontal and cingulate volume have been detected in 
studies involving youths with bipolar disorder (Schneider et al. 2012; Selvaraj et al. 
2012). The rostral and lateral orbiotofrontal cortex subregions have reduced 
activation during manic episodes with a change in activation during depressed 
episodes (Jackowski et al. 2012). In studies involving twins discordant for bipolar 
disorder, volumetric abnormalities in the white matter of unaffected siblings was 
reported that included decreased left hemispheric white matter volume (Noga et al. 
2001; van der Schot et al. 2009). These findings suggest that reduced white matter 
connectivity may represent an endophenotype for bipolar illness. Functional 
abnormalities displayed during performance of cognitive and emotional tasks across 
multiple cognitive domains, including emotional processing, working memory, 
inhibition control and reward processing have been reported in several studies 
(Schneider et al. 2012).  
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, the primary 
hormonal stress response pathway, has been reported in individuals with bipolar 
disorder (Sinclair et al. 2012a, b). Additionally, disruptions in biological rhythms 
including sleep disturbances, social rhythms and life events have long been 
associated with bipolar disorder. Finally, neuroplastic changes at the functional, 
structural and cellular levels contribute to the dysregulation of key circuits in bipolar 
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disorder. These changes include impairments in neurotrophic and neuroprotective 
signaling cascades, altered glutamatergic, serotonergic, dopaminergic, cholinergic 
and glucocorticoid signaling along with changes in the rate of adult neurogenesis. 
1.1.7. Heritability of Bipolar disorder 
A strong genetic basis for psychosis has been apparent for more than five decades, 
with the mention of the hereditary factor in Kraepelin's observations involving 
patients and their families. Substantial evidence from a range of genetic methods has 
confirmed the high heritability of bipolar disorder with genetic factors explaining 
60%-85% variance in risk (Smoller and Finn 2003). Although both genetic and 
environmental factors contribute to the aetiology of the disease, the family, twin and 
adoption studies have shown that there is increased risk of bipolar disorder among 
relatives of bipolar probands compared to normal controls. The observed familial 
risk and the inheritance pattern of psychiatric disorders is consistent with the 
multiple variants with modest effects or intermediate penetrance that cause the 
disease phenotype in an additive and/or multiplicative way (Craddock et al. 2007). 
1.1.7.1. Family studies  
In a family study, a systematic evaluation of families where illness is known to affect 
one member provides a relatively straightforward means of testing the hypothesis of 
genetic transmission. An impressive number of family studies on bipolar disorder 
indicate that the disease aggregates in families. Smoller and Finn (2003) reported 
that first-degree relatives (parents, siblings and offsprings) of bipolar disorder 
patients have approximately a 10-fold increased risk of the disorder compared to the 
unaffected controls. Another study reported that about 15%-20% of the first-degree 
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relatives of bipolar probands are at an increased risk of bipolar or unipolar disorder, 
with the preponderance of unipolar, compared to unaffected controls (Barnett and 
Smoller 2009). Additionally, the risk of a same-sex sibling developing a mood 
disorder is greater than for a sibling of the opposite sex (Tsuang MT 1990). Unipolar 
depression is the most common affective disorder in the families of bipolar probands 
whereas the first-degree relatives of unipolar patients have increased morbidity risk 
for bipolar disorder compared to the general population, suggesting that the overlap 
of risk across these phenotypic categories indicates the shared genetic susceptibility 
(Gershon et al. 1982; Barnett and Smoller 2009). While it has been estimated that 
second-degree relatives have a slightly greater risk for mood disorders than the 
general population (Targum 1988), some studies have suggested that the risk to 
second-degree relatives is similar to that of general population for unipolar illness 
(Gershon et al. 1982; Tsuang MT 1990). However, these studies used telephone 
interviews by students. An increased risk of bipolar related psychiatric disorders 
including unipolar depression and schizoaffective illness is found to be common in 
relatives of bipolar probands. Also, the risk of schizophrenia is sometimes higher in 
relatives of bipolar probands. The heritability of the occurrence of psychosis within 
families multiply affected by bipolar disorder has been reported in some family 
studies (Craddock and Sklar 2009). Greater family history with early onset of bipolar 
disorder is well known, suggesting that early-onset cases are genetically more 
homogeneous (Baldessarini et al. 2012). Thus, gene-environment interactions, as 
evident from the family and twin studies of bipolar and unipolar disorder, play an 
important role in the presentation of varied clinical features of the disorder. 
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1.1.7.2. Twin and adoption studies 
The genetic and environmental contributions to a disorder can be estimated using a 
population of twins by comparing the concordance rate among monozygotic (MZ) or 
dizygotic (DZ) twins. Twins usually share a common environment while sharing 
either all of their genes (identical or MZ) or half of their genes on average (DZ). The 
concordance rate for bipolar disorder is significantly higher among MZ twin pairs 
than among DZ twin pairs (Shih et al. 2004). Assuming that the shared 
environmental influences on MZ twins are not different from the environmental 
influences of DZ twins, significantly higher concordance rates in MZ twins reflect 
the action of genes. Also, the high rate of concordance appears to hold true even if 
the twins are reared apart (Price 1968). In a comprehensive review of twin studies 
published before 1990, Tsuang and Faraone (Tsuang MT 1990) reported a proband-
wise concordance rate of 78% for MZ twins and 29% for DZ twins. The heritability 
of bipolar disorder in a hospital register study of 67 twin pairs in the UK (McGuffin 
et al. 2003) and in a population register study of 19,124 same-sex twin pairs in 
Finland (Kieseppa et al. 2004) was reported to be 89% and 93% respectively. The 
proband-wise concordance rate estimated for bipolar disorder in the two studies was 
67% and 43% for MZ twins and 19% and 6% for DZ twins respectively (McGuffin 
et al. 2003; Kieseppa et al. 2004). However, a Danish study reported equal rate of 
bipolar disorder in twins and singletons (Klaning et al. 2004). A Norwegian study 
investigated the heritability of three different bipolar spectrum disorders – BP I, BP 
II, cyclothymia and different combination of these disorders in 303 same-sex twin 
pairs (Edvardsen et al. 2008). On analysis, the concordance rates were higher among 
MZ than DZ twins for all single diagnoses and main combinations of the diagnoses. 
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Additionally, the largest difference in concordance rate between MZ and DZ pairs 
was observed when the frequency of BP I or BP II among the co-twins of BP I 
probands was compared, with 50% of the MZ co-twins of BP I probands having 
either BP I or BP II while none of the DZ co-twins received this diagnosis 
(Edvardsen et al. 2008). For more accurate results, the concordance can be corrected 
for the age of onset and age at interview of the twins, however, this is rarely done. 
Interestingly, the concordance rate of bipolar disorder in MZ twins is not 100%, 
thereby implying that genes alone cannot explain bipolar disorder, but environmental 
factors also contribute to the disorder. Adoption studies of bipolar disorder have 
been carried out and suggest genetic transmission (Smoller and Finn 2003). 
1.2. Molecular genetic studies of Bipolar 
disorder 
The identification of genes or the variation of a quantitative trait that contribute to 
the risk of a disease has long been one of the goals of human and medical genetics. 
The aetiology of bipolar disorder is complex, probably involving multiple genes and 
environmental factors. The molecular genetic studies of bipolar disorder will be 
discussed in four different stages: linkage studies, association studies, GWAS and 
copy number variation (CNV) studies. Traditionally, both family linkage and allelic 
association methods have been used to narrow the location of such genes to small 
regions of the genome with the hope that the gene and eventually the causal variant 
may be identified and characterized. Before the era of GWAS, molecular genetic 
studies can be theoretically divided into positional and candidate gene approaches. In 
the positional approach, the chromosomal positions of the susceptibility genes are 
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determined using linkage studies that require no prior knowledge of disease 
pathophysiology. In contrast, the candidate gene approach utilizes linkage and 
association studies to recognise the genes involved in the disease based on the 
assumption that there is sufficient understanding of the disease biology required for 
shortlisting the genes to be investigated (Craddock and Jones 1999). Recently, the 
study of common variations (GWAS) and structural variations (CNVs) across the 
whole of human genome has become possible due to advances in technology and 
reduction in genotyping costs. Before discussing the findings from the genetic 
studies in bipolar disorder, understanding the components contributing to the 
complexity of the disorder is very crucial. Even though several studies have been 
carried out on bipolar disorder with some success, the inconsistency of the findings 
among all these studies can be attributed to locus heterogeneity, inadequate sample 
sizes and phenotypic heterogeneity (Schulze and McMahon 2003).  
1.2.1 Factors affecting genetic studies 
Locus heterogeneity 
Locus heterogeneity describes a state when the same phenotype is caused by 
mutations at more than one gene locus. Allelic heterogeneity is a phenomenon when 
more than one allele at a specific gene locus results in the same phenotype (Pericak-
Vance 2006). While linkage analysis is immune to allelic heterogeneity, locus 
heterogeneity reduces the power of linkage and association analysis in detecting 
disease variants. Ascertaining study samples from genetically isolated populations 
could help deal with locus heterogeneity to some extent by reducing the number of 
different susceptibility genes. 
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Choice of statistical methods for linkage analysis 
The lack of understanding of the mode of inheritance is a major hindrance in 
deciding the statistical approach to be used for the linkage data analysis, either 
parametric or non-parametric methods. It can be assumed on the basis of locus 
heterogeneity that the likelihood of the detection of a genetic locus will be 
maximised if multiply affected pedigrees that contain large numbers of cases rather 
than affected sib-pairs (ASP) is considered for linkage analysis. The lack of 
knowledge of allele frequency, the penetrance rate and the mode of inheritance of the 
bipolar disorder points in the direction of using non-parametric linkage method 
whereas much greater power is achieved using large multiply affected families and 
parametric analysis compared to sib-pairs (Alaerts and Del-Favero 2009). 
Sample size 
Another major problem in linkage and association studies of complex disorders such 
as bipolar disorder is the sample size. Several meta-analyses of worldwide genome -
wide scans have been performed in the last decade resulting in the detection of weak 
but inconsistent linkage signals across studies (Craddock and Sklar 2009). Suarez et 
al. (1994) found that for an oligogenic trait simulated under reasonable parameters, 
when sampling families sequentially, the first true linkage to be detected will not 
likely be replicated until many further samples have been studied. In conclusion, the 
power to replicate the first linkage is present only when many samples several times 
larger than the initial sample have been collected and studied (Badner and Gershon 
2002). 
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Phenotypic heterogeneity 
The lack of specific biological markers in bipolar disorder can result in variation in 
the validity of the diagnosis. A clear phenotype best capturing the underlying 
mechanism of bipolar disorder is yet to be defined. Accurate and reliable 
identification of the affected phenotype for BP I is as high as any medical disease but 
BP II disorder is a less valid and reliable diagnosis (Craddock and Jones 1999). 
Different diagnostic categories such as 'narrow’ and 'broad' phenotype, bipolar 
disorder spectrum, referring to different phenotypes have been previously used in 
linkage studies. The endophenotypes of psychiatric comorbidity and treatment 
response have also been used in linkage studies of bipolar disorder to reduce 
phenotypic heterogeneity (Turecki et al. 2001; Gottesman and Gould 2003). These 
approaches have not been successful and suggest that the bipolar spectrum 
phenotype for genetic analysis needs to be as broad as possible. 
Anticipation 
Several studies have shown that early-onset bipolar disorder is characterized by an 
increased number of psychotic symptoms and manic episodes, higher level of 
comorbidity with drug addiction and poor clinical outcomes (Craddock and Sklar 
2009). One explanation might be a phenomenon called anticipation whereby a 
disease becomes more severe and/or presents itself with an earlier onset as it is 
transmitted through the generations of a family. Anticipation is known to involve 
either methylation effects on susceptibility genes or the expansion of segments of the 
genome consisting of trinucleotide repeats and one might assume that this explains 
the utilization of large trinucleotide repeats in early linkage studies in bipolar 
disorder probands. Clinical evidence for anticipation in BPAD has been reported 
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previously but more studies are required to confirm and elucidate its underlying 
mechanism (McInnis et al. 1993). 
1.2.2. Genetic markers 
The genome among humans is approximately 99.5% identical and the 0.1-0.5% 
difference between individuals is caused by several types of sequence variations and 
polymorphisms (Levy et al. 2007). Polymorphic genetic markers are a critical 
component of a disease gene mapping study. Short tandem repeats (STRs) or 
microsatellites, initially described by Weber and May (Weber and May 1989) and 
Litt and Luty (Litt and Luty 1989), have traditionally been the most utilized markers 
for linkage studies (Pericak-Vance 2006). Microsatellites are short di-, tri- or 
tetranucleotide tandem repeat sequences widely distributed in the genome and are 
highly polymorphic among individuals. Single nucleotide polymorphisms (SNPs) are 
bi-allelic markers that are densely spread throughout the human genome occurring 
approximately once every 1000 bp (Pericak-Vance 2006). SNPs have been widely 
used for fine mapping of positional and functional candidate genes. Recently, sets of 
hundreds of thousands of SNPs on a single array chip have been used for GWAS for 
screening of the whole human genome. 
1.2.3. Methods of linkage analysis 
Linkage analysis refers to a group of statistical methods that are used to map a gene 
to the region of the chromosome in which it is located. Genetic linkage is a violation 
of Mendel's law of independent assortment according to which the alleles at two 
chromosomal locations assort independently and are transmitted to offsprings in 
random combinations. Linkage analysis in humans is more difficult than in 
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experimental organisms such as Drosophila because of the limitations in family size, 
inability to do test crosses, long generation time and the lack of knowledge of phase 
in parents who are heterozygous at both loci being studied. Linkage studies have 
previously been successful in the identification of genes that cause Mendelian 
disorders such as cystic fibrosis (CFTR) and Huntington disease (HTT) (Bailey-
Wilson and Wilson 2011). In addition, linkage studies of families with strong 
aggregation of specific complex diseases have also led to the identification of rare, 
high-penetrance risk alleles in certain genes that cause large increases in 
susceptibility to complex diseases, for example the BRCA1 and BRCA2 genes and 
breast cancer (Bailey-Wilson and Wilson 2011). Complex genetic disorders such as 
the psychiatric illnesses are characterised by disease heterogeneity with an unknown 
mode of transmission. Epistatic interactions between genes and among their gene 
products as well as their interactions with environmental risk factors are also 
considered to be a plausible explanation for the complexity (Bondy 2011). 
Genetic recombination is an important process associated with all forms of linkage 
analysis. During meiosis, a free exchange of genetic material occurs between 
homologous chromosomes in an equal and reciprocal fashion resulting in the 
formation of recombinants that are chimeras of maternal and paternal genetic 
material. Linkage is the tendency of two or more genetic loci to be transmitted 
together during meiosis because they are physically close together on a chromosome. 
The strength of genetic linkage is measured by the recombination fraction denoted 
by θ, the proportion of recombinants among all potential haplotypes produced by a 
parent. When the genetic loci are completely linked, no recombination occurs and 
the recombination fraction θ = 0. On the other hand, genes segregating independently 
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appear genetically unlinked θ = 1/2 (Pericak-Vance 2006). Linkage analysis was 
developed to detect excess co-segregation of the putative alleles underlying a 
phenotype with the alleles at a marker locus in family data. Linkage studies are 
feasible with much less dense sets of genetic markers compared to the current 
GWAS and also these methods have the power to detect co-segregation over a much 
larger genetic distance (e.g. 40 million bases of DNA). Linkage methods are 
particularly powerful for the detection of variants with a large effect size, which are 
rare in the population. Power to detect such loci using linkage methods can be 
enhanced by ascertaining families with aggregation of the trait of interest (loaded 
families). Interest in these methods is undergoing a renaissance due to the 
availability of next generation sequencing and its promise to allow identification of 
the rare variants underlying linkage signals (Bailey-Wilson and Wilson 2011).  
Morton (1955) coined the term LOD score and put forward the use of sequential test 
procedures in linkage analysis recognizing that the typical method of sampling small 
families was in fact sequential. The parametric LOD score method was originally 
designed for Mendelian disorders and is considered less suitable for complex 
disorders (Bailey-Wilson and Wilson 2011). 
The family pedigree method or the LOD score linkage analysis involves the 
comparison of likelihoods for specific genetic linkage hypotheses. First, the 
likelihood of observing a specific pattern of markers in a pedigree is calculated 
assuming the null hypothesis of no genetic linkage to be true. Next, the likelihoods 
of observing the pattern of disease and marker alleles for each of several alternative 
hypotheses of linkage are calculated and compared with the likelihood of the null 
hypothesis by means of an 'odds ratio' (Bailey-Wilson and Wilson 2011). The odds 
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ratio is the likelihood of an alternative hypothesis divided by the likelihood of the 
null hypothesis. The alternative hypotheses of linkage are specified by different 
values of the recombination fraction: (1) linkage is so close that no recombinations 
have occurred, θ = 0; (2) linkage is tight, but one-recombination event has occurred 
in 100 meioses (θ = 0.01); (3) linkage is quite close, but relatively more 
recombinations have occurred (θ = 0.05) and so on for increments of θ = 0.05 until 
0.45. The null hypothesis specifies that θ = 0.50 (Schulze and McMahon 2003). A 
LOD score, the base 10 logarithm of the odds ratio, greater than 3.0 is taken as 
evidence of linkage (Lachman 1994). 
Lander and Kruglyak (1994) reported the results of a simulation analysis of a fully 
informative map of markers suggesting LOD scores for significant and suggestive 
linkage. According to them, the LOD score of 3.3 was required to achieve a true 
genome-wide significance in terms of linkage and a LOD of 1.9 to be suggestive 
evidence for linkage. The significant and suggestive LOD scores for ASP model 
were recommended to be 3.6 and 2.2 respectively. However, some researchers have 
criticized these thresholds as overly conservative (Schulze and McMahon 2003). 
Non-parametric linkage analysis is based on the comparison of observed vs. 
expected sharing of the same alleles, known as identity by descent (IBD), between 
pairs of affected relatives. The ASP method is a widely used non-parametric linkage 
analysis method. The sib-pair method would be the least powerful method for 
psychiatric disorders where there is locus heterogeneity. Initially in the sib-pair 
method, individual genetic markers were studied one at a time, thus failing to use the 
full inheritance information provided by multipoint linkage analysis. Later, Lander 
and Kruglyak (Kruglyak and Lander 1995) described methods for complete 
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multipoint analysis to be used for sib-pair analysis methods. However, a major 
weakness of sib-pair analyses is that they do not allow the estimation of the 
recombination fraction and cannot estimate what proportion of families are linked to 
a specific locus assuming heterogeneity (Schulze and McMahon 2003). 
1.2.4. Linkage findings in Bipolar disorder 
Since the 1990's, linkage analysis has been utilized in vast majority of endeavours to 
discover the genetic loci predisposing to mental disorders. The strategy involves 
employing genetic markers and testing for linkage among families with multiple 
affected members. 
Baron et al. (1993) and Egeland et al. (1988) conducted two of the earliest linkage 
studies of bipolar disorder in Israeli and Old Order Amish pedigrees and implicated 
chromosomal regions on X and 11q respectively. Following its identification, the 
Xq28 locus became the focus of several linkage studies with several studies often 
supporting linkage in bipolar disorder at this region (Mendlewicz et al. 1987; Lucotte 
et al. 1992; Berrettini 1998; Massat et al. 2002). Early age at onset, a higher ratio of 
bipolar illness to unipolar illness and a more recurrent and severe form of unipolar 
illness were found in the earlier linkage study of X-linked families (Baron et al. 
1990). Following on the X-linkage of bipolar disorder, a genome scan of a large 
Finnish family with bipolar disorder indicated evidence for linkage at Xq24-q27.1 
with the highest LOD score for the marker DXS994 (Pekkarinen et al. 1995). 
Additionally, this locus was then followed up with increased marker density in the 
large family and 40 additional families reporting evidence of linkage in only a 
fraction of the families (Ekholm et al. 2002). Stine et al. (1997) carried out a genome 
scan using markers on selected chromosomes in 97 families from the NIMH 
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Genetics Initiative Bipolar Group and found evidence supporting linkage at Xq26-
28. 
It was evident right from the beginning that replication of findings in complex 
disorders was a major challenge. Since then numerous genome-wide scans of bipolar 
disorder have been carried out in different ethnic populations and to date, loci 
showing linkage have been found on every single chromosome (Serretti and 
Mandelli 2008). Previously, the numerous single locus linkage studies have been 
reviewed with some strikingly convincing replications on 21q and Xq (Gurling 1986; 
Gurling et al. 1988; Gurling 1998). Independent replication of linkage signals for 
bipolar disorder has been compelling on 12q, 21q 16p, Xq, 15q (Craddock and Jones 
1999). 
The problem of sample size in the linkage studies has been addressed with meta-
analyses of bipolar disorder in which samples from several studies were combined to 
determine the significance of findings (Tang et al. 2011). Recently, two main 
analytical approaches, Multiple Scan Probability (MSP) and the rank-based genome 
scan meta-analysis (GSMA) have been utilized in the meta-analysis of bipolar 
disorder data. MSP is known to be efficient and more powerful in detecting large 
effects that may have high variance, while GSMA has higher power to detect effects 
with small variance across independent studies (Tang et al. 2011). For ease of 
understanding, these approaches will be discussed in detail in the context of the 
studies that used them. 
To date, four meta-analyses of genome-wide linkage scans on bipolar disorder have 
been conducted (Badner and Gershon 2002; Segurado et al. 2003; McQueen et al. 
2005; Tang et al. 2011). 
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Badner and Gershon (2002) performed the first meta-analysis of genome-wide 
linkage scans of bipolar disorder that included 11 studies using the MSP technique. 
In this approach, the probability values (P) were taken from multiple studies and 
combined after correcting each value for the size of the region containing the 
minimum P-value (Badner and Gershon 2002). Strong evidence for linkage with 
bipolar disorder was obtained at 13q (P = 6 x 10
-6
) and 22q (P = 1 x 10
-5
) 
chromosomal regions. Interestingly, the same regions were also significant in their 
meta-analysis of genome-scans of schizophrenia (Badner and Gershon 2002). The 
authors argued that this method was more conservative and powerful than applying a 
statistical criterion to be met by at least one of the several individual studies. Also, 
unlike sample pooling of the data, the MSP was more robust to the presence of study 
heterogeneity where linkage was present in some but not all studies.  
The second meta-analysis of bipolar disorder genome scans was performed by 
Segurado et al. (2003). This study included all published and unpublished data 
available from bipolar disorder genome scans with >20 affected cases and also data 
from every marker in each scan to avoid publication bias. The GSMA method is a 
nonparametric approach used in the meta-analysis that tolerates a degree of 
variability in sampling and statistical methods, yielding largely empirical measures 
of significance rather than an effect size. In other words, GSMA is also capable of 
detecting significant cross-study results for regions that are weakly positive in many 
studies but not sufficiently positive to have been presented in any study (Segurado et 
al. 2003). In total, 18 bipolar disorder genome scan data sets were included in the 
analysis. No chromosomal regions achieved genome-wide statistical significance, 
albeit some support for linkage regions on chromosomes 14q, 9p-q, 10q, 18p-q, and 
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8q was obtained. One of the limitations of the study is that X- and Y-chromosome 
data were not accommodated by the GSMA procedure. 
McQueen et al. (2005) performed the largest and the most comprehensive mega-
analysis of bipolar disorder genome scans. The authors conducted a combined 
analysis using the original genotype data from 11 bipolar disorder genome-wide 
linkage scans comprising 5179 individuals from 1067 families and found significant 
linkage on chromosomes 6q and 8q. Genome-wide suggestive linkage on 
chromosomes 9p and 20p was also observed in the same study. Combining the 
original genotype data from all the studies rather than using only linkage statistics 
and/or P values provided more power and control over sources of heterogeneity 
unlike in previous studies (McQueen et al. 2005). 
Recently, Tang et al. (2011) used comparative linkage meta-analysis (CMLA) to 
compare the meta-analytic findings obtained under MSP and GSMA methods using 
results from published English language genome-wide linkage scans of bipolar 
disorder published between 2000 and 2010. The authors also examined the potential 
implications of convergent and discrepant results for the underlying genetic 
architectures of bipolar disorder given other genetic evidence from GWAS available. 
A total of 13 English-language genome-wide linkage scans were included in the 
MSP and GSMA analyses. The most significant MSP result was found on 5q14.3-
q23.3, with 14q11.2-q13.1 and 5p13.3-q13.3 attaining Lander and Kruglyak (LK) 
significance criteria, and 14q12-q22.3 and 6p23-p21.1 retaining LK-suggestive 
criteria. As a result of the GSMA analysis, significant results were obtained for the 
regions 3p25.3-3p22.1 and 10p14-q11.21, and nominally significant results for 
10q11.21-q22.1. Surprisingly, only 10p11.21-q22.1 and 10q22.1-q24.1 produced 
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partially-overlapping MSP-GSMA significant results. Interestingly, 10p11.21-q22.1 
region contains the Ankyrin 3 (ANK3) gene which is a well replicated gene 
association finding in bipolar disorder. Evidence for association within ANK3 gene 
comes from a bipolar GWAS (Lee et al. 2012), a bipolar GWAS meta-analysis 
(Ferreira et al. 2008), a combined bipolar and major depressive disorder (MDD) 
GWAS (Liu et al. 2011) and two recent combined GWAS meta-analysis (Wang et al. 
2010; Sklar et al. 2011) suggesting that this gene is very likely among the 
contributors to linkage signals.  
Several European linkage studies have been reported since the last meta-analysis of 
bipolar disorder linkage studies (McQueen et al. 2005).  
A genome-wide linkage analysis of 52 families of Spanish, Romany and Bulgarian 
descent confirmed linkage on the previously implicated bipolar disorder 
susceptibility loci, 4q31 and 6q24 and also found borderline significance for 1p35-36 
region based on the MOD-score (LOD score maximized over genetic model 
parameters) analysis method (Schumacher et al. 2005). The gene-gene interaction at 
the association level is a potential strategy in the identification of risk genes for 
complex disorders. With this approach in mind, the first genome-wide interaction 
and locus-heterogeneity linkage scan in BPAD using the same set of linkage data 
was performed and the strongest interaction was reported between genes on 
chromosomes 2q22-q24 and 6q23-q24, albeit evidence of locus heterogeneity was 
obtained at chromosome 2q (Abou Jamra et al. 2007).  
Etain et al. (2006) performed a genome-wide linkage scan in 87 sib-pairs ascertained 
through an early-onset BP I disorder type proband and non parametric multi-point 
analysis found the most significant linkage at 3p14 with a LOD score of 3.51, which 
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increased to 3.83 on additional genotyping with increased marker density. Another 
whole genome linkage scan of bipolar disorder in an Irish population was reported 
by Cassidy et al.(2007) using STRUCTURE-Guided Linkage Analysis (SGLA), 
which is designed to reduce genetic heterogeneity and increase the power to detect 
linkage. The most significant linkage was obtained at 14q24 (NPL LOD = 3.27) for 
BP I only model of affection and suggestive evidence at 4q21, 9p21, 12q24 and 
16p13 was also reported. 
Hamshere et al. (2009) reported results of a genome-wide linkage scan in European 
families multiply affected by bipolar spectrum mood disorder, including individuals 
diagnosed with DSM-IV BP I or schizoaffective disorder, bipolar type. Covariate 
linkage analysis showed genome-wide suggestive evidence for linkage on 
chromosomes 1q32.3, 7p13 and 20q13.31. Interestingly, previous studies on bipolar 
disorder (Curtis et al. 2003) and schizophrenia (Ekelund et al. 2001; Ekelund et al. 
2004) have reported linkage signals in the 1q region, close to Disrupted in 
schizophrenia gene (DISC I), that lies at 1q42. Also, evidence for significant 
familiality of lifetime occurrence of mood-incongruent psychosis, i.e., delusions or 
hallucinations that are not understandable within the context of predominant mood 
state, was observed in individuals with bipolar disorder in the study. 
X-chromosome linkage again came to attention with a genome scan in sibling pairs 
with juvenile-onset mood disorder from 146 Hungarian nuclear families by Wigg et 
al. (2009) which documented evidence for linkage at Xq28 with a non-parametric 
multipoint LOD score of 2.10. 
Mathieu et al. (2010) investigated the relationship between phenotypic heterogeneity 
in bipolar disorder and genetic heterogeneity among the eight susceptible loci 
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reported in a previous study (Etain et al. 2006) using additional markers and an 
extended sample of families. Analysis of the extended sample of families supported 
linkage in four regions, including 2q14, 3p14, 16p23 and 20p12. Genetic 
heterogeneity was observed between early- and late-onset BP I in the 2q14 region 
with only the early form of bipolar disorder being linked to this region. These results 
showed that stratification according to age of onset may be more relevant than DSM-
IV classifications of mood disorders for the 2q14 region and for the identification of 
genetic susceptibility variations.  
A recent method for analysing genome-wide SNP genotype data and family linkage 
analysis uses SNPs to identify extended segments showing increased IBD sharing 
within case-case pairs, relative to case-control or control-control pairs. A significant 
linkage signal on 19q was observed in cases reporting a positive family history of 
bipolar disorder or schizophrenia (Francks et al. 2010). 
In the current study, I have investigated the 1p36 region with positive linkage in the 
family study (Curtis et al. 2003) using tests of linkage and allelic association. 
Therefore, in the next section I will summarize the linkage studies reporting findings 
on the 1p locus in bipolar disorder. 
1.2.4.1. Summary of linkage studies at 1p locus 
Evidence for linkage at the 1p35-p36 locus with a four-point LOD score of 2 was 
reported in a study involving UCL bipolar family pedigree sample and furthermore, 
a single pedigree reporting a LOD of 3.1 for the same region (Curtis et al. 2003). The 
highest nonparametric linkage score of 3.97 was obtained for chromosomal region 
1p35-p36 in the Spanish sample on performing a genome-wide linkage study in 52 
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families of Spanish, Romany and Bulgarian descent and further fine mapping of the 
found susceptibility loci in additional 56 German families. MOD-score analysis 
provided borderline significance for the 1p region (Schumacher et al. 2005). Support 
for linkage at 1p36 has also been reported in isolated populations. Gypsies are a 
population comprising multiple genetically differentiated sub-isolates with strong 
founder effects and limited genetic diversity. A follow-up study (Kaneva et al. 2009) 
in Bulgarian Gypsy families with BPAD involving linkage analyses of the 12 
genomic regions previously showing linkage (Schumacher et al. 2005) showed 
nominally significant support for the 1p36 region in individual families as well as in 
the super-pedigree with 181 members. 
Cheng et al. (2006) conducted a genome-wide linkage scan in 1,060 individuals from 
154 multiplex families from NIMH initiative and performed linkage analyses using 
standard diagnostic models and also using three phenotypic subtypes, psychosis, 
suicidal behaviour and panic disorder. Suggestive linkage was found at 1p13 and 
1p21 for the psychosis sub-phenotype, although no signal was observed for these 
loci using standard diagnostic models. Studies suggesting linkage at 1p with bipolar 
disorder have also been reported in Italian (Vazza et al. 2007), Portuguese (Fanous et 
al. 2012), Colombian (Kremeyer et al. 2010) and Australian population (Fullerton et 
al. 2008; Fullerton et al. 2009). In a genome-wide linkage scan (Fullerton et al. 2008) 
on 15 Australian extended families with bipolar disorder support for 1p13-31 was 
observed. Further study on pooled genotype data from 65 Australian extended 
pedigrees detecting evidence of genetic interaction reported robust interchromosomal 
interaction exceeding Bonferroni correction between regions 4q32-35 and 1p36 
(Fullerton et al. 2009). Linkage analysis of 47 Portuguese families with sib-pairs 
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concordant for schizophrenia, bipolar disorder or psychosis revealed significant 
linkage for chromosome 1p36 with a LOD of 3.51 with bipolar disorder (Fanous et 
al. 2012). Also a meta-analysis of schizophrenia and bipolar datasets as part of a 
population based linkage analysis provided evidence for linkage on 1p34 (Francks et 
al. 2010). 
The initial excitement generated by the identification of linkage markers for bipolar 
illness dissipated quickly due to the lack of replication of many of the early linkage 
results. Susceptibility loci for bipolar loci recognised by analysing the meta-analyses 
and the European linkage studies include 8q, 14q, 10q, 1q, 3p and 2q. A recent study 
confirmed replication of susceptibility loci 6q25 and 17p12 implicated previously 
(Kelsoe et al. 1996; Lachman et al. 1997; Kelsoe et al. 2001), in an extended and 
independent sample of 34 pedigrees segregating bipolar disorder (Greenwood et al. 
2012).  
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1.2.5. Candidate gene association studies of 
Bipolar disorder 
A meta-analysis of genetic association studies on bipolar disorder using random-
effects meta-analysis approach on all polymorphisms reported in three or more case-
control studies was recently published by Seifuddin et al. (2012). The results from 
the meta-analysis were then compared with the findings from a mega-analysis of 
eleven GWAS in bipolar disorder (Sklar et al. 2011). Nominally significant 
associations (P<0.05) were found for polymorphisms in Brain derived neurotrophic 
factor (BDNF), Dopamine Receptor D4 (DRD4), D-amino acid oxidase activator 
(DAOA) and Neuronal tryptophan hydroxylase (TPH1), although the findings did 
not survive multiple testing correction. Only the most replicated and consistent 
association findings will be discussed further as a comprehensive review of all the 
association studies is beyond the scope of this thesis. 
 One of the most widely investigated genes in bipolar disorder is the serotonin 
transporter, SLC6A4, located on 17q reported to be positive in two linkage studies. 
Several association studies and four meta-analyses have also been reported with 
positive findings (Serretti and Mandelli 2008). TPH2 gene encoding rate-limiting 
enzyme in the biosynthesis of serotonin in the central nervous system has been 
positively associated with bipolar disorder in several independent studies, albeit 
negative associations have also been reported in different populations (Cichon et al. 
2008; Serretti and Mandelli 2008; Barnett and Smoller 2009; Choi et al. 2010). 
Serotonin receptor genes HTR1A, HTR2A, HTR2C and HTR7 have also been 
investigated in a few studies with some evidence of association (Serretti and 
Mandelli 2008). 
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Dopaminergic genes DRD1, DRD3, DRD4 and SLC6A3 have been subjected to 
investigations in several studies in different populations. Positive reports for a 
promoter polymorphism and haplotype association along with negative SNP 
associations have been reported for DRD1 (Nothen et al. 1992; Cichon et al. 1996; 
Severino et al. 2005; Dmitrzak-Weglarz et al. 2006). DRD3 has been reported to be 
positive in only one study. There is considerable support for the involvement of 
DRD4 and SLC6A3 genes in bipolar disorder based on several studies (Serretti and 
Mandelli 2008). 
Catechol-O-methyltransferase (COMT) is another promising candidate gene that 
encodes for an enzyme catalysing the degradation of catecholamines including 
dopamine, epinephrine and norepinephrine. The functional Val158Met 
polymorphism in this gene has been widely investigated with mostly negative results 
(Shifman et al. 2004; Serretti and Mandelli 2008). A recent study has reported 
interaction between DRD3 Ser9Gly polymorphism and COMT Val158Met 
polymorphism in BP I patients (Lee et al. 2011b), but this is unreplicated. 
BDNF is a gene selected for having evidence for both positional and functional 
involvement in bipolar disorder. This gene is located at 11p13, a region consistently 
linked to bipolar disorder in previous linkage studies which also contains the DRD4 
locus (Pato et al. 2004; Craddock and Sklar 2009). BDNF codes for a prosurvival 
factor induced by cortical neurons that is necessary for survival of striatal neurons in 
the brain. Reports suggesting effects of the Val158Met polymorphism on BDNF 
secretion and memory have been published (Egan et al. 2001). Variants in BDNF 
have also been reported to be associated with working memory and schizophrenia 
(Diaz-Asper et al. 2008). Two meta-analyses have confirmed association between 
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BDNF and bipolar disorder, particularly in Caucasians (Serretti and Mandelli 2008; 
Craddock and Sklar 2009). 
DAOA is a gene pertaining to the glutamatergic pathway that has been associated 
with bipolar disorder in several studies. Located in a positive linkage region, 
13q33.2, DAOA plays an important role in the activation of NMDA receptors, which 
are implicated in schizophrenia and bipolar disorder (Chumakov et al. 2002; 
Williams et al. 2006). Several independent Caucasian studies have reported positive 
associations with different SNPs in bipolar disorder (Hattori et al. 2003; Chen et al. 
2004; Schumacher et al. 2004; Prata et al. 2008; Bass et al. 2009; O'Donovan et al. 
2009; Cherlyn et al. 2010; Nothen et al. 2010). 
DISC1 was implicated cytogenetically in psychosis and has been found to be 
associated with bipolar disorder in several studies with an inconsistent pattern of 
association (Serretti and Mandelli 2008). Initially, DISC1 was found to be disrupted 
by a translocation that co-segregated with major psychiatric illness including 
schizophrenia, bipolar disorder, recurrent depression and childhood-onset 
behavioural disorder (St Clair et al. 1990). Since then multiple studies have 
confirmed associations between DISC1 and bipolar disorder, however, a pathogenic 
variant is still to be detected (Craddock and Sklar 2009; Hennah et al. 2009). 
Several other genes with replicated positive findings have been identified including 
TRPM2, GSK3β, DTN bipolar disorder1, NRG1, NCAM1, GRIN2B, MOAO, 
P2RX7 and GABA receptor genes (McQuillin et al. 2006; Lachman et al. 2007; 
Serretti and Mandelli 2008; Craddock and Sklar 2009). Genes involved in circadian 
rhythms have been investigated, including CLOCK and BMAL1 (Barnett and 
Smoller 2009). The evidence for allelic association with bipolar disorder at various 
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genes is convincing. The problem of locus heterogeneity gives rise to the “Winner’s 
curse” problem in which an initial report of a genetic association takes a long time to 
replicate (Zollner and Pritchard 2007). In view of the problem of locus and allelic 
heterogeneity, extremely large samples are required for robust identification of genes 
influencing risk and expression of bipolar disorder. 
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1.2.6. Genome-wide association studies in Bipolar 
disorder 
A GWAS involves a comprehensive interrogation of the common variations across 
the entire human genome to identify genetic associations with observable traits 
without the need for prior hypothesis about the location of the variants. Due to the 
extensive correlation or LD between SNPs, the majority of all common genetic 
variation is captured by genotyping only a small proportion of the total number of 
known SNPs using this technique. The genetic architecture of psychiatric disorders 
has proven to be complex with two contrasting hypotheses being routinely used to 
explain it - Common Disease Common Variant (CDCV) and Common Disease Rare 
Variant (CDRV) hypotheses. According to CDCV, the genetic risk in an individual 
and in the population is attributable to many high-frequency variants each conferring 
modest level of risk (Risch and Merikangas 1996). Alternately, the CDRV 
hypothesis states that a large number of rare variants with relatively large effects 
contribute to the disease risk such that hundreds of genes, each with many rare 
variants, contribute to the phenotype (Bodmer and Bonilla 2008). 
Based on the conception that psychiatric disorders have a negative effect on the 
fecundity, natural selection would prevent the causal alleles from reaching common 
frequencies in a population, which supports the CDRV hypothesis (Alaerts and Del-
Favero 2009). Successful identification of common risk variants in complex diseases 
by GWAS has transformed the field of medicine. The list of genetic variants for 
common somatic diseases has expanded considerably within the last few years 
leading to novel genetic findings resulting in a better understanding of diseases, such 
as cancer (Elliott et al. 2010) and obesity (Scherag et al. 2010). As a result of 
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GWAS, several new insights into the field of cancer biology are already being 
translated into clinical benefits for the patients and the potential findings of GWAS 
might soon be part of risk screening programmes in other diseases in the future 
(Bondy 2011). 
GWAS combine the merits of association studies in the power to detect small effects 
with that of linkage studies in that they do not require any knowledge of the 
pathogenesis of the disease. The GWAS approach requires correction for extensive 
multiple testing and for population stratification. The large samples required for 
performing GWAS provide power to detect variants with small or large effects. 
Meta-analyses of bipolar disorder GWAS (Chen et al. 2011) can focus on high or 
lower ranking signals suggesting susceptibility loci rather than on the 'top hits' of 
individual studies. Locus and/or allelic heterogeneity will play an important role in 
diluting true signals even with the usage of large samples (Pritchard and Cox 2002). 
A disadvantage of using large samples is that the LD variation between populations 
could be confounded with disease associations. Population structure/stratification is 
being routinely assessed and corrected for in the GWAS using principal component 
analysis method (Price et al. 2006), logistic regression, identical by state (IBS) 
clustering (Purcell et al. 2007) or linear mixed models (Alaerts and Del-Favero 
2009). 
Imputation methods are used in GWAS to improve the coverage of the human 
genome across different genotyping platforms. Imputation methods (Marchini et al. 
2007; Purcell et al. 2007) impute and test ungenotyped SNPs for association in a 
sample thus adding to the information content. Analysis of GWAS data using more 
sophisticated statistical methods may provide additional power leading to new 
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results and a better understanding of the best ways to interpret the GWAS data. 
Some of the alternative methods previously employed in the analysis of GWAS data 
include multipoint methods combining information across markers with more 
powerful tests for indirect association with untyped variants, simultaneous analysis 
of all SNPs to identify the subset that best predicts disease outcome, and weighted 
analyses incorporating prior information and pathway-based approaches, which 
jointly consider multiple variants in interacting or related genes (Alaerts and Del-
Favero 2009).  
1.2.6.1. Findings of GWAS 
Several GWAS on bipolar disorder have been published in the last five years 
revealing several interesting loci, which are not found in all samples consistently. A 
catalogue of published GWAS is available at http://www.genome.gov/gwastudies/. 
The first GWAS on bipolar disorder was reported by Baum et al. (2008) using 461 
BP I patients and 562 healthy controls of European Caucasian background that were 
obtained from NIMH. A German replication sample consisting of 772 BP I patients 
and 876 matched controls was also used in the study. All patients met DSM-IV 
criteria for BP I. DNA pooling was used to reduce the cost of genotyping in this 
study and over 550,000 SNPs were genotyped in the two samples. Pooling of DNA 
samples reduces the power to detect genetic association but is a cost effective 
method to genotype large number of samples. The strongest association signal was 
detected within the first intron of DGKH (diacyl glycerol kinase) (P = 1.5 × 10−
8
, 
OR=1.59). 
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The Wellcome Trust Case Control Consortium (WTCCC) (2007) conducted a joint 
GWAS to identify genes linked to seven different diseases including bipolar disorder 
in a British population. This bipolar GWAS was a result of the collaboration of three 
different research institutions. The Affymetrix GeneChip 500K Mapping Array set 
was used in this study to genotype ~2000 cases of bipolar disorder and a shared set 
of 3000 controls. Although several regions associated with bipolar disorder were 
found, none reached genome-wide significance level. The strongest region showing 
association with bipolar disorder was at chromosome 16p12 that included genes 
PALB2 (partner and localizer of BRCA2), NDUFAB1 (NADH dehydrogenase 
(ubiquinone) 1, alpha/beta subcomplex, 1) and DCTN5 (dynactin 5). The study also 
found association with KCNC2, which encodes the Shaw-related voltage-gated 
potassium channel, suggesting a role for ion channelopathies in bipolar disorder.  
The second GWAS by a consortium was reported by Sklar et al. (2008) that included 
non-overlapping Caucasian case-control samples from several research groups. The 
study sample consisted of 1461 BP I cases and 2008 controls from systematic 
treatment enhancement program (STEP-BD) study and UCL. A total of 372,193 
SNPs were genotyped in the study using Affymetrix GeneChip Human Mapping 
500K Array Set. Again, none of the SNPs met genome-wide significance on 
association analysis but the top SNPs associated with bipolar disorder were in genes 
MY05B (P = 1.66 x 10
-7
), TSPAN8 (P = 6.11 x 10
-7
) and EGFR (P = 3.26 x 10
-5
). 
Replication was attempted by genotyping 304 SNPs in family-based NIMH samples 
(n=409 trios) and University of Edinburgh case-control samples (N = 365 cases, 351 
controls) and the results showed that 9 out of the 13 SNPs that showed association 
were replicated. The other interesting genes suggesting association with bipolar 
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disorder reported in this study were CACNA1C, MBP, DFNB31, GRM3 and HLA-
DRA. This study did not identify any association between DGKH and bipolar 
disorder as shown previously in a bipolar disorder GWAS (Baum et al. 2008). 
In another collaborative approach, large sample sets from STEP-BD, University of 
Edinburgh and Trinity College, Dublin (ED-DUB-STEP2), were put together to 
perform a GWAS on non-overlapping samples (Ferreira et al. 2008). Over 300,000 
SNPs were genotyped in 1098 bipolar cases and 1267 controls and on analysis no 
chromosomal regions were found to be associated at genome-wide significance 
level. Interestingly, CACNA1C was one of the fourteen regions that showed 
association at P < 5x10
-5
. Furthermore, the genotyping data from the WTCCC, 
STEP-BD-UCL, and ED-DUB-STEP2 studies (4,387 cases and 6,209 controls) was 
combined with additional imputation data from 1,444,258 HapMap SNPs using 
PLINK (Purcell et al. 2007). The strongest associations were observed for the 
imputed SNP in ANK3 (rs10994336, P=9.1 x 10
-9
), a SNP in the third intron of 
CACNA1C (rs1006737, P=7.0x10
-8
) and for the 15q14 region containing C15orf53 
and RSGRP1 (rs12899449, P = 3.5 x 10
-7
). These results again pointed in the 
direction of ion channelopathies being important in the pathogenicity of bipolar 
disorder.  
Scott et al. (2009) performed a GWAS by genotyping 2,076 bipolar cases and 1,676 
controls of European ancestry obtained from the research groups - NIMH/Pritzker, 
and samples collected in London, Toronto and Dundee sponsored by Glaxo Smith 
Kline research and development (GSK) using the Illumina HumanHap550 Beadchip. 
SNP imputations were performed and association analysis was carried out in each 
sample individually followed by a 2-study meta-analysis. None of the SNPs 
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achieved genome-wide significance. A 3-study meta-analysis performed by adding 
genotype data from WTCCC resulting in an overall non-overlapping sample of 3,683 
cases and 14,507 controls resulted in 3 regions with association P ≈ 10-7, 1p31.1, 
3p21 and 5q15. Additionally, previously reported association between bipolar 
disorder and the ANK3 SNP rs10994336 (Ferreira et al. 2008) was replicated in the 
non-overlapping GSK sample (P = 0.042; OR = 1.37). 
Around the same time, Smith et al. (2009) conducted two separate GWAS in 
individuals of European ancestry (EA; n= 1001 cases, 1033 controls) and of African 
ancestry (AA; n = 345 cases, 670 controls). A genetic component of the Bipolar 
Consortium (sponsored by the US National Institute of Mental Health), termed the 
'Bipolar Genome Study (BiGS)' and funded by the Foundation for the National 
Institutes of Health Genetic Information Association Network (GAIN) initiative, 
contributed to the EA samples in this GWAS and some samples have been used in 
other GWAS (Baum et al. 2008; Sklar et al. 2008; Scott et al. 2009). Although not an 
independent sample set, the study found the strongest association signals at Xq27.1 
(P=1.6x10
-6
) and 2q21.1 (NAP5; P=9.8x10
-6
) for the EA sample, and 19q13.11 
(DPY19L3; P=1.5x10
-6
) and 9q21.33 (NTRK2; P=4.5x10
-5
) for the AA sample. 
Again, ANK3 region showed consistent but modest replication in the EA sample 
(rs1938526, P=0.036, OR = 1.31) and borderline support for replication was 
observed for the 15q14 region containing C15orf53. However, the study failed to 
show any support for CACNA1C association. 
Recently, the Psychiatric GWAS Consortium (PGC) (Sklar et al. 2011) reported the 
results of a combined GWAS of 7481 bipolar disorder cases and 9250 controls. This 
dataset was obtained by dividing the primary genotype and phenotype data for 
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overlapping case-control samples from seven previously published studies (Baum et 
al. 2008; Ferreira et al. 2008; Sklar et al. 2008; Scott et al. 2009; Smith et al. 2009; 
Djurovic et al. 2010; Cichon et al. 2011) into 11 different case and control groupings 
and assigning each individual to only one group. On the basis of diagnosis, the cases 
were made up of 84% BP I, 11% BP II, 4% schizoaffective disorder and 1% with 
other bipolar diagnoses. The two regions reaching genome-wide significance in this 
sample were ANK3 on chromosome 10q21 (imputed SNP rs10994397, P = 7.1 x 10
-
9
, OR = 1.35) and SYNE1 on chromosome 6q25 (rs9371601, P = 4.3 x 10
-8
, OR = 
1.15). Furthermore, two other association signals nearing genome-wide significance 
were observed on chromosome 12 and in the region of ODZ4. For replication, 
unpublished data from research groups on an independent sample consisting of 4,496 
bipolar disorder cases and 42,422 controls was used. Although ANK3 and SYNE1 
associations failed to replicate, SNPs mapping to CACNA1C and C11orf80 were 
found to be significantly associated with bipolar disorder following a correction for 
multiple testing. A fixed-effects meta-analysis performed on the combined sample of 
11,974 cases and 51,792 controls identified strong genome-wide association signals 
in the regions containing CACNA1C (P=1.52 x 10
-8
, OR = 1.14) and ODZ4 (P=4.40 
x x10
-8
, OR=0.89). A pathway analysis on the combined sample showed significant 
enrichment of genes encoding calcium channel subunits, CACNA1C and 
CACNA1D. Sklar et al. (2011) also reported a strong association for SNPs at the 
CACNA1C locus and in the region of NEK4-ITIH1-ITIH3-ITIH4 based on the 
combined GWAS analysis of schizophrenia and bipolar disorder. 
Smith et al. (2011) performed a GWAS on a total of 2191 cases and 1434 controls of 
European ancestry collected as part of the BiGS-TGEN and the GAIN initiative. 
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This study sample comprised of 1,190 new bipolar disorder cases from the BiGS 
study and 401 controls (TGEN sample), along with 1,001 cases and 1033 controls 
previously genotyped through the GAIN initiative (Smith et al. 2009). No genome-
wide significant associations for any region were reported. Also, the authors did not 
find any genome-wide significant associations when they performed a meta-analysis 
of SNP genotype data from the current study and WTCCC. Based on the results, 
they hypothesised that the presence of likely common genetic variations associated 
with bipolar disorder near exons (±10 kb) could be identified in larger studies and 
provide a framework for assessing the potential for replication when combining 
results from multiple studies (Smith et al. 2011). A further need is for a Bayesian 
analysis of the GWAS data which can take the place of corrections for multiple 
testing. 
A new bipolar disorder susceptibility candidate, Neurocan (NCAN) has recently 
been reported reaching genome-wide significance (P=3.02 x 10
-8
, OR=1.31) in a 
GWAS conducted by Cichon et al. (2011) on European samples. The association was 
replicated in two follow-up steps in the study in independent samples from Europe, 
USA and Australia surpassing genome-wide significance threshold and the 
combined analysis of all the samples with 8441 cases and 35,362 controls also 
confirmed the association (P=2.14 x 10
-9
, OR=1.17). 
GWAS on bipolar disorder in Han Chinese (Lee et al. 2011a), Norwegian (Djurovic 
et al. 2010), Japanese (Hattori et al. 2009) and Bulgarian (Yosifova et al. 2011) 
samples have also been reported. Although, none of these studies found any SNPs 
showing genome-wide level significance, replication in the form of a modest 
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association was reported for ANK3 in the Chinese study (Lee et al. 2011a) and 
DGKH in the Bulgarian GWAS (Yosifova et al. 2011). 
A meta-analysis of 5 major mood disorder case-control samples including bipolar 
disorder and MDD of European ancestry found genome-wide significant association 
at 3p21.1 (rs2251219, P = 3.63 x 10
-8
, OR = 0.87) (McMahon et al. 2010). Another 
meta-analysis of genome-wide association data of bipolar disorder and MDD was 
conducted by Liu et al. (2011). The bipolar cases were from the US, UK and Ireland 
(WTCCC 2007; Sklar et al. 2008) and the MDD subjects (Penninx et al. 2008) were 
from the Netherlands. This study provided evidence for the role of CACNA1C 
variants in bipolar and unipolar major mood disorders but failed to confirm the 
previous association of bipolar risk locus ANK3 in the meta-analysis. Even larger 
collection of bipolar disorder GWAS signals was analysed for age of onset and 
psychotic symptoms and two sub-phenotypes of bipolar disorder. These included 
GWAS data from GAIN-BP, BiGS, and a German study but it failed to report any 
significant genome-wide associations (Belmonte Mahon et al. 2011). 
Wang et al. (2010) performed a meta-analysis for GWAS data in 653 bipolar cases 
and 1034 controls, and 1172 schizophrenia cases and 1379 controls and found two 
intergenic SNPs in the 9q33 region showing genome-wide significance. No 
replications of previously associated SNPs were reported (Wang et al. 2010). 
Another study comparing the marker allele frequencies between schizophrenia and 
bipolar disorder cases rather than with controls reported a significant association for 
CACNG5 that supports the role of voltage-dependent calcium channel genes such as 
CACNA1C in the susceptibility to bipolar disorder (Curtis et al. 2011). 
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Crossing the intercontinental boundaries, Chen et al. (2011) recently performed a 
meta-analysis of 7773 bipolar disorder cases and 9883 controls of European and 
Asian ancestry and found novel significant associations near the genes TRANK1 
(LBA1), LMAN2L and PTGFR. In vitro studies supporting a functional role for 
TRANK1 showed that valproic acid markedly increased TRANK1 mRNA 
expression in a dose- and time-dependent manner in SH-SY5Y, HeLa, and HEK293 
cells. Additionally, this study also reported associations between ANK3 and bipolar 
disorder as well as markers on a chromosome 3p21 locus. 
The current generation of GWAS technologies is best able to detect association of 
genetic variants present in 1% or more of the population. SNP variants in ANK3, 
ODZ4, SYNE1, CACNA1C, DGKH, and C15orf53 have consistently been 
associated with bipolar disorder in different GWAS. Another approach termed as 
gene-wide analysis of GWAS data sets, which avoids correction for multiple SNPs 
within a gene, has also provided additional evidence for association to these genes 
reported in the previous GWAS (Moskvina et al. 2009). With the growing body of 
evidence for the ‘common disease multiple rare variants’ (Gershon et al. 2011) 
hypothesis of bipolar disorder, there is an urgent need to pursue approaches designed 
to detect rare variants contributing to bipolar disorder. Broadening the spectrum of 
detectable risk alleles can be achieved by next generation GWAS technologies aimed 
at enhancing detection of rare variants and polymorphisms present at <1%, thereby 
enhancing the disease association detection. Further functional studies to elucidate 
the mechanism of risk contributed by common and rare variants are warranted as 
well. 
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1.2.7. CNVs in Bipolar disorder 
CNVs are structural variations of the DNA that include insertions, deletions, inversions 
and duplications that may vary in length from a few kilobases to several megabases (Lee 
et al. 2012). Two human chromosomes in a population differ at a rate of 0.1% according 
to the early surveys of genetic variation (International Hapmap Consortium 2005; 
Marian 2012). Although SNPs account for the most numerous variants in the genome, 
CNVs have been reported to involve upto 12% of the human genome contributing to a 
sizeable amount of phenotypic variation within normal individuals and complex diseases 
including psychiatric disorders like schizophrenia and bipolar disorder. CNVs are 
classified as de novo and inherited. De novo CNVs can occur at the rates of up to four 
folds greater than single nucleotide substitution rates (Lupski 2007). In comparison to 
SNPs, the overall genomic change as measured in nucleotides is high in the case of 
CNVs, in the order of 1000 bp per generation, leading to a larger functional impact per 
site (Malhotra and Sebat 2012). CNV deletions and duplications possibly interfere with 
the regulatory regions or coding sequences of various genes thereby altering their 
genetic makeup and biological functions. Additionally, the presence of CNVs can result 
in the up- or downregulation of dosage sensitive genes, thereby, contributing to disease 
susceptibility variations (Lee et al. 2012). Based on the sheer size and potential to 
impact genes or multiple genes, structural variations are more pathogenic on average 
and de novo CNVs might be more enriched in variants that have a large effect on 
disease risk (Malhotra and Sebat 2012). CNV studies are a formal test of the CDRV 
hypothesis. A widespread distribution of submicroscopic variations (<500 kb in size) in 
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DNA copy numbers in normal human genomes was demonstrated in two landmark 
studies conducted in 2004 (Iafrate et al. 2004; Sebat et al. 2004). Also, CNV deletions 
accounting for the variations in intermediate phenotypes within complex 
neuropsychiatric illnesses such as cognitive impairment or physiological measures have 
previously been reported (Friedman et al. 2008). 
The literature available on the studies examining structural variations in bipolar disorder 
is very limited. In a postmortem brain DNA screening study by Wilson et al. (2006), 
several loci including GRM7, AKAP5 and CACNG2 were reported to contain CNVs. 
These proteins are highly expressed in the brain and are involved in glutamatergic 
signalling which is integral to the normal neuronal function (Wilson et al. 2006). 
Another study by Zhang et al. (2009) analyzed CNVs (≥100 kb) in 1001 bipolar patients 
and 1034 controls as part of a genome-wide CNV survey. Although the singleton 
deletions were present at a higher frequency in patients (16.2%) compared to controls 
(12.3%), the difference was more marked in patients with early age at onset of mania 
(Zhang et al. 2009). A possible limitation of the study was the recruitment strategy 
employed for enrolling cases and controls. The bipolar cases were recruited at 11 data 
collection sites using DSM-IV criteria, whereas the controls were recruited separately 
through a volunteer panel and a web-based psychiatric interview. 
A genome-wide survey of large, rare CNVs in a case-control sample from WTCCC 
(Grozeva et al. 2010) found that the rate of CNVs was higher in controls than in bipolar 
cases. The absence of rare and large structural deletions associated with bipolar disorder 
and their presence in 5%-10% of schizophrenia cases shows that the two disorders are 
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genetically distinct for this type of genetic variation. Similar results were obtained in 
another study utilizing the UCL bipolar disorder research sample (McQuillin et al. 
2011), in which the rare CNV burden was also slightly lower in the cases compared to 
controls. Both the studies (Grozeva et al. 2010; McQuillin et al. 2011) also failed to 
report any association between age-at-onset and singleton deletions as reported 
previously (Zhang et al. 2009). The fact that both studies found higher rates of CNVs in 
controls is difficult to explain but it could be the presence of schizophrenia CNV carriers 
or undiagnosed cases in the controls that are responsible. 
A combined analysis of CNVs in three case-control affective disorder samples from 
Denmark, Norway and Iceland reported no association between the CNVs and affective 
disorders (Olsen et al. 2011). CNVs at 10 genomic loci were investigated in 1223 
unipolar cases, 463 bipolar cases and 11,231 controls. A meta-analysis with the 
inclusion of CNV data from the WTCCC study (Grozeva et al. 2010) for the selected 
loci showed nominal association for only a 9q31.1 locus (P = 0.041, OR = 3.8). 
In the first genome-wide survey involving family trios for the identification of CNVs in 
bipolar disorder (Malhotra et al. 2011), the frequencies of de novo CNVs were 
significantly higher in bipolar disorder patients compared to controls (n= 185, P = 0.009, 
OR = 4.8). Furthermore, the enrichment of these de novo CNVs was more evident 
among the cases with early age-at-onset (≤18 years). This study also included 
schizophrenia cases and concluded that these cases were also enriched with de novo 
CNVs. In contrast, the results of this study were inconsistent with other family-based 
studies of schizophrenia (Xu et al. 2008) and autism (Levy et al. 2011) that have found a 
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strong genetic effect of de novo mutations and a weak genetic effect for inherited 
variants. Recently, a GWAS in a Swedish population reported support for a greater 
CNV involvement in schizophrenia compared to bipolar disorder (Bergen et al. 2012). 
Cumulative evidence on complex psychiatric diseases also suggests that de novo CNVs 
are being found at a higher frequency among sporadic cases, whereas inherited CNVs 
are enriched among familial cases (Levy et al. 2012). 
Priebe et al. (2012) performed a search for the presence of CNVs using genome-wide 
SNP data obtained from a bipolar disorder GWAS (Cichon et al. 2011) conducted in 882 
patients and 872 controls. Genome-wide burden analyses revealed that the frequency 
and size of CNVs did not differ substantially between cases and controls. However, a 
separate analysis of patients with early-onset bipolar disorder (age-at-onset ≤21 years) 
and late-onset bipolar disorder (age-at-onset ≥21 years) revealed that the frequency of 
microduplications was significantly higher (P = 0.0004) and the average size of 
singleton microdeletions was significantly larger (P=0.0056) in patients with early-onset 
bipolar disorder compared to controls. Two microduplications - 160 kb on 10q11 and 
248 kb on 6q27 - were overrepresented in the early-onset subgroup of bipolar disorder 
patients compared to controls (Priebe et al. 2012). These results provided further support 
for the influence of CNVs on early-onset bipolar disorder, and also suggested the 
presence of an aetiological difference between early-onset and late-onset bipolar 
disorder.  
In conclusion, the potential role of CNVs in bipolar disorder is highlighted by some 
publications reporting overrepresentation of CNVs (Zhang et al. 2009; Malhotra et al. 
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2011) in patients with bipolar disorder and others being negative for any associations 
(Grozeva et al. 2010; McQuillin et al. 2011). The effect of de novo CNVs on age-at-
onset in bipolar disorder has consistently been nominally significant in several studies 
(Zhang et al. 2009; Malhotra et al. 2011; Priebe et al. 2012) suggesting that individuals 
with early-onset bipolar disorder may represent a subclass of the disorder in which there 
is a greater contribution from rare CNV alleles of large effect. Support for the notion 
that segregation of early-onset bipolar disorder in families is consistent with major gene 
effects. However, familial segregation of bipolar disorder and unipolar disorders shows 
a wide range of ages of onset and it is not possible to identify clear cut differences in age 
of onset between families. In conclusion, several lines of evidence suggest that the 
overall rare CNV burden is more modest for bipolar disorder, with schizophrenia 
showing a large increase in the number of CNVs found to be associated compared to 
controls (Girirajan and Eichler 2011).
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1.3. Glutamate receptors 
Glutamate is the primary excitatory neurotransmitter in the human brain. Under 
normal conditions, glutamate plays an important role in synaptic plasticity, learning 
and memory, but in pathological conditions it is known to be a potent neuronal 
excitotoxin, triggering either rapid or delayed neurotoxicity (Sanacora et al. 2008). 
Glutamate acts on presynaptic and postsynaptic neurons and glia, the three different 
cell compartments characterizing the 'tripartite glutamatergic synapse'. Disturbances 
in glutamate-mediated transmission have been increasingly documented in a range of 
neuropsychiatric disorders including mood disorders, Alzheimer's disease, 
schizophrenia, substance abuse and autism spectrum disorders (Moghaddam and 
Javitt 2011). In the Central Nervous System (CNS), glutamate binds to both ion 
channel-associated (ionotropic glutamate receptors, iGluRs) and G-protein-coupled 
receptor subtypes (metabotropic glutamate receptors, mGluRs) mediating direct as 
well as fast excitatory and second-messenger evoked transmission respectively 
(Cartmell and Schoepp 2000). Thus, neuronal signalling can be modified by 
presynaptic glutamate receptors that directly regulate glutamate release, or by 
glutamate receptors localized postsynaptically on glutamatergic and 
nonglutamatergic neurons. Presynaptically, the iGluRs and mGluRs act by 
controlling the strength of synaptic transmission by altering the likelihood that the 
synaptic vesicles would be released in response to an incoming action potential 
(Pinheiro and Mulle 2008). 
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1.3.1. Ionotropic glutamate receptors 
Ionotropic glutamate receptors include NMDA, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic (AMPA) and kainate receptors. The NMDA receptors (NMDAR) 
have a slower and more prolonged postsynaptic current than the AMPA or kainate 
receptors (KAR). All iGluRs exhibit fast receptor deactivation and dissociation of 
glutamate. NMDA receptors are ligand-gated ion channels activated in a voltage-
dependent manner and made up of an obligate NMDAR subunit 1 (NR1) together 
with 1 of 4 subunits of NR2A-D. The activation of NMDARs requires glutamate and 
glycine along with membrane depolarization in order to lift the magnesium block. 
An intracellular site for non-competitive antagonists such as phencyclidine (PCP), 
ketamine and MK-801 is also present in NMDARs (Cherlyn et al. 2010; Machado-
Vieira et al. 2012). Reduced levels of NMDARs have been reported in postmortem 
brain from bipolar disorder patients (Rao et al. 2012). The AMPA receptors 
participate in fast excitatory transmission and their activation opens the pore 
permitting the inward flow of sodium resulting in the depolarization of the neuronal 
membrane. Co-expression of AMPA receptors with NMDA receptors has been 
observed at mature synapses, suggesting that they both contribute to synaptic 
plasticity and neuroprotection. However, AMPA receptors have a lower affinity for 
glutamate compared to NMDA receptors, which allows for a more rapid dissociation 
of glutamate and a fast deactivation of the AMPA receptors (Zarate et al. 2010). 
Decreased levels of AMPA receptor subunits (GluR1, GluR2 and GluR3) have been 
reported in the prefrontal cortex and striatum of subjects with mood disorders and 
transgenic animals with lower GluR1 expression exhibit increased depressive-like 
behaviour (Zarate et al. 2010). Kainate receptors activate postsynaptic receptors and 
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inhibit neurotransmission by regulating GABA release. The distribution of kainate 
receptors in the brain is limited and their effect on synaptic signalling and plasticity 
is less than AMPA receptors (Machado-Vieira et al. 2012). In preclinical studies, a 
GluR6 knockout mouse with no kainate receptor subunit genes showed increased 
risk-taking and aggressive behaviours as well as hyperactivity in response to 
amphetamine. These manic-like behaviours decreased after chronic lithium treatment 
(Shaltiel et al. 2008). 
1.3.2. Metabotropic glutamate receptors 
Metabotropic glutamate receptors are members of the most abundant receptor gene 
family in the human genome, the G-protein-coupled receptor (GPCR) superfamily. 
The mGluRs are classified into three groups based on their pharmacology, sequence 
homology, G-protein coupling and association with specific second-messenger 
systems. Group I includes mGluR1 and mGluR5, group II includes mGluR2 and 
mGluR3 and group III includes mGluR4, mGluR6, mGluR7 and mGluR8 (Conn and 
Pin 1997) (Table 1.1). In general, mGluRs contain a large extracellular N-terminal 
domain that contains the glutamate binding site, seven putative transmembrane-
spanning domains separated by short intra- and extracellular loops, and an 
intracellular C-terminal domain that is variable in length and less conserved among 
the members of the same group. Sequence analysis revealed that the N-terminal 
extracellular domain of mGluRs is made up of a Venus Fly Trap (VFT) domain 
similar to the periplasmic bacterial leucine/isoleucine/valine binding protein. This 
VFT domain is linked to the first of the seven transmembrane (TM) domains via a 
cysteine-rich domain (CRD) containing 9 highly conserved cysteine residues 
(O'Hara et al. 1993) (Figure 1.1). The structures of mGluR3 and mGluR7 VFT 
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domains confirm these findings (Muto et al. 2007a; Muto et al. 2007b). The VFT 
domain is composed of two lobes each made of α-helices around a large β-sheet with 
the glutamate binding site located in the cleft between the two lobes (Conn and Pin 
1997). The heptahelical domains of mGluRs share very low homology compared to 
other GPCRs and it has been proposed that the second and the third intracellular 
loops, as well as helix 8 are important in G-protein coupling and are also involved in 
coupling sensitivity (Pin et al. 2003). The majority of characterized positive- and 
negative-allosteric modulators of mGluRs affecting glutamate activity bind within 
the heptahelical domain. The C-termini of mGluRs modulate G-protein coupling and 
are subject to alternative splicing, regulation by phosphorylation and modulatory 
protein-protein interactions (Niswender and Conn 2010). 
 
Figure 1.1 Structure of a metabotropic glutamate receptor 
[Taken from (Conn and Pin 1997)] 
 
 
 
Third party copyright material 
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Earlier studies have predicted that the mGluRs only form homomers. However, 
energy transfer technologies along with systems to control the receptor subunit 
composition have recently shown that mGluRs form heterodimers as well (Nicoletti 
et al. 2011). A recent report by Doumazane et al. (2010) demonstrated that subtypes 
of the same group of mGluRs can form intragroup heterodimers (e.g., mGluR1 with 
mGluR5 and mGluR2 with mGluR3 receptors). Interestingly, group II and group III 
mGluRs can form intergroup heterodimers (mGluR2 with mGluR4). No 
heterodimers can be formed between group I and Group II/III mGluRs suggesting 
that only mGluR subtypes coupled to the same G-protein can form heterodimers. 
The existence of mGluR heterodimers in the brain is evident by the co-localization 
of different mGluR subunits in specific subdomains in neurons (Doumazane et al. 
2010). 
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Table 1.1 Key features of mGluRs 
Group Receptor/splice 
variant 
CNS expression Synaptic localization Signaling pathways of group 
Group I mGluR1 
a, b, c, d, e, f 
Taste mGluR1 
Widespread in neurons 
 
Taste buds 
Predominantly postsynaptic Phospholipase C stimulation 
Stimulation of adenylyl cyclase (some 
systems) 
MAP kinase phosphorylation mGluR5 
a, b 
Widespread in neurons, astrocytes 
Group 
II 
mGluR2 Widespread in neurons Presynaptic and postsynaptic Inhibition of adenylyl cyclase 
Activation of K
+
 channels 
Inhibition of Ca
++
 channels 
mGluR3 
GRM3Δ2 
GRM3Δ4 
GRM3Δ2Δ3 
Widespread in neurons, astrocytes 
Group 
III 
mGluR4 
 
Taste mGluR4 
Widespread in neurons, High in 
cerebellum 
Taste buds 
Predominantly presynaptic Inhibition of adenylyl cyclase 
Activation of K
+
 channels 
Inhibition of Ca
++
 channels 
mGluR6 
a, b, c 
Retina Postsynaptic in ON-bipolar 
retinal cells 
Stimulation of cGMP 
phosphodiesterase (mGluR6) 
mGluR7  
a,b,c,d,e 
Widespread in neurons Active zone of presynaptic 
terminals 
 
mGluR8 
a,b,c 
Lower and more restricted 
expression than mGluR4/7 
Predoninantly presynaptic 
[Taken from (Niswender and Conn 2010)] 
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1.3.2.1. Group I mGluRs  
Group I mGluRs are positively linked to phospholipase C and direct activation of 
mGlu1/5 receptors results in increased phosphoinositide turnover. The majority of 
localization studies of Group I mGluRs have revealed the postsynaptic terminal 
localization of mGLuR1 and mGluR5 (Table 1.1). The activation of these receptors 
often leads to cell depolarization and increase in neuronal excitability (Niswender 
and Conn 2010). The group I mGluRs can also act presynaptically to either increase 
or decrease neurotransmitter release mediated by postsynaptic group I mGluRs and 
release of retrograde messengers, such as endocannabinoids. Group I mGluRs play 
important roles in induction of long-lasting forms of synaptic plasticity, including 
long-term depression (LTD) and long-term potentiation (LTP) of transmission at 
multiple glutamatergic synapses and induce long-lasting changes in neuronal 
excitability (Niswender and Conn 2010). 
The activation of group I mGluRs leads to excitatory effects in the brain, such as 
activation of NMDA receptors or an increase in glutamate release. mGluR1 is 
abundantly present in the cerebellum, the CA3 region of hippocampus, the thalamus, 
the dentate gyrus and the medial central gray whereas mGluR5 is highly expressed in 
the CA1 and CA3 regions of the hippocampus, in the septum, the basal ganglia, the 
amygdala and the nucleus accumbens. As noted above, the abundance of group I 
mGluRs in the limbic structures that are involved in the processes of emotions and 
motivation suggests a role for these receptors in affective disorders (Palucha et al. 
2007). Genetic association studies on group I mGluRs have implicated mGluR5 
(GRM5) in schizophrenia (Devon et al. 2001) but failed to show any association for 
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mGluR1 (GRM1) in bipolar disorder (Kaneva et al. 2009). Recently, GRM5 has 
been associated with ADHD, with an intronic SNP showing second best association 
in a German sample GWAS (Hinney et al. 2011) and the presence of deletions in a 
genome-wide CNV study (Elia et al. 2011). Reduction in the level of mGluR5 
protein in the prefrontal cortex of patients with MDD was demonstrated in a study 
using postmortem brain samples. Several findings have suggested a 
pathophysiological role for mGluR5 in MDD as well as a role in the action of 
antidepressants (Hashimoto 2011). 
The first mGluR to be knocked out in mice was mGluR1 and these animals show 
normal gross brain morphology but exhibit several phenotypes. In a recent study 
recording functional changes taking place at the hippocampal CA3-CA1 synapse 
during the acquisition of an associative task in mGluR1 knockout mice, the animals 
were unable to learn the task and showed significant impairments in the ability to 
induce LTP (Gil-Sanz et al. 2008). Deficits in prepulse inhibition, a measure of 
sensorimotor gating that is impaired in schizophrenic patients and reversed by 
antipsychotics, have been reported in both mGluR1 and mGluR5 knockout animals 
(Brody et al. 2003; Brody et al. 2004). Also, in models of drug abuse and addiction, 
mGluR5 knockout mice failed to self-administer cocaine or increased their 
locomotor activity after cocaine administration (Chiamulera et al. 2001). Group I 
mGluR antagonists have shown potential therapeutic effects in mood disorders. The 
group I mGluR5 antagonists MPEP (2-methyl-6-[phenylethynyl]-pyridine) and 
MTEP [(2-methyl-1, 3-thiazol-4-yl)ethynyl]pyridine) showed antidepressant-like 
activity in animal models. Another mGluR5 antagonist fenobam was associated with 
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significant psychostimulant effects and also showed robust anxiolytic efficacy in a 
double-blind, placebo-controlled trial (Machado-Vieira et al. 2012). 
 
Figure 1.2 Schematic representation of mGluRs at the synapse. 
[Taken from (Niswender and Conn 2010)] 
1.3.2.2. Group II mGluRs 
Group II mGluRs are negatively coupled to adenylyl cyclase and upon activation 
inhibit forskolin-stimulated cyclin AMP formation (Cartmell and Schoepp 2000). 
These receptors are largely present on presynaptic membranes and on glial cells 
where they are believed to modulate glutamatergic neurotransmission by sensing 
glutamate spillover and regulating transmitter release. These receptors are highly 
expressed in brain structures apparently related to emotional states, including the 
forebrain and limbic areas, such as the amygdala, hippocampus and prefrontal cortex 
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(Palucha and Pilc 2007). Thus, the group II receptors mGluR2/3 are extremely 
interesting targets for antidepressant drug development based on their role in 
modulating glutamate neurotransmission. Presynaptic group II mGluRs also regulate 
the release of other neurotransmitters such as GABA, dopamine, serotonin, purines 
and others (Figure 1.2) (Cartmell and Schoepp 2000). Postmortem brain studies have 
demonstrated an elevated level of mGluR2/3 protein in the prefrontal cortex of 
patients with MDD (Feyissa et al. 2010). 
The majority of genetic association studies on mGluRs in psychiatric disorders 
revolve around the group II receptors, which include mGluR2 (GRM2) and mGluR3 
(GRM3). Multiple GWAS have investigated the association of GRM2 with bipolar 
disorder but no meta-analysis has been carried out. Equal number of studies 
recording positive and negative associations of GRM3 with schizophrenia has been 
reported, but there has been no evidence of the involvement of GRM3 in bipolar 
disorder (Joo et al. 2001; Marti et al. 2002; Cherlyn et al. 2010). 
Evidence from several studies suggests that mGluR2/3 -targeted drugs possess both 
antidepressant and anxiolytic properties (Sanacora et al. 2008). With the exception of 
N-acetylaspartateglutamate (NAAG) that selectively activates mGluR3, no 
orthosteric agonists or antagonists can differentiate between mGluR2 and mGluR3. 
Both mGluR2 and mGluR3 have been separately deleted from the mouse genome 
and these animals have contributed greatly to the understanding of the role of these 
receptors. Severe impairment in terms of LTD induced by low-frequency stimulation 
at synapse was observed in mGluR2 knockout mice, along with normal regulation of 
basal synaptic transmission and LTP at mossy fiber-CA3 synapses in the 
hippocampus (Niswender and Conn 2010). mGluR2 knockout mice also showed 
90 
 
increased responsiveness to cocaine suggesting an important role in drug addiction 
and abuse (Morishima et al. 2005) and this receptor has also been shown to 
selectively mediate the beneficial effects of group II agonists in rodent models of 
psychosis (Fell et al. 2008). In a study involving mixed cultures of cortical neurons 
and astrocytes from wild-type mGluR2 and mGluR3 knockout mice, the 
neuroprotective effect of LY379268, a mGluR2/3 agonist, was lost when mGluR3 
was missing from the astrocytes in the culture, whereas activation of mGluR2 were 
found to be excitotoxic (Corti et al. 2007). Phase II clinical trials in the treatment of 
generalized anxiety disorder for another group II selective agonist, LY354740 were 
underway before discontinuation on the basis of findings of convulsions in 
preclinical studies (Dunayevich et al. 2008). MGS0039 is a selective group II 
antagonist that has been shown to exert antidepressant effects in animal models. 
Other effects consistent with antidepressant activity including increasing dopamine 
release in the nucleus accumbens and neurogenesis in the hippocampal dentate gyrus 
have been reported on treatment with MGS0039 (Nicoletti et al. 2011). 
Unfortunately, research into drugs with fast onset of antidepressant activity has not 
yielded any results. Interestingly, low doses of the mGLuR2/3 agonist, LY379268, 
shorten the temporal latency of classical antidepressants in reducing the expression 
of β1-adrenergic receptors in the hippocampus (Matrisciano et al. 2005; Matrisciano 
et al. 2007). Both positive and negative symptoms in schizophrenic patients were 
shown to be reduced in a phase II clinical study involving 21-day treatment with 
LY2140023 (oral prodrug of the mGluR2/3 agonist LY404039) and this reduction 
was comparable with that caused by the antipsychotic, olanzapine (Patil et al. 2007). 
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1.3.2.3. Group III mGluRs 
Group III mGluRs are the largest and the least investigated family of the mGluRs, 
which are classified into four subtypes: mGluR4, mGluR6, mGluR7 and mGluR8. 
The group III mGluRs are similar to group II mGluRs in that they are negatively 
coupled to adenylyl cyclase and their activation inhibits stimulated cAMP formation. 
Unlike all these group III receptors which are expressed in several regions of the 
CNS, mGluR6 subtype is limited to the retina (Nakajima et al. 1993). Both neuronal 
and glial cells express group III mGluRs and their localization on asymmetrical and 
symmetrical synapses have been well documented. Due to their predominant 
localization on axon terminals these receptors control the synaptic availability of 
glutamate as well as GABA, dopamine and serotonin (Figure 1.2) (Hashimoto 2011). 
mGluR4 receptors are localized mainly in the cerebellum, and the receptor knockout 
mice exhibit disturbed motor coordination in the rotarod test suggesting that mGluR4 
may be responsible for motor function (Palucha and Pilc 2007). The mGluR7 is 
highly expressed in the neocortical regions, cingulate and piriphorm cortices, CA1, 
CA3 and dentate gyrus regions of hippocampus, amygdala, hypothalamic and 
thalamic nuclei (Ohishi et al. 1995). The expression of mGluR7 is restricted to the 
presynaptic zones and the sites of synaptic vesicle fusion. The receptor is the main 
one responsible for the regulation of glutamate release under normal physiological 
conditions (Palucha and Pilc 2007). Knockout of mGluR7 results in animals having 
an epileptic phenotype and mGluR7-/- mice show abnormalities in learning tasks 
suggesting an important role mediating amygdala-dependent learning. In addition, 
these mice have demonstrated roles for mGluR7 in anxiety and depression 
(Niswender and Conn 2010). mGluR8 expression seems to be dominant in 
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presynaptic terminals in the olfactory bulbs, piriform cortex, hippocampus and 
cerebellum (Shigemoto et al. 1996; Shigemoto et al. 1997). The mGluR8 knockout 
mice also show enhanced anxiety and weight gain compared to control animals 
suggesting a role for mGluR8 activators in the treatment of anxiety (Linden et al. 
2002; Duvoisin et al. 2005). 
Only one study has reported positive association of mGluR4 (GRM4) with bipolar 
disorder and schizophrenia (Fallin et al. 2005). Genetic studies on GRM8 are limited 
with inconsistent positive association reports with schizophrenia (Bolonna et al. 
2001; Takaki et al. 2004). Elia et al. (2011) investigated CNVs in ADHD and 
reported deletions in GRM8 that were found only in patients. 
Several studies have investigated the relationship between GRM7 and 
neuropsychiatric diosrders. Linkage studies (Pulver et al. 1995) and meta-analysis 
(Lewis et al. 2003) have implicated the GRM7 region, 3p26.1-p25.1 in susceptibility 
to schizophrenia. Furthermore, independent studies have confirmed the association 
between GRM7 and schizophrenia (Bolonna et al. 2001; Ohtsuki et al. 2008; Ganda 
et al. 2009; Shibata et al. 2009). In a recent GWAS of personality traits in bipolar 
patients GRM7 was significantly associated with neuroticism and anxiety (Alliey-
Rodriguez et al. 2011). Although not genome-wide significant, GRM7 was found to 
be nominally and consistently associated with bipolar disorder in several GWAS 
(WTCCC 2007; Baum et al. 2008; Ferreira et al. 2008; Sklar et al. 2008). A recent 
GWAS of response to methylphenidate in children with ADHD found suggestive 
evidence of association with a GRM7 SNP (Mick et al. 2008). CNV studies in 
schizophrenia, ADHD and bipolar disorder have also repeatedly implicated GRM7 
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(WTCCC 2007; Shibata et al. 2009; Zhang et al. 2009; Saus et al. 2010; Elia et al. 
2011; McQuillin et al. 2011). 
Genetic studies have demonstrated that mice carrying the GRM7
BALB/cJ
 gene variant 
had higher abundance of GRM7 mRNA in the brain, and lower level of alcohol 
preference drinking when compared with mice carrying the GRM7
B6By
 variant on the 
same genetic background (Vadasz et al. 2007). A study by Simonyi et al. (2000) 
revealed that chronic exposure of rats to alcohol caused a substantial decrease in the 
mGluR7 levels in the CA3 region of the hippocampus whereas another study by 
Gyetvai et al.(2011) showed that GRM7 knockout mice expressed increased alcohol 
consumption. These findings suggest that constitutively low GRM7 expression may 
contribute to the predisposition to excessive alcohol self-administration in these 
animals. mGluR7 has also been implicated in animal models of addiction (Li et al. 
2010a). 
It is widely hypothesised that the development of depression and anxiety disorders 
can be traced back to chronic exposure to stress and stressful life events (O'Connor 
et al. 2010). Additionally, chronic exposure to stress may induce long-term 
vulnerability to cognitive deficits in later life (Lupien et al. 2009) whereas acute 
activation of the stress systems during learning can facilitate memory consolidation 
(Sandi 2004). It is possible that a number of converging cellular targets, including 
mGluR7, influence the manifestation of plasticity in specific brain regions coincident 
with stress- and glucocorticoid-related cognitive and psychiatric alterations (Lupien 
et al. 2009). Experiments using mGluR7 agonist AMN082 (N, N_-Bis 
(diphenylmethyl)-1,2-ethanediamine) in rats showed that mGluR7 activation 
attenuated LTP in the amygdala. Another interesting observation is that extinction of 
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fear is due to the formation of new memories, and mGluR7 knockout animal studies 
suggest that the receptor plays an essential role in fear extinction (Callaerts-Vegh et 
al. 2006). RNA interference mediated mGluR7 knockdown led to impairment in the 
extinction of conditioned taste aversion learning (Fendt et al. 2008). Interestingly, 
AMN082 administration causes both impairment in the acquisition of fear and fear 
extinction, processes of active learning (Fendt et al. 2008). These contradictory 
results might be explained by differential expression of mGluR7 in brain regions, the 
amygdala being responsible for acquisition of fear while the prefrontal cortex for 
extinction learning (O'Connor et al. 2010). 
Pharmacological studies of group III mGluRs are limited because of the lack of 
subtype specific and bioavailable pharmacological tools. Thus, the role of these 
receptors in anxiety and depression along with the potential anxiolytic and 
antidepressant-like effects of their ligands require more development. 
Antidepressant-like effects were observed for the group III mGluR agonist ACPT-I 
[(1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid] in the forced-swim test 
and these effects were antagonized by group III mGluR antagonist CPPG [(RS)-
alpha-cyclopropyl-4-phosphonophenyl glycine] (Hashimoto 2011). Administration 
of a systemically active, potent and specific mGluR7 agonist, AMN082, elevated 
plasma levels of corticosterone and adrenocorticotropic hormone (ACTH) in control 
animals and not in mGluR7 deficient mice (Mitsukawa et al. 2005). However, in the 
same study increased levels of glucocorticoid receptors and 5-HT1A receptors in the 
hippocampus of mGluR7 deficient mice were reported suggesting increased negative 
feedback action of the HPA axis leading to suppression of HPA hyperactivity and to 
an antidepressant and anxiolytic phenotype (Mitsukawa et al. 2005). In another 
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similar study, AMN082 showed antidepressant-like effects without altering the 
behaviour of the mice suggesting that mGluR7 is involved in the antidepressant-like 
activity of AMN082 (Palucha et al. 2007). The first selective mGluR7 antagonist 
MMPIP (6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo[4,5-c]pyridin-
4(5H)-one hydrochloride) was reported by Suzuki and colleagues but no in vivo 
studies of this drug have been carried out (Suzuki et al. 2007). Furthermore, evidence 
from clinical and preclinical studies have emphasized the role of group III 
presynaptic mGluRs in reversing motor deficits in Parkinson's Disease (PD) and 
dopamine-deficient mice (Feeley Kearney and Albin 2003; Lopez et al. 2007). In a 
study by Greco et al. (2009), AMN082 administration at efficacious doses reduced 
the duration of haloperidol-induced catalepsy in a mGLuR7 dependent manner in 
wild-type but not mGluR7 knockout mice. However, higher doses of AMN082 had 
no effect on the same models of PD (Greco et al. 2009). 
mGluR8 agonist (RS)-PPG ((RS)-4-phosphonophenylglycine) also showed dose-
dependent antidepressant-like effects in the forced-swim test in rats (Palucha et al. 
2004). 
In summary, our understanding of the mGluRs has grown exponentially within the 
past decade. An analysis of mGluR genes using published GWAS data is yet to be 
carried out. The magnitude and extent of the abnormalities associated with bipolar 
disorder in the glutamatergic system require further clarification. Preclinical studies 
on mGluR5 negative allosteric modulators (MPEP, MTEP), group II mGluR 
agonists (LY354740, LY544344) and group III mGluR ligands (AMN082) have 
been very encouraging regarding their antidepressant-like and anxiolytic effects. 
However, problems with efficacy and adverse effects need to be further investigated. 
96 
 
An improved understanding of the function, anatomy and localization of different 
glutamate receptors in the brain would help in developing subunit-selective agents 
necessary for improved drug treatments. 
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Chapter 2  
Aims of the Thesis 
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The main aim of the thesis was to elucidate the genetic basis of bipolar disorder by 
employing two strategies. The positional approach was exploited for localizing the 
susceptibility gene/loci in the linkage region identified in the UCL bipolar family 
linkage study. In the following sections of the thesis the association of two mGluRs 
in the UCL1 bipolar GWAS was investigated further in a replication sample (UCL2) 
and the genes were resequenced for the identification of novel rare variants 
associated with bipolar disorder. The specific aims of the thesis were: 
1. To fine map the 1p36 linkage region with increased marker density in order 
to identify the gene conferring susceptibility to bipolar affective disorder at 
this locus in the UCL1 bipolar research sample. 
2. To replicate the association of the three most significantly associated GRM7 
SNPs in the UCL1 bipolar GWAS, in the UCL2 replication sample. 
3. To resequence the GRM7 gene in a sub-sample of bipolar cases selected for 
carrying a disease haplotype in the UCL1 GWAS data and matching controls 
for the identification of rare allelic variants in GRM7 associated with bipolar 
disorder. 
4. To validate the CNVs found in the UCL1 bipolar GWAS using QRT-PCR. 
5. To replicate the UCL1 Bipolar disorder GWAS association of GRM3 gene 
by genotyping the three most significantly associated SNPs in the UCL2 
replication sample. 
6. To identify rare variants associated with bipolar disorder in the GRM3 gene 
by resequencing the gene in a sub-sample of bipolar cases carrying a disease 
haplotype in the UCL1 GWAS data and matching controls. 
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7. To examine the possible role of any aetiological base pair changes found to 
be associated with bipolar disorder in the three genes investigated in this 
study using functional assays.  
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Chapter 3  
Materials and Methods 
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3.1. General methods 
3.1.1. Research subjects 
3.1.1.1. UCL bipolar research sample 
The UCL bipolar research sample consisted of 1099 affected bipolar research 
subjects and 1152 normal comparison subjects. The research subjects were sampled 
in two cohorts and all of them gave informed signed consent. The first cohort called 
UCL1 comprised of 506 BP I cases and 510 screened normal comparison subjects 
(Sklar et al. 2008; Sklar et al. 2011; Dedman et al. 2012). The second cohort (UCL2) 
comprised of 409 BP I (69%) cases, 184 BP II cases and 642 screened and 
unscreened (75%) normal research subjects (Dedman et al. 2012). The sample of 
1152 normal comparison subjects consisted of 672 subjects screened for the absence 
of psychiatric disorders and with no first-degree relatives with a psychiatric disorder, 
and 480 randomly selected unrelated British normal subjects whose DNA was 
obtained from the European Collection of Animal Cell Cultures (ECACC, UK). The 
cases were recruited from National Health Service (NHS) psychiatric services and 
from volunteers who were members of a support organisation for sufferers of bipolar 
disorder living in South East England. The screened control subjects were recruited 
from London branches of the National Blood Service, from local NHS family doctor 
clinics and from university student volunteers. In order to reduce the likelihood of 
population stratification between the case and control samples, the bipolar disorder 
case and control recruitment was strictly based on an ancestry questionnaire. For 
selection into the study, the ancestry of both parents and all four grandparents must 
have been Irish, Welsh, Scottish or English. Jewish subjects were excluded. Subjects 
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were also included if one of the four grandparents was of European Union (EU) 
ancestry before the 2004 EU enlargement. All case and control subjects were 
interviewed using the Lifetime Version of the Schizophrenia and Affective Disorders 
Schedule (SADSL) (Spitzer 1977). This information was supplemented by material 
from case-notes. Diagnoses were assigned using the Research Diagnostic Criteria 
(RDC) (Spitzer et al. 1978). A second psychiatrist confirmed the diagnoses. All the 
bipolar research subjects were also rated with the 90-item OPCRIT checklist 
(McGuffin et al. 1991). The research was approved by the UK NHS Multicentre 
Research Ethics Committee (MREC) and National Research Ethics Service. The 
sample has been used for several previous allelic and haplotypic association studies 
as well as GWAS of bipolar disorder (Ferreira et al. 2008; Bass et al. 2009; 
McQuillin et al. 2009; Vine et al. 2009; Nyegaard et al. 2010; Curtis et al. 2011; 
Dedman et al. 2012; Kandaswamy et al. 2012). The use of microarrays with up to 
500,000 SNP markers in the GWAS allowed for an analysis of the genetic 
stratification between UCL1 cases and controls, which showed that no correction for 
population stratification was necessary (Ferreira et al. 2008; Sklar et al. 2008). DNA 
was obtained from blood samples for the cases and controls in UCL1 and the 
remaining screened controls in UCL2, and from saliva samples for the cases in 
UCL2. 
3.1.1.2. UCL schizophrenia research sample 
The UCL schizophrenia research sample consisted of 617 affected research subjects 
recruited from the UK NHS psychiatric services. The subjects were selected based 
on a strict ancestry questionnaire used for selecting UCL bipolar cases described in 
section 3.1.1.1. Ethical approval was obtained from the UK NHS MREC and local 
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research ethics centre. All subjects signed an approved consent after reading an 
information sheet. All the schizophrenia cases were selected for having an ICD-10 
(WHO 1993) diagnosis of schizophrenia recorded in the NHS medical case-notes. 
Research subjects with short-term drug-induced psychoses, learning disabilities, 
head injuries and other symptomatic psychoses were excluded. All the affected 
research subjects were interviewed by a psychiatrist using the Lifetime Version of 
the SADS-L (Spitzer 1977). The cases were also rated using the 90-item OPCRIT 
checklist (McGuffin et al. 1991) and the diagnoses were assigned using RDC 
(Spitzer et al. 1978). Blood was collected from the subjects and the DNA was 
extracted. 
3.1.1.3. UCL alcohol dependence research sample 
The alcohol dependence sample consisted of 976 research subjects sampled in two 
cohorts and all of them gave informed signed consent. The first collection of subjects 
was recruited from the Centre for Hepatology at the Royal Free Hampstead NHS 
Trust between 1997 and 2008. The second wave of samples were recruited from 
several community substance misuse services including the Bexley Substance 
Misuse Service, South London and Maudsley Alcoholism Service, East Herts 
Community Drug Action Team and the Max Glatt Unit. All the patients fulfilled the 
criteria for a diagnosis of alcohol dependence using DSM-IV (APA 1994) or ICD-10 
(WHO 1993). None of the patients was currently misusing illegal drugs. The 
selection of the alcohol dependence subjects was also based on a strict ancestry 
questionnaire similar to the UCL bipolar research sample described in section 
3.1.1.1. 
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3.1.2. DNA extraction 
3.1.2.1. DNA extraction from blood samples 
Genomic DNA was extracted from whole blood samples using a standard 
phenol/chloroform extraction method that ran over two days. Isolation of leukocytes 
followed by lysis to release the genomic material was performed on the first day of 
extraction. Following an overnight digestion of proteins with proteinase K, the 
genomic DNA was extracted on the subsequent day.  
Day I 
The blood samples stored at -80
o
C were allowed to gently thaw in a water bath at 30-
35
o
C. This was done to prevent the cells from lysing due to shock and from the 
release of damaging enzymes such as DNase. The thawed blood was then stored on 
ice followed by a transfer to 50 ml falcon tubes and topped up to 50 ml with 1X lysis 
buffer. The tube was inverted several times to ensure mixing. The lysis buffer breaks 
up the whole red blood cells (erythrocytes) whilst leaving the DNA containing white 
blood cells (leukocytes) intact. The lysate was then spun in a centrifuge at 2000 g at 
4
o
C for 15 minutes to pellet out the white blood cells. The pellet was resuspended in 
50 ml of 1X lysis buffer to remove any remaining red blood cells and again 
centrifuged at 2000 g for 15 minutes. The cleaned white blood cell pellet was 
resuspended in 10 ml of proteinase K buffer and 500 µl of 10% sodium dodecyl 
sulfate (SDS). The proteinase K buffer provides stable optimum conditions for the 
proteinase K enzyme while SDS breaks open the cells by disrupting the lipid 
membrane, thus releasing the cell's contents including the genomic DNA into the 
solution. 50 µl of proteinase K was added to the lysate, which aids in the efficient 
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removal of complex proteins by digesting them and also deactivates any damaging 
enzymes such as DNases and RNases. The lysate was then incubated in a water bath 
at 55
o
C (just below the optimum temperature of proteinase K at 65
o
C) on a shaking 
platform overnight. Meanwhile, 1 g of PVPP (Polyvinylpolypyrrolidine) was 
weighed out into a fresh falcon tube and 5ml TE was added to it. These PVPP-TE 
containing tubes were also incubated overnight in a water bath at 55
o
C. 
Day II 
The cell lysate was transferred to the falcon tube containing PVPP dissolved in TE. 
To this mixture, 5 ml of buffered phenol along with 5ml of 1:24 Isoamyl alcohol: 
chloroform mix was added. The phenol-chloroform mixture dissolves the lipids and 
agglomerates the proteins. The mixture was then centrifuged at room temperature for 
15 min at 2000 g that allows the mixture to separate out into an organic solvent 
(phenol-chloroform) layer at the bottom (containing lipids), a protein interphase, and 
a top aqueous layer containing the nucleic acid. On centrifugation, PVPP holds down 
the protein interphase along with the organic solvents allowing the maximum 
removal of the aqueous layer without contamination. This aqueous layer was 
carefully transferred into a fresh and labelled 50 ml falcon tube for DNA 
precipitation. The organic solvents were disposed off safely in accordance with 
UCL’s health and safety disposal of hazardous solvents protocol. The DNA was 
precipitated from this aqueous layer by adding 1500 µl of 3M sodium acetate and 30 
ml of absolute ethanol. The tube was inverted gently until the DNA precipitated out 
of the solution into a condensed white clump. The DNA clump was removed with a 
plastic rod and then washed in 70% ethanol to remove as much sodium acetate as 
possible to prevent interference with the Polymerase Chain Reaction (PCR). The 
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DNA clump was then transferred into a labelled 1.5 ml microcentrifuge tube 
containing 500 µl of low EDTA TE. The DNA samples were stored at room 
temperature for about a week to allow the DNA to dissolve into the solution before 
quantification.  
3.1.2.2. DNA extraction from saliva samples 
The Oragene DNA Self-Collection Kit (DNA Genotek) is a non-invasive method of 
collecting DNA samples from patients. This is an all-in-one system for the 
collection, preservation, transportation and purification of DNA from saliva. Donor 
patients give a saliva sample into the base of an Oragene sample collection kit. The 
lid of the container has a preservative which stabilizes the DNA, and allows the 
samples to be kept up to 5 years at room temperature. The preservative in the lid is 
immediately released when the lid is tightened after the saliva collection.  
DNA from the saliva samples was extracted according to the manufacturer's 
instructions. The saliva sample container was incubated in a water bath at 50
o
C 
overnight or for a minimum of 1 hour. This heat-treatment step maximizes DNA 
yield and ensures that nucleases are permanently inactivated. 160 µl of Oragene 
DNA Purifier was added to 4 ml of sample and the mixture was incubated on ice for 
10 minutes. The samples were centrifuged at 13000 rpm for 10 minutes at room 
temperature. The clear supernatant was transferred to a fresh centrifuge tube and the 
pellet was discarded. Equal volume of room temperature absolute ethanol was added 
to the supernatant and the contents were mixed gently by inversion. The samples 
were mixed well until a DNA precipitate could be seen and the sample was left 
standing at room temperature for 10 minutes to allow the DNA to fully precipitate. 
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The samples were then spun in a centrifuge at 3000 g for 10 minutes at room 
temperature. The supernatant was discarded and the DNA pellet was washed using 1 
ml of 70% ethanol and then left to dry. The DNA was rehydrated in 500µl of TE 
containing microcentrifuge tube and stored at room temperature for a week. 
3.1.3. DNA quantification 
All DNA samples were quantified using Picogreen (Molecular Probes) on an LC480 
(Roche Diagnostics Ltd, UK). Picogreen is an ultra-sensitive fluorescent nucleic acid 
stain that specifically binds to double stranded DNA (dsDNA) and aids in the 
quantification of dsDNA. Dilutions of the DNA samples were prepared by adding 2 
µl of the stock DNA to 78 µl of TE and used as a working stock. In a 384-well 
Roche PCR plate, 2 µl of the working stock of DNA sample was dispensed into 
wells containing 8 µl of TE. Alongside, known concentrations of DNA derived from 
calf thymus were dispensed in a series of wells in order to produce a standard curve. 
The known concentrations used to prepare the standard curve were 0, 1, 2, 5, 10, 15, 
20 ng/µl. Fresh PicoGreen working solution was prepared everytime by diluting the 
PicoGreen reagent 1:200 in TE. Equal volume (10 µl) of PicoGreen working stock 
was added to each well containing known and unknown DNA samples and mixed 
well. The 384-well plate was then sealed and spun in a centrifuge at 1000 rpm for 1 
minute and read on an LC480 to quantify the DNA. The fluorescence is directly 
proportional to the quantity of DNA present. The standard curve was then plotted 
and used to derive the concentrations of the unknown DNA samples. Based on the 
results, dilutions of 25 ng/µl were prepared for all DNA samples and stored under 
5
o
C, thereby forming the working stock. The remaining DNA was stored as stock at 
-20
o
C.  
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3.1.4. Polymerase chain reaction 
3.1.4.1. Primer design guidelines 
1. The optimal length of the primers is 18-22 bp. 
2. The forward primer sequence is complimentary to the reverse strand of DNA 
and the reverse primer to the leading strand. 
3. The GC content of the primer sequence is kept within 40-60%. 
4. The absence of stop codons (either TTA at the 3' end or TAG/TAA/TGA at 
the 5' end) is maintained. 
5. The primer does not end with a T because the Taq DNA polymerase does not 
bind well and therefore is prone to mispriming. 
6. The melting temperature (Tm) of the primer is the temperature at which one 
half of the DNA duplex dissociates to become single stranded, which 
indicates duplex stability. The optimal Tm is 55-65
o
C. Ideally, the Tms of the 
two primers is within 5
o
C of each other. The Tm is calculated using the 
formula: 
Tm = [(2
o
C x AT) + (4
o
C x CG)] - 2 
7. GC clamp is the presence of G or C bases within the last five bases from the 
3′ end of the primers and it helps to promote specific binding at the 3′ end 
due to stronger bonding of G and C bases. More than 3 G's or C's should be 
avoided in the last 5 bases at the 3′ end of the primer. 
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8. Absence of hairpins or dimerization in primers is required. 
9. Repeats along with long runs of a single base are avoided. 
Primers were designed using Primer 3 software 3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). NetPrimer (Premier Biosoft) 
(http://www.premierbiosoft.com/servlet/com.pbi.crm.clientside.FreeToolLoginServl
et#), a free primer analysis software that analyzes primers for amplification related 
properties such as Tm, GC %, secondary structures, 3′ end stability etc., was used to 
determine the quality of the primers. For difficult regions such as GC rich regions 
and regions with repeats, the primers were designed by using the general guidelines 
described above. 
3.1.4.2. General PCR principle 
A conventional PCR consists of three steps - DNA denaturation, primer annealing 
and polymerase extension. The denaturation step, usually performed at 95
o
C for 
about 30 seconds to 5 minutes, renders all the dsDNA in the reaction mix to become 
single stranded. The optimal annealing temperature is about 5
o
C lower than the 
primer-template Tm and the extension temperature is calculated based on one minute 
per kb of DNA to be amplified. Optimal primer sequences and primer concentrations 
are essential for the maximal specificity and efficiency of PCR. Limited primer 
concentration adversely affects the efficiency of PCR whereas too high primer 
concentration increases the chance of mispriming and the subsequent extension of 
misprimed molecules results in nonspecific PCR products. The optimal primer 
concentration for most PCR applications is between 0.1 and 0.5 µM. PCR buffers 
contain cations such as K
+ 
and NH4
+
 that neutralize the negatively charged phosphate 
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groups on the DNA backbone thereby, weakening the electrorepulsive forces 
between the DNA strands. This reduction of the repulsive forces facilitates the 
annealing process between the primer and the template and maintains a high ratio of 
specific to nonspecific primer-template binding over a wide temperature range. 
Addition of Magnesium ions (Mg
2+
) to the reaction mix stabilizes primer annealing, 
influences enzyme activity and increases the Tm of dsDNA. Mg
2+
 also forms soluble 
complexes with (deoxynucleoside triphosphate) dNTPs in the reaction mix to 
produce the actual substrate that the polymerase recognizes. The optimal 
concentration for each dNTP to minimize polymerase error is 200 µM. Adjuvants 
such as dimethyl sulfoxide (DMSO), betaine, and glycerol are sometimes used to 
improve the amplification efficiency by melting the secondary structures and 
decreasing non-specific products. 
3.1.4.3. General PCR optimisation 
The optimisation of primers was performed using four common master mix 
conditions to optimise MgCl2 concentration and the presence or absence of betaine 
(Table 3.1) on MWG-HT Primus 96 thermocycler. Three standard PCR programs, 
Standard 55
o
C, Standard 60
o
C and Touchdown, were used to amplify the PCR 
products. The annealing temperature and the number of cycles were adjusted in these 
protocols in order to obtain the best PCR condition to amplify the target region. The 
three cycling conditions used for PCR optimisation are described in Table 3.2. 
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Table 3.1 PCR primer optimisation layout 
Component 
Volume (µl) 
2 mM MgCl2 
+ Betaine 
2 mM MgCl2 + 
No Betaine 
2.5 mM MgCl2 + 
Betaine 
2.5 mM MgCl2 
+ No Betaine 
10 X Buffer 2.5 2.5 2.5 2.5 
Betaine 5M 5 0 5 0 
50 mM MgCl2 1 1 1.25 1.25 
25 mM dNTP 0.2 0.2 0.2 0.2 
F primer (10 pmol/µl) 1 1 1 1 
R primer (10 pmol/µl) 1 1 1 1 
Taq polymerase (1 U/µl) 0.5 0.5 0.5 0.5 
DNA 25 ng/µl 2 2 2 2 
Water 11.8 16.8 11.55 16.55 
Total volume 25 25 25 25 
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Table 3.2 The PCR cycling conditions used for optimisation 
  
Standard 55
o
C (STD55) Standard 60
o
C (STD60) Touch Down (MHTD) 
Lid heated to 105
 o
C Lid heated to 105
 o
C Lid heated to 105
 o
C 
Products denatured at 94
 
o
C for 5 minutes 
Products denatured at 94
 
o
C for 5 minutes 
Products denatured at 94
 
o
C for 5 minutes 
35 cycles of 35 cycles of 3 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 94
o
C - 30 seconds 
55
o
C - 30 seconds 60
o
C - 30 seconds 63
o
C - 30 seconds 
72
o
C - 30 seconds 72
o
C - 30 seconds 72
o
C - 30 seconds 
  3 cycles of 
Hold at 72
o
C - 10 minutes Hold at 72
o
C - 10 minutes 94
o
C - 30 seconds 
Store at 4
o
C Store at 4
o
C 60
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  57
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  54
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  51
o
C - 30 seconds 
  72
o
C - 30 seconds 
  3 cycles of 
  94
o
C - 30 seconds 
  48
o
C - 30 seconds 
  72
o
C - 30 seconds 
   
  Hold at 72
o
C - 10 
minutes 
  Store at 4
o
C 
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3.1.4.4. Detection of PCR products using agarose gel 
electrophoresis 
During electrophoresis, the mobility of a molecule in an electric field is inversely 
proportional to molecular friction, which is the result of its molecular size and shape, 
and directly proportional to the voltage and charge of the molecule. For the gel, 
appropriate amount of agarose (1% w/v) was weighted into a conical flask and the 
required volume of 1X TBE was added. The solution was boiled in a microwave 
oven for one minute to dissolve the agarose completely and then cooled down to 
around 50
o
C - 60
o
C. A 10 mg/ml stock solution of the gel staining dye ethidium 
bromide was prepared and added to the gel at a final concentration of 0.5 μg/ml. The 
gel was then poured into a casting tray containing selected combs and allowed to set 
for 20-30 minutes. Upon solidification, the combs were removed and the gel was 
transferred to the electrophoresis gel tank and 1X TBE was added to fill the buffer 
tanks just enough to cover the gel. Biotaq red DNA polymerase contains a red dye 
that eliminates the need for loading buffer and provides sufficient density to the 
samples so that they can be loaded directly onto the agarose gel. Thus, 5 µl of the 
PCR products and Hyperladder IV or Hyperladder I (Bioline, UK), the molecular 
size marker, were pipetted into separate wells. The electophoresis apparatus was then 
connected toa power supply and run at 120 V for 30 minutes. After the 
electrophoresis, the gel was visualized under a UV transilluminator (UVP Gel-doc-it 
Imaging systems, UK) and the image was captured using a camera attached to the 
gel doc system. 
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3.1.4.5. Purification of general PCR procucts 
The PCR products were purified using MicroCLEAN (Microzone Limited, UK). 
MicroCLEAN is a DNA clean-up reagent that purifies or concentrates dsDNA from 
reaction buffers, enzymes, primers, primer dimers or dNTPs that can interfere during 
the sequencing reaction. 
MicroCLEAN protocol for tubes 
An equal volume of microCLEAN was added to the DNA sample. The solution was 
mixed using a vortex and left at room temperature for 5 minutes. The DNA-
microCLEAN solution in the tubes was spun in a microcentrifuge at 13000 rpm for 7 
minutes. The supernatant was removed and the tubes were spun again briefly to 
remove all the liquid. The pellet was resuspended in 5 µl of PCR water (Sigma-
Aldrich, UK) and allowed to rehydrate for 5 minutes at room temperature for further 
usage. 
MicroCLEAN protocol for 96 well plates 
An equal volume of microCLEAN was added to the DNA sample and the solution 
was mixed using a Mixmate (Eppendorf, Germany). The sample mix was spun in a 
centrifuge at 4000 g for 40 minutes. The supernatant was removed by placing the 
plates upside down on a tissue in the centrifuge holder and spinning at 1000 g for 30 
seconds. The pellet was resuspended in 5 µl PCR water and left at room temperature 
to rehydrate. 
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3.1.5. DNA Sequencing 
3.1.5.1. Big Dye sequencing reaction 
Big Dye terminator sequencing, similar to the Sanger-Coulson sequencing, is a 
fluorescence-based cycle sequencing method. This method uses fluorescent dyes to 
label the extension products, where the components are combined in a reaction that 
is subjected to cycles of annealing, extension, and denaturation in a thermal cycler. 
Thermal cycling of the sequencing reactions creates and amplifies extension 
products that are terminated by one of the four dideoxynucleotides. The ratio of 
deoxynucleotides to dideoxynucleotides is optimized to produce a balanced 
population of long and short extension products. Because each dye emits a unique 
wavelength when excited by light, the fluorescent dye on the extension product 
identifies the 3′ terminal dideoxynucleotide as A, C, G or T (Figure 3.1). 
 
Figure 3.1 Schematic representation of Big Dye sequencing procedure 
(Taken from Big Dye Sequencing kit 3.1 manual, Applied Biosystems, UK) 
The region of interest was amplified under optimum conditions using forward and 
reverse M13 tailed primers and the products were purified using microCLEAN 
(described in section 3.1.4.5) and resuspended in 5 µlof PCR water (Sigma-Aldrich, 
UK). Sequencing PCR was carried out using the resuspended amplified products and 
Third party copyright material 
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the Big Dye Terminator v3.1 sequencing kit (Applied Biosystems, UK) according to 
manufacturer's instructions. Two reactions for each sample, one using M13 forward 
primer and one with M13 reverse primer were performed for each sample using the 
reaction mix (Table 3.3) and the cycling conditions described below. 
Table 3.3 Reaction mix used for Big Dye sequencing reaction 
Reagent Final concentration Volume (µl) 
Terminator ready reaction mix 1X 1 
BigDye Sequencing buffer 5X 1X 1.5 
10µM M13 primer F/R  0.32 pmol 0.32 
Template (0.5-1 kb PCR product) (5-20ng) 1 
Water  6.18 
Total volume  10 
 
The cycling conditions used for Big Dye sequencing were: 
 Heat the lid to 105oC 
 Initial denaturation 
94
o
C for 5 minutes 
 25 Cycles of 
96
o
C - 10 seconds 
50
o
C - 5 seconds 
60
o
C - 4 minutes 
 Store the reactions at 4oC
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3.1.5.2. Purification of extension products from 
sequencing PCR 
The salts and unincorporated dye terminators were removed from the extension 
products prior to electrophoresis to obtain clean sequencing data. Purification of the 
extended products in 96-well plates was carried out using the ethanol/EDTA 
precipitation method. To each 10 µl reaction, 2.5µl of 125 mM EDTA and 30 µl of 
absolute ethanol were added. The reaction mix was mixed using a MixMate and left 
at room temperature for 10 minutes to allow the precipitation of the extension 
products. The reactions were spun in a centrifuge at 3000 g for 60 minutes. The 
supernatant was discarded by inverting the reaction plate on a paper towel and 
spinning at 1000 g for 1 minute. A 70% wash step was performed on the reaction 
plate by adding 30 µl of 70% ethanol to each pellet and spinnig at 3000 g for 10 
minutes. The supernatant was again discarded as described above using a paper 
towel. The reaction plate was left at room temperature for 15 minutes to evaporate 
off any residual ethanol. The pellets were resuspended in 15 µl of Hi-Di™ 
formamide per well and sent off for sequencing at the Center of Comparative 
Genomics, Department of Biology, UCL and the NHS North East Thames Regional 
Genetics Laboratory, London. The samples were run on the 3730xl DNA Analyzer 
(Applied Biosystems, UK) (Figure 3.2). 
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Figure 3.2 Representation of the Applied Biosystems 3730xl DNA Analyzer run 
cycle 
(Taken from ABI Sequencing manual) 
3.1.5.3. Analysis of sequencing data 
The sequencing data was analysed using the Staden Package (Staden 1996). The 
assembly program consists of Gap4 and Pregap4. Gap4 performs assembly, contig 
joining, assembly checking, repeat searching, experiment suggestion, read pair 
analysis and contig editing. Pregap4 provides a graphical user interface to set up the 
processing required to prepare trace data for assembly or analysis. 
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3.1.6 Genotyping of genetic markers 
3.1.6.1. Genotyping of microsatellite markers 
Primer design for amplification of microsatellites 
Tailed primer approach was used for the amplification of the STRs or the 
microsatellites. One of the primers was synthesized with an M13 forward or reverse 
primer sequence on the 5' end. The PCR products were labeled during amplification 
by incorporating an IRDye-labeled M13 (700 or 800 nm) primer that was included in 
the PCR reaction. Li-Cor M13 forward and reverse primer sequences are as follows: 
Forward IRDye 800-labeled primer, 19-mer: 5'-CACGACGTTGTAAAACGAC-3′ 
Reverse IRDye 800-labeled primer, 20-mer: 5'-GGATAACAATTTCACACAGG-3′ 
Amplification of microsatellites by PCR 
Genomic DNA was amplified by PCR under specific temperature and cycling 
conditions for each pair of oligonucleotide primers. The PCR reaction for each DNA 
sample was prepared by mixing all the components described in Table 3.4. 
Table 3.4 Reaction mix for amplification of microsatellites 
Component Final concentration Volume (µl) 
10X buffer 1X 1 
Betaine  2 
50 mM MgCl2 2.5 mM 0.5 
25 mM dNTPs 0.25 mM 1 
10 µM F primer 1 µM 1 
10 µM R primer 10 µM 1 
5 µM M13 primer (700/800) 0.5 µM 1 
Taq 1 U/µl 0.2 U 0.2 
DNA (25 ng/µl) 50 ng 2 
dH2O  0.3 
Total Volume  10 
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The cycling conditions STD55 or MHTD were used for the amplification of the 
microsatellites as described previously in section 3.1.4.3. Where possible, markers 
were designed to be pooled together so that markers with differing allele size ranges 
could be run simultaneously on each wavelength. This strategy was not only cost-
effective but also less time-consuming. PCR products were then prepared for 
electrophoresis. 
Detection of amplified microsatellites using polyacrylamide gel 
electrophoresis (PAGE) 
SequaGel XR system, used for preparing the polyacrylamide gel, consists of two 
components: 
(i) SequaGel XR monomer solution containing urea as well as acrylamide and 
acrylamide derivatives in a propreitary ratio dissolved in deionized distilled water, 
and 
(ii) SequaGel complete buffer solution containing 5X TBE and TEMED in deionized 
distilled water. 
The two components were mixed together to form the SequaGel mix, which was 
used within one month. 
Microsatellite allele sizes were resolved by PAGE on dual laser LiCor 4200L 
(LiCor, UK) sequencers that detect IRDye 700 and IRDye 800 at the same time 
without spectral overlap between detection channels. The IRDye infrared dye-
labeled products separate according to their sizes on an acrylamide gel. A solid-state 
diode laser excites the infrared dye on the DNA as it migrates past the detector 
window. A focusing fluorescence microscope containing a solid-state silicon 
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avalanche photodiode scans back and forth across the width of the gel collecting data 
in real time. 
Assembling the gel apparatus 
The 25 cm glass plates and 2 mm spacers were thoroughly cleaned and rinsed with 
deionized water and ethanol to remove any grease spots. The plates were air dried 
and assembled with spacers in a gel caster. The gel solution was prepared by adding 
200 µl of 10% APS to 25 ml SequaGel XR mix. This solution was stirred well and 
poured into the plates using a 50 ml syringe and a rectangular comb was gently 
inserted that later forms a trough. The gel was allowed to set for 30 minutes. Once 
the gel was set, the comb was removed, trough was cleaned and the sharktooth comb 
was inserted for loading the samples. The plates were again cleaned using deionized 
water and ethanol and placed in the LiCor 4200 sequencer. The upper and lower 
buffer tanks were filled with 1X TBE and the lids were placed. The connectors on 
the buffer tanks were fully inserted into their respective places and the gel was pre-
run for 15 minutes. During the pre-electrophoresis run, Quick SequenceIR software 
automates the processes of focusing, autogain and setting the electrophoresis 
parameters.  
Preparation and loading of the samples 
The gel was pre-heated to 45
o
C and run at a constant voltage of 1200V for 15 
minutes to prevent the formation of secondary structure and allow the linear DNA to 
run in proportion to its size. An equal volume of 0.001 % fuchsin (w/v fuchsin 
dissolved in formaldehyde) (Sigma-Aldrich, UK) loading buffer was added to the 
samples and the samples were denatured at 95
o
C for 3 minutes immediately before 
loading. Using an 8 channel Hamilton syringe, the denatured samples and an IRD-
122 
 
labeled DNA size standard MicroSTEP20a (Microzone, UK) were loaded into the 
sample wells. The DNA size standard was loaded every 15 samples to assist the 
sizing of allelic fragments. The fragment sizes of the molecular weight standard were 
- 70, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 310, 330, 340, 350, 
360, 380 and 400 bp. 
Running the gel 
The gel was run at 1200V for approximately 2 hrs. 
Genotyping data analysis 
The fluorescent images were analysed using SAGA-GT software (LiCor, 
Cambridge, UK) (Figure 3.3). SAGA
GT
 is an advanced genotyping software that 
automates electrophoresis, lane finding, location of standards, calibration of band 
sizes, and allele scoring. Genotypes were read by two independent assessors blind to 
each other’s genotypes and blind to diagnosis. The genotypes that could not be 
agreed upon were repeated. The genotyping data for each marker from SAGA
GT 
was 
finally input into Microsoft Access database and analysed for conflicts arising from 
individuals who have been genotyped more than once. After resolving the conflicts, 
the final data was used for association and haplotype analysis. 
 
Figure 3.3 An example of a genotyping gel for a microsatellite marker 
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3.1.6.2. SNP genotyping 
SNP genotyping for common SNPs was performed by allele-specific PCR at 
KBiosciences using KASPar reagents (Kbiosciences, Hoddesdon, UK). SNP 
genotyping for rare variants was performed in-house using KASPar and High 
Resolution Melting Curve analysis (HRM) techniques.  
3.1.6.2.1. KASPar genotyping assay 
Primer design for KASPar assay 
The primers for SNPs were designed using the primer picker software provided by 
KBiosciences. A sequence containing the SNP along with 25 bases on each side was 
pasted into the sequence input window and analysed using the software. The results 
provided by the primer picker software consisted of two forward primers for the 
alternate alleles of the SNP and two reverse primers. The reverse primer was 
optimised to find the best reverse primer for the KASPar assay. 
KASPar reaction 
KASP (KBioscience Competitive Allele-Specific PCR) genotyping system is a 
homogeneous, fluorescent FRET based, endpoint-genotyping technology. The KASP 
genotyping system consists of two components: 
1. Assay mix: The assay mix is comprised of three unlabelled oligonucleotides, two 
allele-specific forward primers (one for each allele of the SNP), each labelled with a 
unique unlabelled tail sequence at the 5' end and one common reverse primer. The 
composition of the allele mix is described in Table 3.5. 
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Table 3.5 Allele mix for KASPar assay 
Component 
Concentration 
in Assay Mix 
(µM) 
Volume in 
Assay Mix 
(µl) 
Allele specific primer F1 
(100µM) 
12 12 
Allele specific primer F2 
(100µM) 
12 12 
Common reverse primer R 
(100µM) 
30 30 
H2O  46 
Total  100 
2. Reaction mix (2X): The reaction mix contains Taq polymerase enzyme and the 
passive reference dye 5-carboxy-X-rhodamine, succinimidyl ester (ROX), two 5' 
fluor-labelled oligos, one labelled with FAM and the other with CAL Fluor Orange 
560, two oligos with quenchers bound at the 3′ ends. 
Principle 
During the initial stage of PCR, the allele-specific forward primer binds to the 
complementary region directly upstream of the SNP, the 5' fluor-labelled oligos 
inturn interact with the sequences of the tails of the allele-specific primers whereas 
the oligos with quenchers bound at the 3′ ends are complementary to those of the 
fluor-labelled oligos, thereby, quenching the fluorescent signal until required. The 
common reverse primer also binds to the DNA. As PCR proceeds further, one of the 
fluor-labelled oligos corresponding to the amplified allele also gets incorporated into 
the template, and is hence no longer bound to its quencher-bound complement. As 
the fluor is no longer quenched, the appropriate fluorescent signal is generated and 
detected (Figure 3.4). 
Method 
The individual primer pairs were optimised as described in Table 3.6. 
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The optimum conditions thus derived were used to carry out the PCR reaction for 
cases and controls on 384-well plates containing dried DNA. Previously, case and 
control DNA (10 ng) was dispensed individually into 384-well plates using 
Epmotion 5075 (Eppendorf, UK) and dried in a hot air oven at 50
o
C. For each 
KASPar assay, the mastermix was prepared in bulk and dispensed into the 384-well 
plates. The reactions were mixed using a Mixmate and spun in a centrifuge briefly 
before loading into LC480. The cycling conditions used for the KASPar assay are 
described in Table 3.7. 
 
Figure 3.4 Diagrammatic representation of Amplifluor genotyping 
Taken from (Bengra et al. 2002) 
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Table 3.6 KASPar optimisation layout 
Component 
Volume (µl) 
1.8 mM 
MgCl2 
2.2 mM 
MgCl2 
2.5 mM 
MgCl2 
2.8 mM 
MgCl2 
1.8 mM 
MgCl2 + 5% 
DMSO 
1.8 mM 
MgCl2 + 10% 
DMSO 
DNA (10 ng/µl) 1 1 1 1 1 1 
KASP Reaction 
mix (2x) 
2 2 2 2 2 2 
Assay mix 0.055 0.055 0.055 0.055 0.055 0.055 
MgCl2 0 0.032 0.56 0.8 0 0 
H2O 0.945 0.913 0.385 0.145 0.745 0.545 
DMSO 0 0 0 0 0.2 0.4 
Total volume  4 4 4 4 4 4 
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Table 3.7 KASPar cycling conditions - Dual colour hydrolysis probe/UPL probe program on LC480 
Program 
name 
Cycles Analysis 
mode 
Temp 
(
o
C) 
Acquisition 
mode 
Hold Ramp rate 
(
o
C/s) 
Acquisitions 
(per 
o
C) 
Sec 
Target 
(
o
C) 
Step Size (
o
C) Step delay 
(cycles) 
Hot start 
activation 
1 None 94 None 15 min      
1st 
amplification 
20 Quantification 94 None 10 s 2.5  0 0 0 
57 Single 5 s 2.5  0 0 0 
72 None 10 s 4.8  0 0 0 
2nd 
amplification 
18 Quantification 94 None 10 s 2.5  0 0 0 
57 Single 20 s 2.5  0 0 0 
72 None 40 s 4.8  0 0 0 
Reading 1 Melting 
Curves 
40 None 1 s 2.5     
41 Continuous  0.06 5    
3rd 
amplification 
3 Quantification 94 None 10 s 2.5     
57 Single 20 s 2.5     
72 None 40 s 4.8     
Reading 1 1 Melting 
Curves 
40 None 1 s 2.5     
41 Continuous  0.06 5    
4th 
amplification 
3 Quantification 94 None 10 s 2.5     
57 Single 20 s 2.5     
72 None 40 s 4.8     
Reading 2 1 Melting 
Curves 
40 None 1 s 2.5     
41 Continuous  0.06 5    
Cooling 1 None 40 None 10 s 2.5  0 0 0 
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Endpoint genotyping analysis 
The KASP assays were run on an LC480 (Roche Diagnostics Ltd, UK) and analyzed 
using the Endpoint genotyping LC480 software (Figure 3.5). 
 
Figure 3.5 An example of the endpoint analysis performed after KASPar PCR 
reaction. 
3.1.6.2.2. HRM genotyping assay 
Primer design 
Primers with melting temperatures of around 60
o
C were designed according to the 
standard protocol described in section 3.1.4.1. The primers were designed to amplify 
around 100 -250 bp of the DNA sequence surrounding the SNP and then optimised 
using available HRM mastermixes in the laboratory according to the manufacturer's 
instructions. 
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HRM reaction 
HRM analysis is a post-PCR analysis method used for fast genotyping and high-
throughput mutation scanning of disease-related genes (Herrmann et al. 2006; 
Vossen et al. 2009; Wittwer 2009). This method involves PCR in the presence of 
saturating dsDNA binding dyes such as LCGreen, EvaGreen, SyBr Green etc., 
followed by a short melting step and subsequent analysis of the melting profile of the 
amplicons to detect sequence variations. Using optimum conditions and HRM 
mastermix, the reactions were performed on a 384-well plate containing 10 ng dried 
DNA. 5 µl of HRM mastermix was dispensed and the reactions were mixed using a 
Mixmate. The 384-well plate containing the reaction mixes was briefly spun in a 
centrifuge and loaded into the LC480 and the HRM program was run. The cycling 
conditions used for HRM are described in Table 3.8. During the high-resolution 
melting step following amplification, the LC480 records a large number of 
fluorescence data points per change in temperature with high precision. This change 
of fluorescence during an experiment can be used to measure temperature- induced 
DNA dissociation during high resolution melting. The melting profile of the 
amplicon depends on the GC content, sequence, length and heterozygosity. 
Therefore, any variations in the sequence will result in heteroduplexes with a 
different melt profile compared to the wild-type sequence. 
HRM gene scanning analysis 
The data was analysed using the LC480 Gene Scanning software (Roche Diagnostics 
Ltd, UK). The software analysed the different melting profiles of the amplicons by 
first normalising the data and then temperature shifting the curves such that the 
differences in the melting temperatures between both homozygous and heterozygous 
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could be noticed. In the end, the software groups the samples according to the three 
possible genotypes (Figure 3.6). 
 
 
Figure 3.6 An example of HRM genotyping analysis 
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Table 3.8 HRM cycling conditions 
Program 
name 
Cycles Analysis mode Temp (
o
C) Acquisition 
mode 
Hold Ramp rate 
(
o
C/s) 
Acquisitions 
(per 
o
C) 
Sec Target 
(
o
C) 
Step Size 
(
o
C) 
Step delay 
(cycles) 
Pre-Incubation 1 None 95 None 10 min  None 0 0 0 
Amplification 45 Quantification 95 None 10 s 4.8  0 0 0 
65 None 15 s 2.5  53 0.5 1 
72 Single 10 s 4.8  0 0 0 
High 
Resolution 
Melting 
1 Melting Curves 95 None 1 min 4.8     
40 None 1 min 2.5     
65 None 1 s 1     
95 Continuous  0.02 25    
Cooling 1 None 40 None 10 s 2.5  0 0 0 
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3.1.6.2.3. Bioinformatic analysis of novel SNPs 
Bioinformatic analysis was carried out using the UCSC genome browser 
(http://genome.ucsc.edu/), PolyPhen-2 (genetics.bwh.harvard.edu/pph2/) (Adzhubei 
et al.) RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese/) (Fairbrother et al. 
2002), TESS (http://www.cbil.upenn.edu/cgi-bin/tess/tess) and UTRsite 
(http://utrsite.ba.itb.cnr.it/) (Grillo et al. 2010) to identify potentially novel functional 
SNPs found by resequencing genes. Bioinformatic analyses using polyphen 2 
(Adzhubei et al. 2010) were used to predict the potential damage from coding 
mutations. mFold (http://mfold.rna.albany.edu/?q=mfold) and RNAfold 
(rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) were used for predicting the RNA 
structure and RegRNA (regrna.mbc.nctu.edu.tw/) was used for predicting the 
miRNA binding sites. 
3.1.7. GWAS data 
The UCL1 research sample has been genotyped using Affymetrix GeneChip Human 
Mapping 500K Array in a collaborative GWAS (Sklar et al. 2008). A total of 506 BP 
I cases and 510 controls recruited as part of the UCL bipolar research sample were 
genotyped and the genotypes were called using the Bayesian Robust Linear Model 
with Mahalanobis distance classifier. Data analysis and quality control were 
performed using PLINK software package 
(http://pngu.mgh.harvard.edu/purcell/plink/). 
3.1.8. Imputation using 1000 genomes data 
To refine the association of the genes with bipolar disorder in the current study, I 
utilized the data from the European ancestry samples in the 1000 genomes 
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sequencing panel (www.1000genomes.org) and performed proxy association using 
PLINK. In this approach, flanking markers and haplotypes that are in strong linkage 
disequilibrium with a reference SNP are detected and tested for association with the 
disease within a haplotype-based framework. The data for SNPs in the exons and 
exon/intron boundaries of the genes was extracted from the European ancestry 
samples in the 1000 genomes database located at FTP directory 
/vol1/ftp/release/20110521 at ftp.1000genomes.ebi.ac.uk using a windows version of 
tabix. Tabix indexes a TAB-delimited genome position file 'in.tab.bgz' from a 
position sorted and compressed input data file. Tabix was run with the following 
command that was modified according to the gene: 
tabix -h 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20110521/ALL.chr.phase1_release_
v3.20101123.snps_indels_svs.genotypes.vcf.gz chr:position from-to file name.tabix 
The extracted data was pruned and the genotypes were correctly decoded and the 
codes were replaced with the alleles of the SNP. The ped and map files were created 
and merged with the SNP data from all other resources for the genes and the 
proxyassocall command on PLINK was performed. 
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3.1.9. Association and haplotypic analysis 
programs 
3.1.9.1. Haplotypic and statistical analysis for 
microsatellite markers 
Genotyping quality control was assured by genotyping 17% duplicates for cases and 
controls. A minimum call rate of 90% for the microsatellite markers and 95% for the 
SNPs was set as the standard. The final data was analysed to confirm Hardy-
Weinberg equilibrium (HWE). The markers with lack of HWE were rejected and 
repeated. Genotypic and allelic associations for SNPs were tested using χ2 tests. 
The microsatellite data was analyzed for allelic association with bipolar disorder 
using CLUMP which employs an empirical Monte Carlo test of significance and 
does not require correction for multiple alleles (Sham and Curtis 1995). Subtests of 
the CLUMP programme are: 
 T1 - Pearson's 2 statistic of the raw contingency table 
 T2 - the 2 statistic of a table with rare alleles grouped together to 
prevent small expected cell counts 
 T3 - the largest of the 2 statistics of 2 × 2 tables each of which 
compares one allele against the rest grouped together 
 T4 - the largest of the 2 statistics of all possible 2 × 2 tables 
comparing any combination of alleles against the rest.  
Tests of haplotypic association were carried out using SCANASSOC and 
GENECOUNTING. A preliminary analysis of the haplotypes was done using 
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SCANASSOC. SCANASSOC is part of the GENECOUNTING program that 
computes the maximum likelihood estimates of haplotypic frequencies from phase-
unknown data similar to GENECOUNTING. However, it does not perform 
permutation testing (Zhao et al. 2002; Curtis et al. 2006). This means that 
SCANASSOC gives a raw result but does not calculate the empirical significance of 
those results. GENECOUNTING, in addition, performs permutation testing, thereby, 
producing an empirical significance P-value (Zhao et al. 2002; Curtis et al. 2006). 
The analysis of haplotype block structure was performed using HAPLOVIEW 
(Barrett et al. 2005). GENECOUNTING was also used to calculate pairwise linkage 
disequilibrium between all markers and their relationship was viewed on LocusView 
2.0 (Petryshen and Kirby, unpublished software; 
http://www.broad.mit.edu/mpg/locusview). COMBASSOC was used to combine all 
the markers to implicate association at the level of the whole gene rather than just for 
individual markers or haplotypes. This program combines the P values from all 
single loci and/or multilocus analyses of different markers according to the formula 
of Fisher, X = Σ(−2ln(pi)), and then assesses the empirical significance of this 
statistic using permutation testing (Curtis et al. 2008). 
3.1.9.2. Haplotypic and statistical analysis for SNP 
markers 
PLINK and Haploview were used for the allelic association and haplotypic 
association analyses of SNP markers. PLINK is a free, open-source whole genome 
association analysis toolset developed by Shaun Purcell to perform basic, large-scale 
analyses in a computationally efficient manner 
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(http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml). Association analysis, 
merging datasets, and meta-analyses were performed using PLINK (Purcell et al. 
2007). Haploview (Barrett et al. 2005) was used for the haplotype analysis of SNPs. 
Haploview is a software designed to simplify and expedite the process of haplotype 
analysis by providing a common interface to several tasks relating to such analyses. 
3.1.9.3. Genetic power calculation for replication analysis 
In this thesis, UCL2 sample was used as the replication sample for testing 
association of the previously associated GWAS SNPs in UCL1 sample. Power 
calculation for the UCL2 sample performed using Genetic Power Calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html) (Purcell et al. 2003) for 
different combinations of odds ratios and minor allele frequencies are reported in 
appendix VI.  
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3.2. Methods for Chapter 4. Fine mapping 
of a new bipolar affective disorder 
locus on chromosome 1p36 
3.2.1. Research subjects 
Six hundred research subjects with bipolar disorder and 605 supernormal control 
subjects from the UCL1 cohort along with additional samples from the UCL2 cohort 
that were available during the study were used for the fine mapping of 1p36 region. 
3.2.2. Selection of genetic markers for fine 
mapping of 1p36 
Fine mapping of the 1p36 region was carried out in two stages in this study. In stage 
1, a follow-up of the previously identified linkage region, 1p36 was carried out using 
increased marker density. Four microsatellite markers on chromosome 1p36, close to 
and including the marker D1S243, which had the maximum LOD score in the UCL 
bipolar disorder family linkage study were selected. Markers PRKCZ (GT)17, 
PRKCZ(CA)13 and PRKCZ(AC)24 were identified from the UCSC Genome Browser 
database May 2004 assembly. In stage 2, single nucleotide polymorphisms (SNPs) in 
LD with PRKCZ were selected for genotyping from the HAPMAP database (Barrett 
et al. 2005; Barrett 2009) for further fine mapping of the region.  
3.2.3. Genotyping of genetic markers in 1p36 
region 
The four microsatellite markers were genotyped using the standard protocol 
described previously in section 3.1.6.1. The primers for the markers PRKCZ (GT)17, 
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PRKCZ(CA)13 and PRKCZ(AC)24 were designed using Primer 3. The sequences are 
listed in appendix III. The primer sequence for D1S243 was obtained from Ensembl. 
All four microsatellite markers were genotyped in 440 controls and 600 BPAD 
patients. 
The SNPs were genotyped in two batches as this study was carried out during a 
period of sample collection. The first batch of six SNPs (rs908742, rs3107156, 
rs3753242, rs384726, rs12134873 and rs262688) was genotyped in 600 bipolar 
disorder patients and 440 controls and the second batch comprising SNPs rs3128296, 
rs2503706 and rs12132341 was genotyped in 600 bipolar disorder patients and 554 
controls. The SNPs were genotyped using allele-specific PCR method at 
KBiosciences (Kbiosciences, Hoddesdon, UK) as described in section 3.1.6.2.1. 
3.2.4. GWAS data 
Additional data from eight SNPs genotyped in the UCL case-control sample as part 
of a GWAS (Sklar et al. 2008) in the region surrounding PRKCZ was included in the 
association analysis with bipolar disorder. 
3.2.5. Gender-based association analysis 
Gender based association analysis of all the microsatellite markers and SNPs was 
carried out using CLUMP and PLINK. For female-only and male-only analyses 
female-female case-control pairs and male-male case-control pairs were analysed 
respectively. 
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3.2.6. Association and haplotypic analysis 
Tests of allelic association were carried out using CLUMP (Sham and Curtis 1995) 
and Haploview (Barrett et al. 2005) described in section 3.1.9. Haplotype association 
analysis was carried out using the program Haploview for SNPs and 
GENECOUNTING (Curtis et al. 2006) for combinations of SNPs and 
microsatellites.
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3.3. Methods for Chapter 5. Mutation 
screening of the GRM7 glutamate 
receptor gene in Bipolar disorder 
3.3.1. Research subjects 
The UCL1 and UCL2 cohorts were used for the association study of GRM7 in 
bipolar disorder. These samples have been previously described in section 3.1.1. 
3.3.2. Selection of subjects for resequencing 
GRM7 
The most significantly associated GRM7 marker in the UCL1 GWAS was the SNP 
rs1508724 [P = 0.0028; OR (95% CI) = 1.33 (1.10 - 1.60)]. In the absence of any 
strongly associated haplotype, DNA samples from 32 bipolar research subjects 
homozygous or heterozygous for the rare allele of rs1508724 and also with an early 
age of onset of bipolar disorder were selected for sequencing. On the basis of 
previous studies by different research groups, I hypothesised that cases selected with 
early age-at-onset would provide a more homogeneous sample for the detection of 
rare variants. Also, 32 random control subjects were selected for the sequencing of 
GRM7. 
3.3.3. Resequencing GRM7 
Sequencing was carried out on 15 exons included in all the GRM7 isoforms (UCSC, 
March 2006 assembly), exon/intron boundaries, ~3 kb of the promoter region of the 
isoforms ENST00000486284(main isoform) and ENST00000463676, and 1 kb 
promoter region of the isoform ENST00000458641, 5'-UTR and 3′-UTR of the 
GRM7 gene. The sequence of primers used for sequencing is listed in appendix II. 
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Sequencing was performed and the data was analysed using the standard protocol 
described in sections 3.1.4 and 3.1.5. 
3.3.4. SNP genotyping 
The three most significantly associated GRM7 markers in the UCL1 GWAS dataset 
were genotyped in the UCL2 bipolar sample at Kbiosciences (Kbiosciences, 
Hoddesdon, UK). Novel rare varaints and potentially aetiological SNPs based on 
bioinformatic analyses described in section 3.1.6.2.3 were genotyped in the complete 
UCL sample. HRM and KASPar assays were used for genotyping SNPs as described 
in section 3.1.6.2. The primers used for the genotyping assays are listed in appendix 
III. 
3.3.5. Association and haplotype analysis 
Genotype data for the GRM7 SNPs was extracted from the UCL1 GWAS dataset 
and used in the association analysis. Genotypic and allelic associations along with 
haplotypic tests of association for SNPs were tested as described in section 3.1.9. 
Imputation of GRM7 SNPs from European sub-sample of the 1000 genomes dataset 
was performed using protocol described in section 3.1.8. 
3.3.6. CNV validation using QRT-PCR 
CNVs detected in the UCL1 samples were validated using QRT-PCR. TaqMan
®
 
RNase P Copy Number Reference (CNR) Assay, Human (Applied Biosystems, UK) 
was used for the CNV validation. In the duplex real-time PCR experiment, a UPL 
primer-probe (Universal Probe Library, Roche diagnostics Ltd, UK) combination 
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was used for the detection of the target gene (GRM7) and the TaqMan
®
 RNase P 
CNR assay was used for the detection of a reference gene (RNase P). The reference 
gene, Ribonuclease P RNA component H1 (H1RNA) gene (RPPH1) located on 
14q11.2, is known to be present in two copies in a diploid genome. The CNR assay 
was comprised of two components: 
1. two unlabeled primers for amplifying the reference sequence and 
2. one TaqMan TAMRATM probe including the VIC® reporter dye attached to 
the 5' end and a TAMRA
TM
 quencher attached to the 3′ end for detecting the 
reference sequence.  
The primer-probe pair for the amplification and detection of GRM7 was designed 
using the UPL assay design service (https://www.roche-applied-science.com) 
(Appendix IV). The UPL probe is a hydrolysis probe formed of 8-9 nucleotides and 
labelled with fluorescein (FAM) at the 5' end and a quencher at the 3′ end. 
Incorporation of Locked Nucleic Acids (LNA), DNA nucleotide analogues with 
increased binding strengths compared to standard DNA nucleotides, into the UPL 
probes helped maintain the specificity and Tm required by the qPCR probes. Each 
transcript in the human transcriptome is detected by approximately 16 different 
probes. The UPL assay design program designs an optimal set of PCR primers and a 
probe for the region of interest. For the QRT-PCR reaction, LightCycler
®
 probes 
master reaction mix containing FastStart Taq DNA polymerase for hot start PCR and 
optimal MgCl2 concentration was used. During PCR, the genomic DNA template 
was denatured and the assay primers annealed to the target sequence. The probes 
annealed specifically to the complementary sequence between forward and reverse 
primer binding sites and when intact, the reporter dye signal was quenched due to its 
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proximity to the quencher dye. With each round of PCR, the target and the reference 
sequences were amplified by the FastStart Taq DNA polymerase resulting in the 
cleavage of probes hybridized to each amplicon. As a result, the quencher was 
separated from the reporter dye, thereby, increasing the fluorescence of the reporter. 
This increase in the fluorescence of each reporter dye at each PCR cycle was 
monitored and this was proportional to the accumulated PCR products (Figure 3.7). 
For each reaction in a 384-well plate, 10 ng of template DNA, 0.2 µl each of 10 µM 
forward and reverse primers and 10 µM probe, 0.5 µl of RNase P CNR assay mix 
and PCR water were added to a total volume of 10 µl. The reaction contents were 
mixed using a MixMate and spun briefly in the centrifuge at 1000 g. The plate was 
loaded into the LC480 and the UPL Dual hydrolysis probe reaction was run. The 
cycling conditions used are described in Table 3.9. 
Table 3.9 The cycling conditions for the CNV validation assay 
Stage Temperature Time 
Hold 95
0
C 10 min 
Cycle (40 Cycles) 95
0
C 15 sec 
60
0
C 60 sec 
Data analysis was performed using the LightCycler relative quantification method.  
The relative quantification method measures the relative change in mRNA levels of 
the target and reference genes. The threshold cycle (Ct) or the crossing point is the 
cycle at which there is a significant detectable increase in fluorescence and is a 
function of the amount of starting template.
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Figure 3.7 Schematic representation of PCR detection of target and reference DNA sequences in the RNase P CNR assay 
(Taken from TaqMan® RNase P CNR assay manual). 
Third party copyright material removed 
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In the ΔΔCt method of QRT-PCR data analysis, the difference between the Ct values 
(ΔCt) of the target gene and the housekeeping gene is calculated for each 
experimental sample and then the difference in the ΔCt values between the 
experimental and control samples (ΔΔCt) is calculated. The fold-change in 
expression of the target gene between the two samples is then equal to 2
-ΔΔCt
. 
ΔΔCt = (Ct
target
 - Ct
reference
) time x - (Ct
target
 - Ct
reference
)time0 
where, timex is any time point and time0 represents the 1X expression of the target 
gene normalized to the reference gene (Livak and Schmittgen 2001) 
  
146 
 
3.4. Methods for Chapter 6. Mutation 
screening of the GRM3 glutamate 
receptor gene in bipolar disorder 
3.4.1. Genetic association of GRM3 with bipolar 
disorder 
3.4.1.1. Research subjects 
The combined sample of UCL1 and UCL2 cohorts was used for the association 
study of GRM3 in bipolar disorder. Schizophrenia and alcohol dependence 
syndrome samples were also used for association analysis of the 5′-UTR variant 
rs148754219. All these samples have been described in section 3.1.1. 
3.4.1.2. Selection of subjects for resequencing GRM3 
The G allele of rs2237563 was the most strongly associated SNP in the UCL1 
sample (P = 3.85 x 10
-5
) (Ferreira et al. 2008; Sklar et al. 2008). In the absence of 
any strongly associated haplotype, DNA from 32 bipolar research volunteers were 
selected for being homozygous or heterozygous for the G allele of rs2237563 and 32 
random normal comparison subjects were also selected for sequencing. 
3.4.1.3. Resequencing GRM3 
Sequencing was carried out on the promoter region 1000 bp upstream of the 
transcriptional start site, 5' untranslated region (UTR), the exons and intron/exon 
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junctions and the entire 3′-UTR of the GRM3 isoform 1 (NM_000840) which 
contains all 6 exons. The primer sequences used for sequencing GRM3 are listed in 
appendix II. The PCR products were amplified using the standard protocol and then 
purified using MicroCLEAN described in section 3.1.4. Sequencing was done using 
the Big Dye terminator v3.1 Cycle Sequencing kit (Applied Biosystems, UK) on an 
ABI 3730xl DNA Analyzer using the standard protocol described in section 3.1.5. 
3.4.1.4. SNP genotyping 
SNP genotyping for the three most significantly associated GRM3 SNPs, rs2237563, 
rs274621, and rs2158786, in the UCL1 bipolar disorder GWAS was performed in 
the UCL2 samples by allele-specific PCR at KBiosciences (Kbiosciences, UK). 
Novel rare varaints and potentially aetiological SNPs based on bioinformatic 
analyses described in section 3.1.6.2.3 were genotyped in the complete UCL sample 
using KASPar assay. 
3.4.1.5. Association and haplotype analysis 
Genotype data for the GRM3 SNPs was extracted from the UCL1 GWAS dataset 
and used in the association analysis. Genotypic and allelic associations along with 
haplotypic tests of association for SNPs were tested as described in section 3.1.9. 
Imputation of GRM7 SNPs from European sub-sample of the 1000 genomes dataset 
was performed using protocol described in section 3.1.8. 
Genotypic and allelic associations of SNPs were tested using χ2 tests and PLINK. 
Haplotype tests of association were performed using Haploview (Barrett et al. 2005). 
The protocol used for these analyses is described in section 3.1.9. 
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3.4.2. Functional characterization of GRM3 Kozak 
sequence variant 
3.4.2.1. Animal cell-culture 
Cell-lines 
Two human cell-lines were used in this study, HEK293 and SH-SY5Y. HEK293 
cells were a kind gift from Dr Josef Kittler and SH-SY5Y cells were obtained from 
European Collection of Animal Cell Cultures (ECACC, UK). HEK293, first 
described in 1977, is a cell-line generated by the transformation of human embryonic 
kidney cells with sheared adenovirus 5 DNA (Graham et al. 1977). Interestingly, 
speculations by scientists including Van der Eb predict that the cells may be 
neuronal in origin because of the presence of the mRNA and other proteins normally 
expressed in neuronal lineage cells (Graham et al. 1977). HEK293 cells do not 
adhere to the substrate at room temperature but re-attach to the flask over a period of 
several days in culture at 37
o
C. SH-SY5Y cell-line is a thrice-cloned neuroblastoma 
sub-line of bone marrow biopsy-derived SK-N-SH and the cells grow as a mixture of 
floating and adherent cells. These cells grow as clusters of neuroblastic cells with 
multiple, short, fine cell processes (neurites) and have a 48 hr doubling time.  
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Subculturing the cells 
HEK293 and SH-SY5Y cells were subcultured in 75cm
2
 T-flasks (Nunc, UK) after 
reaching 70 - 80% confluency. The growth medium was removed and the cells were 
washed with 2ml of 1X PBS. To detach the adherent cells from the flask surface, 1 to 
2 ml of trypsin-EDTA solution was added and the cells were incubated at 37
o
C with 
5% CO2 for 1-2 minutes. The sides of the flask were gently tapped to dislodge the 
cells and the detached cells were observed under a microscope to confirm complete 
dislodging. Immediately, 5 ml of fresh growth medium was added to the flask to stop 
the trypsinisation reaction and the cell suspension was aspirated into a fresh 15 ml 
falcon tube. The cell suspension was spun in a centrifuge at 1500 rpm for 5 minutes 
and the pellet was resuspended in 5 ml of fresh growth medium. Appropriate 
aliquots of this cell suspension were dispensed into fresh culture flasks containing 10 
ml final volume of complete growth medium and incubated at 37
o
C with 5% CO2. 
The cells were weekly subcultured in 1:5 to 1:10 ratio and the medium was changed 
every 3-5 days. 
Counting of cells using haemocytometer 
A haemocytometer is a specialised microscope slide used for estimating the number 
of cells in a measured volume under a microscope (usually blood cells). An 
improved Neubauer haemocytometer is a thick glass slide with two counting 
chambers and the main divisions separate each chamber into nine large squares 
(Figure 3.8). 
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Figure 3.8 An improved Neubauer haemocytometer 
(Taken from Haemoctymeter Instructions, Haemocytv3.doc  Dr Neville A. Punchard) 
Each square has a surface area of 1 mm
2
 and the depth of the chamber is 0.1 mm. 
With the coverslip in place, each square of the haemocytometer represents a total 
volume of 0.1 mm
3
 or 10
-4
 cm
3 
(1 cm
3
 = 1 ml). The cell suspension used for counting 
should be dilute enough to avoid clumps of cells and mixed thoroughly to ensure 
uniform distribution. The cell concentration per ml was determined using the 
following calculations: 
Cells per ml = the average count of cells per square x the dilution factor x 10
4 
Cell counting 
The surface of the haemocytometer and the coverslip was washed with 70% alcohol. 
The sides of the coverslip were moistened by breathing on the surface and aligning it 
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over the counting chamber using gentle downward pressure. The cell suspension was 
prepared using the standard protocol used for subculturing and 100 µl of the uniform 
suspension was dispensed into a sterile microcentrifuge tube. Equal volume of trypan 
blue solution (dilution factor of 2) was added to the suspension in the 
microcentrifuge tube and mixed gently by pipetting. Trypan blue is a vital dye that 
does not interact with the cells unless the membrane is damaged. Viable cells 
exclude the dye and remain colorless and cytoplasm of non-viable or dead cells take 
up the dye and turn blue. A thoroughly mixed aliquot (10-20 µl) of cell suspension 
was dispensed at the edge of the chamber allowing to fill with capillary action. The 
same process was followed for the second chamber and the haemocytometer was 
observed under the microscope using 20X magnification. Systematically, the cells in 
the four corner squares were counted excluding the cells touching the outer 
perimeter. 
Viable Cell count = Average live cell count x dilution factor x 10
4
 
Non-viable cell count = Average dead cell count x dilution factor x 10
4
 
Percentage Viability = Viable cell count / Total cell count x 100 
Cryogenic storage and recovery of cells 
Cryopreservation of cells ensures continuous supply and back up of cells in case of 
contamination and to have a lower passage number stock of cells. It is good practice 
to cryopreserve cells when they are at their maximum growth rate to aid in good 
recovery during the thawing of cells. The freezing medium was prepared using 
DMSO (Sigma-Aldrich, UK), a cryoprotective agent that reduces the freezing point 
of the medium and also allows a slower cooling rate thereby, reducing the risk of ice 
crystal formation which can damage cells. The cells were harvested using the 
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standard protocol used for subculturing and suspended in 2.5 ml of Dulbecco's 
modified eagle medium (DMEM) supplemented with 20% foetal bovine serum 
(FBS) and 1% Penstrep. In a fresh falcon tube, 20% DMSO was added to 2.5ml of 
DMEM supplemented with 20% FBS and 1X Penstrep, and this medium was then 
added drop by drop to the tube containing cells. After mixing the culture to form a 
uniform suspension 1ml aliquots of this cell suspension were dispensed into 1.5 ml 
cryogenic vials (Nunc, UK) and stored in a freezer container, Nalgene®, Mr.Frosty 
(Sigma-Aldrich, UK) at -80
o
C. The polycarbonate freezer container contains a high-
density polyethylene tube holder and foam insert. 100% isopropyl alcohol was added 
to the container and the tubes containing cells were placed into the tube holder. The 
container provides the critical and repeatable, 1
o
C/min cooling rate that is required 
for successful cryopreservation of cells. Mr. Frosty container was kept at -80
o
C 
undisturbed for a minimum of 4 hrs and then transferred to liquid nitrogen containers 
for long-term storage. The cells can be stored at -80
o
C for 6 months or in liquid 
nitrogen for 2 years. 
Thawing process 
The thawing of the cells from -80
o
C was done quickly to maximise the recovery of 
cells and minimise the loss of cells due to the presence of DMSO in the freezing 
medium. The cryovials were removed from -80
o
C freezer and immediately placed in 
a 37
o
C water bath for less than a minute or until around 80% of the suspension had 
thawed. The contents of the cryovial were pipetted into a fresh 15 ml falcon tube 
containing 5 ml pre-warmed growth medium and mixed gently by pipetting. The 
cells were centrifuged at 1500 rpm for 3 minutes and the supernatant discarded. The 
pellet was resuspended in 1 ml of growth medium and the cells were seeded in T-75 
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flask containing 9 ml of complete growth medium and incubated at 37
o
C with 5% 
CO2. 
3.4.2.2. Electromobility Shift Assay (EMSA) 
Preparation of nuclear extract from SH-SY5Y cells 
SH-SY5Y cells were grown in 75 cm
2
 T-flasks to 70-80 % confluency in the 
complete growth medium. The growth medium was removed and the cells were 
washed with cold 1X phosphate buffered saline (PBS). Two millilitres of 
cytoplasmic lysis buffer was added to each flask and the cells were harvested into 
pre-chilled 1.5 ml eppendorf tubes using cell scrapers (Nunc, UK). The cells were 
lysed by adding 90 µl of 10 % NP-40 solution to each eppendorf tube containing 1 
ml of the cells and vortexing vigorously for 10 seconds. The homogenate was then 
centrifuged at 2000 g for 10 minutes at 4
o
C and the supernatant containing the 
cytoplasmic proteins was discarded. The nuclear pellets were resuspended in 32 µl 
nuclear lysis buffer and the nuclei were disrupted by three freeze-thaw cycles in dry 
ice with ethanol and a water bath at 37
o
C. The cellular debris was removed by 
centrifugation at 13000 g for 10 minutes and the supernatant (nuclear extract) was 
stored in aliquots of 20 µl at -80
o
C. 
Protein quantification using Bradford assay 
The protein concentration of the nuclear lysate was quantified using Bradford assay 
reagent (Sigma-Aldrich, UK) according to the manufacturer's instructions. The 
reagent contains Brilliant Blue G dye that forms a complex with the proteins in the 
solution causing a shift in the absorption maximum of the dye from 465 to 595 nm. 
The amount of absorption is thus, proportional to the protein present in the solution. 
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The Bradford reagent was brought to room temperature before performing the assay 
and bovine serum albumin (BSA) was used as the protein standard. Protein standards 
of 1 µg/ml, 2 µg/ml, 5 µg/ml, 10 µg/ml, and 20 µg/ml were prepared by diluting 10 
mg/ml BSA in nuclear lysis buffer. One part of the protein sample was mixed with 
30 parts of the Bradford reagent in a disposable cuvette and incubated at room 
temperature for 5 minutes. The absorbance of the colored solution was measured at 
595 nm using a UV spectrophotometer (Pye Unicam PU8600 UV/VIS 
spectrophotometer, Philips) within 60 minutes of adding the Bradford reagent as the 
protein-dye complex is stable upto 60 minutes only. A standard curve was created to 
determine the protein concentrations of the nuclear lysate by plotting the net 
absorbance at 595 nm versus the protein standard concentrations (Figure 3.9). 
 
Figure 3.9 Standard curve for the quantification of protein concentration in the 
nuclear lysate using Bradford assay reagent 
Preparation of 4% native polyacrylamide gel 
In a 100 ml glass beaker, 5 ml of 40% polyacrylamide stock solution, 2.5 ml of 10X 
TBE, 80 µl of TEMED and 300 µl of 10% APS were added and MilliQ water was 
added to a final volume of 50 ml. The solution was mixed by swirling and poured 
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between 40 cm glass plates with 0.75 mm spacers and comb and allowed to set for 1 
hr. 
Preparation of oligos 
Oligonucleotides with the wild-type (G) and the mutant (A) allele of rs148754219 
were 5′ end-labelled with infrared dye DY-682 (Eurofins MWG, Ebersberg, 
Germany). Aliquots of 5 µl 20 pmol/µl of each pair of labelled oligonucleotides were 
denatured at 100
o
C for 3 min and slowly cooled to room temperature to generate 
dsDNA. 
Binding reaction 
The binding reaction was performed in dark at room temperature by incubating 50 
fmol of labelled double-stranded oligonucleotides with 10 µg of nuclear extract in 
1X binding buffer to a final volume of 20 µl for 30 min. Poly (dI.dC) in the binding 
buffer prevents non-specific binding of proteins in the nuclear extract to the 
oligonucleotide probes thereby reducing background. 
Electrophoresis 
One microlitre of Orange dye (10X) was added to the binding reactions and mixed 
by pipetting. The samples were then resolved by electrophoresis on a 4% native 
polyacrylamide gel at 10 V/cm at 4
o 
C in 0.5 X TBE buffer. The DNA-protein 
complex was detected on a LiCor 4200L sequencer (LiCor, Lincoln, Nebraska, 
USA). A further follow-up experiment was carried out to compete out the band 
formed by the mutant allele and determine the binding specificity by incubating 
varying amounts of unlabelled competitor probe (10X, 20X, 50X, 100X, 200X) for 
the wild-type and mutant alleles in separate tubes. The principle behind the 
competition reaction is that when excess of unlabelled DNA is added to the binding 
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reaction, it competes with the labelled DNA for binding sites and eliminates labeled 
oligo binding causing the removal of the band shift, thereby, indicating that the 
binding reaction is specific. The competition reaction experiment was repeated three 
times. 
3.4.2.3. Construction of reporter plasmids 
3.4.2.3.1. Plasmid vectors 
Vectors are carrier DNA molecules that can replicate autonomously or independent 
of host genome replication in host cells and facilitate the manipulation of a newly 
created recombinant DNA molecule. Other properties of vectors include containing a 
multiple cloning site formed of a number of unique restriction endonuclease 
cleavage sites and carrying a selectable marker to distinguish the host cells carrying 
the vectors from the host cells that do not contain a vector. 
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pJET1.2 cloning vector: The pJET1.2/blunt cloning vector (Figure 3.10) is part 
of the CloneJET
TM
 PCR Cloning kit that enables cloning of blunt and sticky ended 
DNA or PCR products generated with Pfu DNA polymerase, Taq DNA polymerase 
or any other thermostable DNA polymerases. This vector is a linearized vector that 
accepts inserts from 6 bp to 10 kb and the 5' ends of its cloning site contain 
phosphoryl groups making phosphorylation of the PCR primers unnecessary. The 
vector contains a lethal gene, which is disrupted only by successful ligation of a 
DNA insert into the cloning site due to which only recombinant plasmids are able to 
propagate. This cloning vector eliminates the need for blue/white screening as 
recircularized vector cannot propogate due to the expression of the lethal restriction 
enzyme. 
 
Figure 3.10 pJet1.2/blunt vector map 
(Taken from pJet1.2/blunt PCR cloning kit, Fermentas, UK) 
  
Third party copyright material 
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pGL3 Luciferase reporter vectors: The pGL3 luciferase reporter vectors were 
used in this study to quantitatively analyse the functional effects of a polymorphism 
in GRM3 in regulating mammalian gene expression. The backbone of the pGL3 
luciferase reporter vectors is designed for increased expression compared to pGL2 
vectors and contains a modified coding region for firefly (Photinus pyralis) 
luciferase that has been optimized for monitoring transcriptional activity in 
transfected eukaryotic cells. The pGL3 luciferase reporter vectors used in this study 
are - pGL3-basic and pGL3-promoter.  
pGL3-basic vector: pGl3-basic vector lacks the eukaryotic promoter and enhancer 
sequences thereby, allowing maximum flexibility in cloning putative regulatory 
sequences (Figure 3.11). The functional effect of a promoter polymorphism can be 
determined by observing the expression of luciferase activity in cells transfected 
with the wild-type and mutant plasmid constructs.  
 
Figure 3.11 pGL3-Basic vector map 
(Taken from pGL3 Luciferase reporters manual, Promega, UK) 
Third party copyright material 
removed 
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pGL3-promoter vector: The pGL3-promoter vector is similar to the pGL3-basic 
vector in all respects but additionally contains an SV-40 promoter upstream of the 
luciferase gene (Figure 3.12). DNA fragments containing putative enhancer elements 
can be inserted upstream or downstream of the promoter-luc+ transcriptional unit 
and the effect of polymorphisms in these regions can be explored.
 
Figure 3.12 pGL3-Promoter vector map 
(Taken from Luciferase reporters manual, Promega, UK) 
3.4.2.3.2 Amplification of PCR products for cloning into reporter plasmids 
The rs148754219 variant is located in the first exon of the gene, which is transcribed 
but not translated in the main isoform of GRM3. In the study by Corti et al. (2001) 
there is a suggestion of a silencer element being present in exon 1 of the GRM3 
gene. Furthermore, rs148754219 is at -2 position from the ATG start codon of the 
GRM3 isoform transcript (RefSeq accession no. NM_000840 ) forming part of the 
Kozak sequence for that particular transcript. Therefore, five different plasmid 
constructs were constructed to explore the possibility of the effect of this SNP on the 
transcriptional and post-transcriptional/translational regulation of the gene. 
Third party copyright material 
removed 
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(a) Amplification of 5'-UTR of GRM3 
A 972 bp PCR product comprising the whole of Exon 1 of GRM3 was amplified 
using the primers F: 5′-CTCGCAGTGTGCAGTTGAGT-3′ and R: 5′- 
CTTACCTCGCACCGACAACT - 3′ (Sigma-Aldrich, UK). In a 96-well plate, 
master mix comprising of 2.5 µl of 10X Pfx amplification buffer, 5µl of 5 M betaine, 
2.5 µl of 10X enhancer buffer, 1 µl of 50 mM MgSO4, 0.2 µl of 25 mM dNTPs, 1 µl 
each of 10pmol/µl F and R primers, 0.4 µl Platinum® Pfx DNA polymerase 
(Invitrogen, UK) and PCR water was added to a final volume of 23 µl and dispensed 
into a well containing 2µl of of genomic DNA (50 ng). Platinum® Pfx DNA 
polymerase, a highly processive polymerase that contains a 3′-5' proofreading 
exonuclease and lacks a 5'-3′ exonuclease activity, was used in the PCR reaction to 
improve the fidelity and specificity of the PCR product. All the reagents, except 25 
mM dNTPs (Bioline, UK) and betaine for the PCR, were obtained from Invitrogen, 
UK. The PCR program MHTD.pyex_1k was used to amplify the product and the 
cycling conditions are described in Table 3.10. 
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Table 3.10 Cycling conditions used for PCR amplification of GRM3 inserts for 
cloning 
MHTD.pyex_1k MHTD.pyex_2k 
Lid heated to 105
 o
C Lid heated to 105
 o
C 
Hot start at 94
 o
C for 3 
minutes 
Hot start at 94
 o
C for 3 
minutes 
3 cycles of 3 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 
63
o
C - 30 seconds 63
o
C - 30 seconds 
72
o
C - 1 minute 72
o
C - 2 minutes 30 seconds 
3 cycles of 3 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 
60
o
C - 30 seconds 60
o
C - 30 seconds 
72
o
C - 1 minute 72
o
C - 2 minutes 30 seconds 
3 cycles of 3 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 
57
o
C - 30 seconds 57
o
C - 30 seconds 
72
o
C - 1 minute 72
o
C - 2 minutes 30 seconds 
3 cycles of 3 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 
54
o
C - 30 seconds 54
o
C - 30 seconds 
72
o
C - 1 minute 72
o
C - 2 minutes 30 seconds 
3 cycles of 3 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 
51
o
C - 30 seconds 51
o
C - 30 seconds 
72
o
C - 1 minute 72
o
C - 2 minutes 30 seconds 
33 cycles of 33 cycles of 
94
o
C - 30 seconds 94
o
C - 30 seconds 
48
o
C - 30 seconds 48
o
C - 30 seconds 
72
o
C - 1 minute 72
o
C - 2 minutes 30 seconds 
  
Hold at 72
o
C - 20 minutes Hold at 72
o
C - 20 minutes 
Store at 8
o
C Store at 8
o
C 
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(b) Amplification of a 972 bp 5'-UTR with HindIII and NcoI restriction sites 
A 972 bp GRM3 5'-UTR PCR product with HindIII and NcoI restriction sites was 
amplified using the primers (Sigma-Aldrich, UK) 
F- 5′- CCTCTCAAGCTTCTCGCAGTGTGCAGTTGAGT - 3′ 
R - 5′- CTCCTCTCCATGGCTTACCTCGCACCGACAACT - 3′ 
using the standard protocol described in section 3.4.2.3.2 (a). 
(c) Amplification of 1495 bp PCR fragment comprising promoter and 5'-UTR 
of GRM3 
A 1495 bp PCR product comprising the whole of Exon 1 of GRM3 and a 523 bp 
minimal promoter containing the CCAAT and the TATA box required for GRM3 
gene transcription as deduced from the Corti et al. (2001) was amplified using the 
primers F: 5’-TCTGTAGCTGGCAGCCTATT -3′ and R: 5’- 
CTTACCTCGCACCGACAACT - 3′. Master mix comprising of 2.5 µl of 10X Pfx 
amplification buffer, 5 µl of 5 M betaine, 2.5 µl of 10X enhancer buffer, 1 µl of 50 
mM MgSO4, 0.2 µl of 25 mM dNTPs, 1 µl each of 10 pmol/µl F and R primers, 0.4 
µl Platinum® Pfx DNA polymerase (Invitrogen) and PCR water was added to a final 
volume of 23 µl and dispensed in a 96-well plate containing 2µl of of genomic DNA 
(50 ng). The PCR program MHTD.pyex_2k was used to amplify the product and the 
cycling conditions are described in Table 3.10. 
3.4.2.3.3 Gel extraction of PCR products for cloning into reporter plasmids 
The size of the PCR products was confirmed by running the products on 1% agarose 
gel with ethidium bromide and hyperladder I as the size marker. Upon verification, 
the PCR product band was extracted from the gel using Qiagen MinElute Gel 
163 
 
Extraction Kit (Qiagen, UK). The rehydrated purified PCR product was quantified 
using a Nano1000 (Thermo scientific, UK) and delivered to be sequenced at the 
Scientific Support Services at the Wolfson Institute for Biomedical Reasearch 
(WIBR), UCL to verify the sequence of the PCR product. 
3.4.2.3.4. Cloning of PCR fragments into reporter plasmids 
(A) Cloning of the PCR fragment into pJet1.2/blunt vector 
Ligation: Initially the blunt end 972 bp 5'-UTR PCR product was cloned into the 
pjet1.2 blunt cloning vector (Fermentas) according to the manufacturer’s 
instructions. A 5 minute ligation reaction was carried out at room temperature with 
3:1 insert/vector ratio (0.15/0.05 pmol ends), 2X reaction buffer, T4 DNA ligase and 
PCR water to a final volume of 20 µl.  
Transformation: An aliquot of 100 µl of Max efficiency DH5α competent cells 
(Invitrogen) was transformed with 2.5 µl of the ligation mixture according to the 
manufacturer's instructions. 100 µl of competent cells were thawed on ice and 2.5 µl 
of the ligation mix was added to the cells gently. The cells were then incubated on 
ice for 30 minutes and then heat shocked at 42
o
C water bath for 45 seconds. The 
cells were immediately placed on ice for 2 minutes and then 0.9 ml of room 
temperature S.O.C medium was added to the cells. The tubes containing the cells 
were then placed in a shaker incubator at 37
o
C for one hour at 225 rpm. After the 
incubation period, aliquots of 50 µl, 100 µl and 250 µl of cells were spread on LB 
agar plates containing 100 µg/ml ampicillin and the plates were incubated overnight 
at 37
o
C. Also, another aliquot of 100 µl of competent cells were transformed in 
parallel with 50 pg of control DNA (pUC19) to determine the transformation 
efficiency. As the vector contains a lethal gene that is interrupted by the successful 
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cloning of an insert, only transformed colonies survive on LB-amp agar plates. On 
the next day, the transformed colonies were screened for the presence of the cloned 
insert using colony PCR. 
Colony PCR: Colony PCR is a protocol designed for quick screening of the plasmid 
inserts directly from bacterial colonies. A single colony from the transformation 
plate was picked using a sterile 10 µl pipette tip and dipped in a 96-well plate 
containing 5 µl of PCR water and the tip was then inoculated into a fresh 15 ml 
falcon tube containing 3 ml of LB broth with ampicillin. The master mix containing 
all the PCR reagents described in section 3.4.2.3.2 for the amplification of 972 bp 
and 1495 bp PCR product was added to the 96-well plate containing cells and the 
appropriate cycling conditions were used based on the insert of interest. At the end 
of the PCR, the products were run on 1% agarose gel to determine their specificity 
(Figure 3.13). 
 
Figure 3.13 Colony PCR for identifying pJet1.2 clones containing 972 bp GRM3 
5'-UTR. 
Lanes 1 and 18, Hyperladder I; Lanes 2-17, randomly selected pJet1.2 clones for screening 
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3.4.2.3.5. Isolation, quantification and sequence verification of plasmid DNA 
Meanwhile, the falcon tubes inoculated with single transformed colonies containing 
the vector along with the insert were selected and grown overnight in a shaker 
incubator at 37
o
C and 225 rpm. On the next day, the cultures were subjected to 
plasmid isolation using QIAprep Spin Miniprep Kit (Qiagen, UK) based on the 
manufacturer's protocol. The plasmid DNA isolated was quantified using a 
NanoDrop® ND-1000 or NanoDrop 2000 Spectrophotometer (Thermo-Scientific, 
UK) and delivered to be sequenced at WIBR, UCL using pJET1.2 F and R primers 
(Appendix IV). 
3.4.2.3.6. Sub-cloning of the GRM3 inserts into pGL3 vectors  
(i) Sub-cloning of the GRM3 inserts from pjet1.2 vector into pGL3 vectors 
(Clones A, B and C) 
Upon sequence verification of the pJet1.2 clones containing 972 bp (5'-UTR) and 
1495 bp (promoter and 5'-UTR) of GRM3 gene, these inserts were subcloned into 
pGL3-basic and pGL3-promoter vectors resulting in three different constructs. I 
chose to utilize these two vector types as they differ in the basal transcriptional level 
of the luciferase, which is very low in the case of the pGL3-basic due to the lack of a 
constitutive promoter sequence and higher in the pGL3-promoter because of the 
presence of an SV-40 derived promoter. Two double digestion reactions using 
restriction enzymes (XhoI and BglII) common to the pJet1.2 and pGL3 vector of 
interest were performed - one was to excise the insert from the pJet1.2 vector and the 
other to cleave the pGL3 vector. The restriction enzyme digest was set up by adding 
2 µl of 10 X restriction enzyme buffer, 0.2 µl of acetylated BSA (10 µg/µl), 1 µl of 
plasmid DNA (1 µg/µl) and sterile deionized water to a final volume of 15.3 µl and 
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finally adding 0.5 µl of each restriction enzyme (10 U/ µl).
 
Figure 3.14 Restriction digestion of the pJet1.2 construct for subcloning 
Lanes 1 and 2, pJet1.2/blunt construct containing 972 bp GRM3 5'-UTR insert treated with XhoI and 
BglII, Lanes 4 and 5, undigested pJet1.2/blunt clone containing the 972 bp GRM3 5'-UTR insert, 
Lane 7, Hyperladder I. 
The contents in the tube were mixed gently by pipetting and spun briefly and 
incubated at 37
o
C for 4 hours. BSA in the digestion reaction stabilizes the enzymes 
by protecting them from proteases, non-specific adsorption and harmful 
environmental factors such as heat, surface tension and interfering substances. In 
double restriction digestion reactions the most optimal buffer or the compatible 
buffer for the activity of both the enzymes was used. The digested reaction mix was 
then run on 1% agarose gel to confirm the completion of the cleavage of the plasmid 
DNA and separate the vector and the insert. On successful separation, two bands of 
appropriate sizes for the vector and the insert were visible on the gel for pJet1.2 
vector digest (Figure 3.14) and one band for the cleaved pGL3 vector. The cleaved 
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and linear pGL3 vector ran faster than the circular uncleaved vector on the gel. The 
972 bp or 1495 bp insert and the digested pGL3 vector were then extracted from the 
gel using QIAquick Gel Extraction Kit (Qiagen, UK). The DNA was quantified 
using Nano1000 and ligation reactions were carried out using T4 DNA ligase 
(Promega, UK) according to manufacturer's instructions. A 3:1 molar ratio of 
insert:vector DNA was used for ligation reaction and the amount of vector and insert 
DNA was calculated using this formula: 
ng of insert = (ng of vector x kb size of insert/kb size of the vector) x (molar ratio of 
insert/vector) 
The ligation reactions were performed at 4
o
C overnight and the following day, 2 µl 
of the ligation mix was used to transform 50 µl of maximum efficiency DH5α/XL-10 
Gold competent cells according to the standard protocol described in section 
3.4.2.3.4. The transformed cells were spread on LB agar plates containing 100 µg/ml 
of ampicillin. The following day the transformed colonies were screened for the 
presence of the insert of interest by colony PCR. Plasmid DNA was extracted for 
colonies containing the correct insert the following day and delivered for sequencing 
at WIBR, UCL. The three resulting constructs and there compositions were: 
1. Clone A: The 972 bp GRM3 5'-UTR was subcloned into pGL3-basic vector 
using XhoI and BglII restriction sites upstream of the luciferase gene.  
2. Clone B: The 1495 bp PCR product comprising the whole of Exon 1 of 
GRM3 and a 523 bp minimal promoter was subcloned into pGL3-basic 
vector using the XhoI and BglII restriction sites. 
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3. Clone C: The 972 bp GRM3 5'-UTR was cloned upstream of the SV-40 
promoter in the pGL3-promoter vector using XhoI and BglII restriction sites.  
(ii) Sub-cloning of the 972 bp GRM3 5'-UTR PCR product into pGL3-
promoter vector (Clone D) 
The 972 bp GRM3 5'-UTR PCR fragment amplified using primers with HindIII and 
NcoI restriction sites was used for the construction of Clone D. Therefore, in Clone 
D, the GRM3 5'-UTR is cloned just outside and downstream of the SV-40 promoter 
and upstream and in-frame to the luciferase gene. A restriction digestion reaction 
was set up for the PCR product and pGL3-promoter vector in separate tubes using 
HindIII and NcoI restriction enzymes (Promega, UK) according to the standard 
protocol described before in section 3.4.2.3.6. The pGL3-promoter vector was 
dephosphorylated using calf intestinal alkaline phosphatase at 37
o
C for 30 minutes. 
The digested insert and the vector were run on 1% agarose gel and extracted using 
the QIAquick Gel Extraction Kit. An overnight ligation reaction at 4
o
C was set up 
using 3:1 molar ratio of insert: vector DNA and 2 µl of the ligation mix was used for 
transformation the following day. The transformed colonies were screened using 
colony PCR and restriction digestion with HindIII and NcoI to confirm the size and 
orientation of the insert. The colonies containing the insert of the correct size and 
orientation were processed for plasmid isolation and sequence verification. 
(iii) Mutating the A base of the ATG of luciferase gene in Clone D to produce 
Clone E 
In Clone E, the A base of the start codon of the luciferase gene of Clone D was 
replaced with the G base using the QuikChange II XL system (Strategene, LA Jolla, 
CA) according to the manufacturer's instructions for site-directed mutagenesis 
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described in section 3.4.2.3.7. In this clone, the translation of the gene is under the 
control of in-frame ATG start codon of GRM3 972 bp 5′ UTR. The sequence and 
orientation of the experimental construct was verified by DNA sequencing. 
3.4.2.3.7. Site-directed mutagenesis 
Single base mutations were introduced in all the constructs by site-directed 
mutagenesis utilizing the QuikChange II XL system (Strategene, UK) according to 
the manufacturer's instructions. The primers for site-directed mutagenesis were 
designed using web-based QuikChange Primer Design Program available online at 
www.agilent.com/genomics/qcpd. The HPLC purified oligos (Sigma-Aldrich, UK) 
were reconstituted with PCR water on arrival. The mutant strand synthesis reaction 
was set up by adding 5 µl of 10X reaction buffer, 10 ng of wild-type plasmid DNA, 
125 ng of F and R primers, 1 µl of dNTP mix, 3 µl of Quicksolution and PCR water 
to a final volume of 50 µl in a 96-well PCR plate. Finally 1 µl of PfuUltra HF DNA 
polymerase (2.5 U/ul) was added to the reaction mix and mixed well by pipetting. 
The samples were then subjected to PCR and the cycling conditions used are 
described in Table 3.11. 
Table 3.11 Cycling conditions for site directed mutagenesis 
Cycles Temperature Time 
1 95
o
C 1 minute 
18 95
o
C 50 seconds 
60
o
C 50 seconds 
68
o
C 1 minute/kb of plasmid length 
1 68
o
C 7 minutes 
After the PCR, the reactions were cooled by keeping on ice for 2 minutes. To the 
reaction mix, 1 µl of DpnI restriction enzyme (10 U/µl) was added and gently mixed 
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by pipetting. The reaction mix was spun down in a centrifuge briefly and incubated 
at 37
o
C for 1 hour to digest the parental supercoiled dsDNA. Following the 
incubation, XL10Gold ultracompetent cells were transformed using 2 µl of the DpnI 
digested DNA in a 14 ml BD round bottom falcon tube using the standard protocol 
described in the kit manual. S.O.C medium was added to the falcon tubes after heat 
shock and the cells were incubated at 37
o
C for 1 hr with shaking at 225 rpm. 
Aliquots of cells were plated on LB-ampicillin plates and the plates were incubated 
at 37
o
C overnight. A mutagenesis control was performed in parallel using 
pWhitescript 4.5-kb control plasmid and the competent cells transformed with this 
plasmid were plated on LB-ampicillin plates containing 80 μg/ml X-gal and 20 mM 
IPTG. A successful pWhitescript control mutagenesis reaction resulted in blue 
colonies. The transformed colonies were screened using colony PCR and plasmid 
was isolated the following day and sequence verified for the presence of the 
mutation. 
3.4.2.4. Large-scale plasmid preparation 
For transfection experiments, plasmid DNA was isolated on a large-scale using 25 
ml of cultures of the clones inoculated in LB-ampicillin medium and grown 
overnight. The plasmid was extracted using QIAfilter Plasmid Midi Kit (Qiagen, 
UK) according to the manufacturer's instructions. 
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3.4.2.5. Preparation of glycerol stocks for long-term 
storage of clones 
The culture of the clones was streaked on LB-ampicillin plates for isolating single 
colonies. The following day, a single colony was inoculated in 3 ml LB-ampicillin 
medium and incubated overnight at 37
o
C. After the incubation, 0.5 ml of the culture 
was added to 0.5 ml of 80% sterile glycerol in a sterile screw cap tube. This glycerol 
stock was mixed by vortexing and then stored at -80
o
C. The plasmid was isolated 
from 1 ml of the same culture using the Qiagen miniprep kit and sequence verified 
for confirmation. 
3.4.2.6. Transient transfection 
Day before transfection 
Twenty four hours before transfection, HEK293 and SH-SY5Y cells were seeded in 
24 well plates at approximately 0.5 x 10
5 
and 1 x 10
5 
cells/well for HEK293 and SH-
SY5Y cells respectively in 500 µl of antibiotic-free medium (DMEM + 10% FBS). 
The plates were incubated at 37
o
C with 5% CO2 and were 90-95% confluent at the 
time of transfection. 
Day of transfection 
Transfection was performed using Lipofectamine
TM
 2000 (Invitrogen, UK) 
according to the manufacturer’s protocol. For each well to be transfected, two 
microcentrifuge tubes were prepared. In one tube, 0.8 µg of the reporter plasmid 
DNA along with pRL-SV40 renilla luciferase reporter vector at a ratio of 50:1 (16 
ng/well) was diluted in 50 µl of Optim-MEM®I reduced serum medium. pRL-SV40 
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plasmid DNA was used as a control in the experiment to determine the transfection 
efficiency. In the second tube, 2 µl and 4 µl of Lipofectamine
TM
 2000 for HEK293 
and SH-SY5Y cells respectively, was diluted in 50 µl of Optim-MEM®I medium 
and incubated for 5 minutes at room temperature. At the end of the incubation 
period, the contents of tube one and two were mixed together gently to form 
transfection complexes and incubated for 20 minutes at room temperature. The 100 
µl of DNA-lipofectamine complexes were then added to each well to be transfected 
and mixed gently by rocking the plate back and forth. The cells were incubated at 
37
o
C in the CO2 incubator. The medium was changed after four hours of incubation 
with complete growth medium and the cells were incubated for further 48 hours at 
37
o
C with 5% CO2. 
3.4.2.7. Luciferase reporter assay 
The Dual-Luciferase® Reporter (DLR
TM
) Assay system (Promega Corp, USA) was 
used to quantify the reporter activity after transfection. In the DLR
TM 
Assay, the 
firefly and renilla luciferase activities can be measured sequentially from a single 
sample. The components of this system are: 
 Passive Lysis buffer (PLB, 5X): PLB promotes rapid lysis of cultured 
mammalian cells, prevents foaming during lysis and provides optimum 
performance and stability of firefly and Renilla luciferase reporter enzymes. 
Working stock of PLB was prepared by adding one volume of 5X PLB to 4 
volumes of distilled water and mixing well. The diluted PLB (1X) can be 
stored at 4
o
C for up to one month. 
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 Luciferase Assay Reagent II: The firefly luciferase reporter activity was 
measured using LAR II. Working stock of LAR II was prepared by 
resuspending the lyophilized luciferase assay substrate in 10 ml of luciferase 
assay buffer II. Aliquots of 1 ml LAR II were stored at -80
o
C. 
 Stop & Glo® Reagent: This reagent quenches the firefly luciferase 
luminescence and concomitantly activates Renilla luciferase. Fresh Stop & 
Glo® reagent was prepared everytime by adding one volume of 50X Stop & 
Glo® substrate to 50 volumes of Stop & Glo® buffer. 
Preparation of cell lysate 
The cells were harvested 48 hours after transfection and the activity of firefly and 
renilla luciferase was measured using the Dual Luciferase Reporter® Assay System 
(Promega) on a Turbo 20/20 luminometer. The growth medium was removed from 
the wells and the cells were washed with 1X PBS. To each well, 100 µl of 1X PLB 
was added and the plate was placed on an orbital shaker at room temperature for 15 
minutes. The lysate was then transferred to a microcentrifuge tube and the lysate was 
cleared by centrifugation at 13000 rpm for 30 seconds at 4
o
C. The clear lysates were 
transferred to fresh microcentrifuge tubes. 
Measurement of reporter activity using a luminometer 
For each sample to be assayed, 100 µl of LAR II was predispensed into a 
microcentrifuge tube. The DLR II Promega program was selected on the Turbo 
20/20 luminometer (Turner Biosystems, UK) for reporter activity measurement. The 
luminometer was programmed to perform a 2 second premeasurement delay 
followed by a 10 second measurement period for each reporter assay. In the tube 
containing LAR II, 20 µl of the cell lysate was transfered carefully and mixed by 
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pipetting and the tube was placed in the luminometer for reading. This was the 
luciferase activity measurement for the sample. After recording the initial reading, 
the tube was removed and 100 µl of Stop & Glo® reagent was added and mixed by 
pipetting. The tube was replaced in the luminometer and the reporter activity 
recorded. This reading was the Renilla luciferase activity measurement for the 
sample.  
Statistical analysis 
Transfections were performed in triplicate and repeated three times. Firefly 
luciferase luminescence was expressed as a ratio to that of the Renilla luciferase 
activity and the normalized data was compared with a Student’s t-test or Mann-
Whitney U-test (SPSS, version 18.0). A cut-off significance of P < 0.05 was used. 
3.4.2.8. mRNA expression analysis 
Transfection 
One day before transfection, HEK293 and SH-SY5Y cells were seeded in 6-well 
plates at approximately 5 x 10
5
 and 1 x 10
6
 cells/well in an antibiotic-free medium. 
Transfections were performed for HEK293 and SH-SY5Y cells using 10 µl/ well and 
15 µl/well Lipofectamine 2000 respectively following the standard protocol 
described in section 3.4.2.4. 2.4 µg of Clone D reporter construct and 48 ng/well of 
pRL-SV40 at a ratio of 50:1 per well were transfected into each well containing the 
cells. The medium was changed to a complete growth medium after four hours and 
the plates were incubated for 24 hours at 37
o
C with 5% CO2. 
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RNA extraction 
Total RNA was extracted after 24 h of incubation using Illustra RNAspin Mini RNA 
Isolation Kit (GE Healthcare Life Sciences, UK) and subjected to DNAse treatment 
using RQ1 RNase-free DNase (Promega, UK) for 1 hour at 37
o
C in order to 
eliminate plasmid DNA according to the manufacturer’s instructions. The RNA was 
quantified using Nano2000 (Thermo scientific, UK) by using 1 µl of the sample. 
cDNA preparation 
DNAse treated RNA was used to make cDNA in the presence of Superscript
TM
 III 
Reverse Transcriptase (Life Technologies, UK) according to the manufacturer’s 
instructions. In a nuclease-free microcentrifuge tube, 2 µg of total RNA, 500 ng of 
oligo(dT)15 and 1 µl of 10 mM dNTP mix were added and PCR water was added to a 
final volume of 13 µl. The mixture was heated in a thermocycler at 65
o
C for 5 
minutes and immediately incubated on ice for 1 minute. The tube was then 
centrifuged briefly and to each tube 4 µl of 5X first-strand buffer, 1 µl of 0.1 M 
DTT, 1 µl of Recombinant Rnasin® Ribonuclease inhibitor (Promega, UK) and 1 µl 
of SuperScript
TM
 III RT (Invitrogen, UK) was added. The contents in the 
microcentrifuge tube were mixed gently by pipetting and incubated at 55
o
C for 60 
minutes. The reaction was inactivated by heating the tube at 70
o
C for 15 minutes. A 
negative control or a non-RT reaction was maintained by excluding the RT enzyme 
in the reaction contents. The resulting cDNA was then used for Quantitative real 
time PCR (QRT-PCR). 
Quantitative real time PCR 
Firefly luciferase mRNA was quantified using primers F – 
CCTTCGATAGGGACAAGACAA, R- AGCGACACCTTTAGGCAGAC and 
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Universal Probe Library probe #82 (UPL; Roche Diagnostics Ltd, UK) using an 
LC480. Renilla luciferase mRNA was also quantified using primers F-
TGTGTCAGTTAGGGTGTGGAA, R- CACCTGGTTGCTGACTAATTGA and 
UPL probe #29 (Roche Diagnostics Ltd, UK) to take into account differences in 
transfection efficiencies between constructs. A housekeeping gene, RPLPO, was 
quantified as an internal control using primers F - CGACAATGGCAGCATCTAC 
and R - GGTAGCCAATCTGCAGAC, and UPL probe #6 (Roche Diagnostics Ltd, 
UK). In a 384 well plate, 9 µl master mix containing 5 µl of probes master mix 
(Roche Diagnostics Ltd, UK), 100 nM UPL probe primer, 200 nM forward and 
reverse primers was added to 1 µl of cDNA sample and each sample was amplified 
in quadruplicate. The dual hydrolysis probe/UPL probe program was run on the 
LC480. Firefly luciferase was normalized to that of renilla luciferase to control the 
transfection efficiency. The ΔΔCt method was employed by the LC480 software for 
the analysis of the results and is described in section 3.3.6.  
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Chapter 4  
Fine mapping of a new Bipolar 
affective disorder locus on 
chromosome 1p36 
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4.1. Introduction 
Accumulating evidence from family linkage studies suggests the presence of a 
BPAD susceptibility locus on 1p36. The linkage findings implicating chromosome 
1p have been previously discussed in section 1.7.4.1. The 1p36 linkage region that 
included the positive marker of the linkage study (Curtis et al. 2003), D1S243, and 
10 Mbp on either side of the marker spans about 187 RefSeq genes. Some of the 
candidate genes in this region are GABRD, GPR153, FBXO, PER3, MTHFR and 
PRKCZ. On close inspection of the linkage disequilibrium (LD) pattern, the marker 
D1S243 lies in an LD block comprising genes PRKCZ, C1orf86 and SKI (Figure 
4.1). Of these, protein kinase C, zeta type (PRKCZ) was one of the promising 
candidate genes as it is very highly expressed in all parts of the brain including the 
prefrontal cortex, amygdala and hypothlalamus. PRKCZ is a member of the PKC 
family of serine/threonine kinases, which are involved in cell proliferation, 
differentiation and secretion. PRKCZ protein has an N-terminal regulatory domain 
followed by a hinge region and a C-terminal catalytic domain. The second 
messengers stimulate PKCs by binding to the regulatory domain, translocating the 
enzyme from cytosol to membrane and producing a conformational change that 
removes autoinhibition of the PKC catalytic activity. PRKCZ has been implicated in 
cardiac muscle function (Wu and Solaro 2007), B-cell function (Martin et al. 2002), 
and insulin-stimulated glucose transport (Bandyopadhyay et al. 2002). Allelic and 
haplotypic association studies were carried out in the UCL bipolar disorder case-
control sample for this thesis in order to confirm the role of the PRKCZ in genetic 
susceptibility to affective disorders. The method relies on the detection of 
evolutionarily determined relationship of linkage disequilibrium (LD) between 
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polymorphic markers within or very close to the PRKCZ gene and unknown 
aetiological base pair changes within PRKCZ. Positive evidence for LD is found by 
discovering allelic or haplotypic association between markers and disease status 
compared to ancestrally matched unaffected comparison subjects.
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Figure 4.1 RefSeq genes in the linkage region including the positive marker D1S243 and 10 Mbp on either side of D1S243 
 
Linkage region implicated in the UCL family linkage study (Curtis et al. 2003)
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4.2. Hypothesis 
On the basis of modest evidence from family linkage studies I hypothesised that the 
chromosome 1p36 locus contains a BPAD susceptibility gene. 
4.3. Aims 
The aim of this study was to fine map the 1p36 region using microsatellite markers. 
Furthermore, tagging SNPs were sought to improve the association signal between 
PRKCZ and bipolar disorder. The previously reported gender-based association of 
1p36 region with bipolar disorder was also investigated in the UCL research sample. 
4.4. Results 
Genotyping of four microsatellite markers was initially carried out in a total of 440 
controls and 600 BPAD patients. Marker D1S243 showed positive allelic association 
with bipolar disorder (P = 0.037; CLUMP T1) as shown in Table 4.1. The three other 
microsatellite markers – PRKCZ (GT)17, PRKCZ(CA)13 and PRKCZ(AC)24 (Table 
4.1) failed to show any association with bipolar disorder (P = 0.555, 0.472, 0.68 
respectively). The Hapmap LD structure of all the SNPs between the markers 
PRKCZ (AC)24 and PRKCZ(CA)13 is shown in Figure 4.1. It is evident from Figure 
4.1 that D1S243 falls into an LD block which spans the genes PRKCZ, SKI and 
C1orf86 and there is a distinct break in the LD outside this region. Therefore, this 
region was fine mapped by genotyping nine haplotype tagging SNPs spanning the 
PRKCZ gene (Figure 4.2). All the SNP markers were in HWE. SNP rs3128296 was 
significantly associated with bipolar disorder (P = 0.040) and another SNP 
rs2503706 (P = 0.057) showed a trend towards association (Table 4.2).  
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Figure 4.2 Graphical representation of the markers genotyped for the fine mapping of 1p36 locus 
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Table 4.1 Tests of allelic association of microsatellite markers with Bipolar affective disorder at the 1p36 region 
Marker Marker 
Location  
Bp 
from 
prior 
marker 
Number 
of 
samples 
(N) 
Allelic bases or fragment sizes with observed allele counts (allele frequency %) below  χ2 Pa-
value 
PRKCZ(AC)24 
Case 
 
Control 
1809303   
563  
 
397  
232   234   236   248   250   252   254  256   258   260    262   264   266   268   270   272  274 
 1       331    11      0       1       6       23   224     50    180    215     42     20     12        9      0       1  
(0.1) (29.4)  (1)    (0)   (0.1) (0.5) (2.0) (19.9)(4.4)  (16)  (19.1)(3.7) (1.8) (1.1)  (0.8)   (0)   (0.1) 
 0       224      8      1       0       3       12   142     41    132    182     23     15      7          3      1       0 
(0)    (28.2)   (1)   (0.1) (0)   (0.4) (1.5) (17.9) (5.2)(16.6)(23.0)(2.9)(1.9) (0.9)   (0.5) (0.1)   (0) 
 
13.53 
 
0.634 
PRKCZ(GT)17 
Case 
 
Control 
2123652 314349  
558 
 
380 
295   297   299   301   303   305   307   309   311   313   315 
 1       31     281    24    574     93     13     11     85      3       0 
(0.1)(2.8) (25.2)(2.2) (51.4) (8.3) (1.2)  (1.1)(7.6) (0.3)  (0)  
 0       20     193    15    381     59      11     12    60      8       1 
(0)    (2.6)(25.4) (2.1) (50.1)(7.8)  (1.5) (1.6) (7.9) (1.1) (0.1)  
 
8.956 
 
0.536 
D1S243 
Case 
 
Control 
2171436 47784  
595 
 
436 
  159   161   163   165   167  169   171   173   175   177   179   181   183   185   187   189 
  355     1        1       1        7      98   220    66     23     55      75    189    78      21     0         0 
(29.8)(0.1) (0.1)  (0.1)( 0.6) (8.2) (18.5) (5.6) (1.9)(4.6)  (6.3) (15.9)(6.6) (1.8)   (0)      (0)   
  240     4        0       0        1      91   138    51      10    56     56     128    68      27     1         1 
(27.5)(0.5)   (0)    (0)    (0.1)(10.4)(15.8)(5.9) (1.2) (6.4) (6.4) (14.7)(7.8) (3.1)  (0.1)   (0.1)    
 
26.13 
 
0.037 
PRKCZ(CA)13Case 
 
Control 
2309397 137961  
581 
 
394 
 
231   233    235   237   239   241   243   245  247   249   251   253   255 
  2        2      287   342    65    254      6      11   119    51      16       1       6 
(0.2) (0.2)(24.7)(29.4)(5.6)(21.9)(0.5)  (0.9)(10.2)(4.4) (1.4)  (0.1)  (0.5) 
  1         0     195   233    42    150     11       6     91     38     18       1       2 
(0.1)   (0)  (24.7)(29.6)(5.3)(19.0)(1.4) (0.8)(11.5)(4.8) (2.3)  (0.1)  (0.3)  
 
11.66 
 
0.473 
a
 Two-tailed significance from 2 x 2 χ2, with 1 df; df, degrees of freedom, from CLUMP Monte Carlo subtest T1. Bold values signify P<0.05, Marker positions on chr 1 
based on NCBI35 build hg17. 
  
184 
 
No significant differences were observed in the allele distributions of SNPs 
rs908472, rs3107156, rs384726, rs12134873, rs12132341 and rs262688 between 
patients and controls. After the initial fine mapping study, data from eight more 
SNPs in the region spanning PRKCZ gene was retrieved from the UCL1 bipolar 
GWAS (Ferreira et al. 2008; Sklar et al. 2008) and included in the final allelic and 
haplotypic association analysis. These SNPs are marked with an asterisk in Table 
4.2. The SNP rs3753242 was genotyped in both the studies i.e. fine mapping at UCL 
and UCL1 GWAS, and the merged data from these two studies is reported in Table 
4.2. One SNP rs3128309 approached significance in the association analysis with 
bipolar disorder (P = 0.060). The results of pairwise LD statistics between all 21 
markers (microsatellites and SNPs) genotyped are shown in Figure 4.3. Strong LD 
was observed between the positive marker D1S243 and the positive SNPs 
rs3128296, rs3128309 and rs2503706 near the PRKCZ gene. The SNP rs3128296 
was not in LD with rs2503706 (D' = 0.553, r
2 
= 0.02) but was in moderate LD with 
rs3128309 (D'=0.943, r
2
=0.747). SNPs rs3128309 and rs2503706 are in LD (D' = 1, 
r
2 
= 0.055). The UCL controls recruited in this study are supernormal because they 
have been psychiatrically screened. To determine if the LD pattern in this group of 
controls represents the normal population, the LD structure of the SNP data of the 
controls genotyped in the UCL1 bipolar GWAS was compared to that of the Hapmap 
controls. The results suggested that the LD pattern of the two groups was similar 
(Figure 4.4). 
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Table 4.2 Genotype and allele frequencies of single nucleotide polymorphisms in 
the PRKCZ gene in the UCL research sample. 
SNP Position N Genotype counts Allele counts (frequency) χ2 Pa-value 
rs7513222* 
Case 
Control 
2060063  
543 
510 
AA 
62 
50 
AG 
245 
231 
GG 
236 
229 
A 
369 (0.34) 
331 (0.33) 
G 
717 (0.66) 
689 (0.67) 
0.553 0.457 
rs908742 
Case 
Control 
2065418  
576 
428 
AA 
58 
46 
GA 
263 
191 
GG 
255 
191 
A 
379 (0.33) 
283 (0.33) 
G 
773 (0.67) 
573 (0.67) 
0.006 0.940 
 
rs3107146* 
Case 
Control 
2079746  
543 
510 
AA 
5 
9 
AG 
114 
116 
GG 
424 
385 
A 
124 (0.11) 
134 (0.13) 
G 
962 (0.89) 
886 (0.87) 
1.446 0.230 
rs3107156 
Case 
Control 
2092792  
577 
434 
CC 
217 
147 
CT 
271 
224 
TT 
89 
63 
C 
705 (0.61) 
518 (0.60) 
T 
449 (0.39) 
350 (0.40) 
0.415 0.520 
rs3107157* 
Case 
Control 
2094131  
537 
501 
AA 
94 
88 
AG 
258 
253 
GG 
185 
160 
A 
446 (0.41) 
429 (0.43) 
G 
628 (0.59) 
573 (0.57) 
0.352 0.553 
 
rs3128296 
Case 
Control 
2101068  
584 
543 
GG 
8 
10 
TG 
113 
131 
TT 
463 
402 
G 
129 (0.11) 
151(0.14) 
T 
1039 (0.89) 
935 (0.86) 
4.23 0.0402 
rs3753242*¹ 
Case 
Control 
2101843  
591 
605 
CC 
508 
535 
CT 
80 
68 
TT 
3 
2 
C 
1096 (0.93) 
1138 (0.94) 
T 
86 (0.07) 
72 (0.06) 
1.702 
 
0.192 
rs2503706 
Case 
Control 
2107413  
580 
550 
CC 
286 
236 
CT 
239 
256 
TT 
55 
58 
C 
811 (0.70) 
728 (0.66) 
T 
349 (0.30) 
372 (0.34) 
3.62 0.057 
rs384726 
Case 
Control 
2108217  
579 
429 
AA 
3 
2 
GA 
80 
56 
GG 
496 
371 
A 
86 (0.07) 
60 (0.07) 
G 
1072 (0.93) 
798 (0.93) 
0.138 0.710 
rs385039* 
Case 
Control 
2109571  
543 
510 
CC 
44 
35 
CT 
224 
213 
TT 
275 
262 
C 
312 (0.29) 
283 (0.28) 
T 
774 (0.71) 
737 (0.72) 
0.251 0.616 
rs12134873 
Case 
Control 
2123984  
570 
435 
AA 
0 
0 
GA 
6 
7 
GG 
564 
428 
A 
6 (0.01) 
7 (0.01) 
G 
1134 (0.99) 
863 (0.99) 
0.595 
 
0.441 
rs12132341 
Case 
Control 
2126694  
580 
554 
AA 
0 
1 
AG 
23 
24 
GG 
557 
529 
A 
23 (0.02) 
26 (0.02) 
G 
1137 (0.98) 
1082 (0.98) 
0.355 
 
0.551 
rs262641* 
Case 
Control 
2137143  
535 
507 
CC 
44 
37 
CT 
221 
209 
TT 
270 
261 
C 
309 (0.29) 
283 (0.28) 
T 
761 (0.71) 
731 (0.72) 
0.240 0.624 
  
rs3128309* 
Case 
Control 
2138040  
542 
507 
AA 
1 
6 
AG 
98 
107 
GG 
443 
394 
A 
100 (0.09) 
119 (0.12) 
G 
984 (0.91) 
895 (0.88) 
3.532 0.060 
 
rs626479* 
Case 
Control 
2142422  
530 
504 
AA 
38 
33 
AG 
208 
202 
GG 
284 
269 
A 
284 (0.27) 
268 (0.27) 
G 
776 (0.73) 
740 (0.73) 
0.011 
 
0.916 
 
rs262688 
Case 
Control 
2145727  
571 
433 
AA 
293 
222 
CA 
235 
183 
CC 
43 
28 
A 
821 (0.72) 
627 (0.72) 
C 
321 (0.28) 
239 (0.28) 
0.064 0.801 
rs262683* 
Case 
Control 
2188031  
536 
503 
CC 
386 
382 
CT 
131 
107 
TT 
19 
14 
C 
903 (0.84) 
871 (0.87) 
T 
169 (0.16) 
135 (0.13) 
2.286 0.131 
Position on Chr 1 (bp)(UCSC May 2004 release); N, Number of samples; *SNPs genotyped in the GWAS 
(Ferreira et al. 2008; Sklar et al. 2008); *¹ SNPs genotyped in the GWAS and fine mapping study; 2The P-value 
does not survive multiple testing  
aTwo-tailed significance P-value from 2 x 2 χ2 1 df; df, degrees of freedom; Bold values signify P<0.05 
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Figure 4.3 Linkage disequilibrium between all markers genotyped within and 
near the PRKCZ gene locus in the UCL sample 
The figure was generated using Locusview 2.0. Genomic positions are in accordance with the NCBI 
information build 35 hg 17 of the human genome assembly. 
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Figure 4.4 Comparison of LD between all SNP markers genotyped within and 
near the PRKCZ gene locus in the UCL control sample and Hapmap LD 
between the same SNP markers 
The figure was generated using Locusview 2.0. Genomic positions are in accordance with the NCBI 
information build 35 hg 17 of the human genome assembly. 
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In the combined haplotype analysis of all the 17 SNPs, using the solid spine of D' = 
1 rule in Haploview, there were three main haplotype blocks but none remained 
associated with bipolar disorder after permutation testing. Therefore, further 
exploratory haplotypic association analysis was undertaken. I found evidence for 
haplotypic association at PRKCZ when the three SNPs rs3128296, rs2503706 and 
rs3128309 were analysed as a single haplotype in Haploview (empirical P = 0.004) 
(Table 4.3). Tests of haplotypic association using GENECOUNTING were carried 
out. Two locus and three locus combinations of the associated SNPs and D1S243 
were analysed. A trend towards haplotypic association was observed when D1S243 
marker data was included with the SNP data from all the three associated SNPs 
(empirical P = 0.06). 
Table 4.3 Haplotypic association tests with BPAD at the 1p36 region with 
markers within and near PRKCZ gene 
No. of markers 
and haplotype 
reference 
Haplotype Alleles Frequency χ2 Global 
empirical 
P-value* Cases 
(%) 
Controls 
(%) 
2 marker 
haplotypes 
Hap 1 
 
rs3128296 – 
rs2503706 
 
T-C 
 
60.3 
 
54.4 
 
8.20 
 
0.009 
Hap2 rs2503706 – 
rs3128309 
C-G 60.4 54.9 7.57 0.008 
Hap3 rs3128296 – 
rs3128309 
T-G 88.5 85.7 6.53 0.016 
3 marker 
haplotypes 
Hap4 
 
rs3128296-
rs2503706-
rs3128309 
 
T-C-G 
 
59.9 
 
54.0 
 
8.48 
 
0.004 
P*, Haplotype-permutation test empirical P, based on 9,999 permutations. 
Association analysis of female cases with female controls using PLINK showed that 
SNPs rs3128296 and rs3128309, which were previously associated in the whole 
sample, became more significantly associated (P = 0.0035; OR = 0.6197; 95% CI 
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0.45 – 0.86 and P =0.0159; OR = 0.646; 95% CI 0.45 – 0.92 respectively) (Table 
4.4). In the females only analysis an additional SNP rs3107146 became significant 
(P = 0.044; OR = 0.703; 95% CI 0.50 – 0.99). None of these SNPs survived multiple 
correction. None of the microsatellite markers showed gender-specific association 
with bipolar disorder in the female-only analysis (Table 4.4). Additionally, only one 
of the markers rs2503706 showed association with bipolar disorder when males only 
case-control pairs were analysed (Table 4.5). 
Table 4.4 Association analysis of PRKCZ SNPs with bipolar disorder after 
excluding males in the UCL sample 
Marker MAF in cases  MAF in controls χ2 OR P-value 
PRKCZ(AC)24   8.051  0.947
a
 
rs7513222 0.357 0.322 1.668 1.166 0.197 
rs908742 0.344 0.324 0.506 1.094 0.477 
rs3107146 0.101 0.137 4.085 0.703 0.043 
rs3107156 0.385 0.400 0.250 0.941 0.617 
rs3107157 0.419 0.433 0.243 0.945 0.622 
rs3128296 0.105 0.158 8.507 0.62 0.004 
rs3753242 0.066 0.056 0.598 1.189 0.440 
rs2503706 0.310 0.320 0.138 0.957 0.710 
rs384726 0.077 0.066 0.479 1.175 0.489 
rs385039 0.299 0.278 0.666 1.107 0.414 
PRKCZ(GT)17   11.977  0.287
b
 
rs12134873 0.007 0.013 0.871 0.571 0.351 
rs12132341 0.023 0.027 0.285 0.829 0.594 
rs262641 0.301 0.278 0.802 1.119 0.370 
rs3128309 0.089 0.131 5.809 0.646 0.016 
rs626479 0.280 0.266 0.316 1.074 0.574 
rs262688 0.289 0.266 0.751 1.122 0.386 
D1S243   20.022  0.172
c
 
rs262683 0.168 0.135 2.722 1.301 0.099 
PRKCZ(CA)13   7.257  0.840
d
 
MAF, minor allele frequency; Bold values signify P<0.05 , and these do not withstand multiple correction; a 
Empirical Clump T1 significance (16 df);  b Empirical Clump T1 significance (10 df); c Empirical Clump T1 
significance (15 df) ; d Empirical Clump T1 significance (12 df); df, degrees of freedom.  
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Table 4.5 Association analysis of PRKCZ SNPs with Bipolar disorder after 
excluding females in the UCL sample. 
Marker MAF in cases MAF in controls χ2 OR P-vlaue 
PRKCZ(AC)24 
  
16.417 
 
0.219 
rs7513222 0.313 0.328 0.212 0.934 0.646 
rs908742 0.305 0.339 1.088 0.856 0.297 
rs3107146 0.136 0.123 0.300 1.119 0.584 
rs3107156 0.396 0.408 0.129 0.950 0.720 
rs3107157 0.410 0.422 0.124 0.952 0.725 
rs3128296 0.120 0.115 0.066 1.054 0.798 
rs3753242 0.083 0.064 1.371 1.332 0.242 
rs2503706 0.286 0.363 6.162 0.703 0.013 
rs384726 0.070 0.075 0.056 0.938 0.812 
rs385039 0.269 0.277 0.057 0.964 0.812 
PRKCZ(GT)17 
  
9.485 
 
0.487 
rs12134873 0.002 0.003 0.008 0.882 0.929 
rs12132341 0.016 0.019 0.140 0.827 0.708 
rs262641 0.270 0.280 0.121 0.947 0.728 
rs3128309 0.097 0.098 0.003 0.988 0.959 
rs626479 0.249 0.266 0.302 0.916 0.582 
rs262688 0.269 0.289 0.402 0.906 0.526 
D1S243 
  
18.579 
 
0.234 
rs262683 0.140 0.134 0.076 1.057 0.782 
PRKCZ(CA)13 
  
18.194 
 
0.11 
MAF, minor allele frequency; Bold values signify P<0.05 , and these do not withstand multiple correction; 
a Empirical Clump T1 significance (16 df);  b Empirical Clump T1 significance (10 df); c Empirical Clump T1 
significance (15 df) ; d Empirical Clump T1 significance (12 df); df, degrees of freedom. 
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4.5. Discussion 
In the present study, I show nominally significant associations between genetic 
markers in the PRKCZ gene and BPAD. In the fine mapping study, two markers 
D1S243 and rs3128296 showed association with bipolar disorder with P-values of 
0.037 (permuted P-value) and 0.040 respectively. A trend towards association with 
bipolar disorder was observed for SNP rs2503706 (P = 0.057). None of these SNPs 
remained significant after testing for multiple correction. Additionally, data from 
eight more SNPs from the UCL1 bipolar GWAS was added to the association 
analysis, resulting in the SNP rs3128309 (P = 0.060) showing a trend towards 
association. The markers outside of the PRKCZ gene failed to show any association 
with bipolar disorder. 
Exploratory haplotypic association analysis of all three associated SNPs rs3128296, 
rs2503706 and rs3128309 resulted in a significant association with bipolar disorder 
(global empirical P = 0.004). All associated SNPs are intronic in the PRKCZ gene. 
They are, however, in the regulatory or promoter region of the two shorter isoforms 
of the gene with SNP rs2503706 being approximately 640bp from the 5'-UTR of one 
of the short isoforms (UCSC Human genome GRCh37/hg19 Feb 2009 assembly). 
Transcription factor binding analysis using TESS software 
(http://www.cbil.upenn.edu/) predicted that the mutant allele of the SNP rs2503706 
bound to new and more transcription factors like Egr-1, CACCC-binding factor, 
gammaCAC1, gammaCAC2 and Sp1 compared to the wild-type allele. The SNPs in 
gene regulatory regions such as promoter and enhancer regions can alter gene 
expression by altering binding affinities to transcription factors (Chorley et al. 2008). 
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Thus, it is possible that these SNPs regulate expression of the alternative isoforms of 
PRKCZ. 
In an earlier whole genome linkage scan of recurrent depressive disorder, there is 
suggestive evidence for linkage on chromosome 1p36 where the LOD score for 
female-only cases exceeded 3.00 (McGuffin et al. 2005). This region is slightly 
different from the chromosome 1 region, reported by Curtis et al. (Curtis et al. 2003) 
to be linked to bipolar and unipolar affective disorders, being approximately 5Mb 
from the linkage region reported in the McGuffin et al. (2005) study. Another 
genome-wide linkage analysis of 972 bipolar pedigrees of European ancestry failed 
to report any evidence of linkage at 1p (Badner et al. 2011). Interestingly, female-
only analysis of all the microsatellite and SNP markers in the current study resulted 
in two previously associated SNPs rs3128296 and rs3128309 becoming more 
significantly associated, whereas only one of the other markers, rs2503706 showed 
association in male-only analysis, suggesting a 'sex' effect. The frequency of men 
and women suffering from neuropsychiatric disorders is all but proportionally 
distributed with women being more susceptible than men in the precipitation of 
depressive symptomatology (Pitychoutis et al. 2010). Some studies associate this 
sex-specific vulnerability to the pronounced genetic predisposition that women may 
present towards the development of depressive disorders. Additionally, clinical 
evidence has shown that women may have a better outcome when treated with SSRIs 
compared to tricyclic antidepressants suggesting that antidepressant response is also 
characterised by sex-specific manifestations (Kornstein et al. 2000; Khan et al. 
2005). Therefore, the genetic makeup of an individual, in terms of 'sex', needs to be 
adequately addressed for the development of pharmacogenetic drugs in psychiatry. 
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Association studies of the PRKCZ gene with bipolar disorder have been done as part 
of GWAS but no meta-analyses have been carried out. MTHFR is another interesting 
candidate gene located on chromosome 1p36 which has been studied in bipolar 
disorder, but it lies almost 12Mb from the positive marker D1S243 in the UCL 
linkage study. GABRD is localised close to D1S243 and a recent study has reported 
association of GABRD gene with childhood-onset mood disorders (Feng et al. 
2010). GABRD is at the distal end of the telomere which is prone to higher rates of 
recombination. The signal from the markers in this study does not seem to be from 
GABRD because there is almost negligible LD between the two genes PRKCZ and 
GABRD. Previous GWAS have failed to report any association between PRKCZ 
and bipolar disorder (WTCCC 2007; Baum et al. 2008). 
PRKCZ (OMIM176982) encodes an atypical protein kinase C (PKCz) that is 
necessary for mediating axonal differentiation induced through Wnt signaling 
(Zhang et al. 2007). PKC zeta exhibits a kinase activity which is independent of 
calcium and diacylglycerol but not of phosphatidylserine. It has only a single zinc 
finger module and alternative splicing results in multiple transcript variants encoding 
different isoforms. A brain-specific, constitutively active isoform of the kinase, 
PKMzeta is necessary and sufficient for long-term potentiation at synapses that are 
responsible for memory (Hernandez et al. 2003; Sajikumar et al. 2005). Nerve injury 
triggers long-term plastic changes along sensory pathways, which in turn contribute 
to pain, perception, fear and memory. Li et al. (2010b) found that PKMzeta 
contributes to neuropathic pain by modulating excitatory synaptic transmission 
within the anterior cingulated cortex thereby, providing a potential new therapeutic 
target for chronic pain. A study by Navakkode et al. (2010) identified PKMzeta as a 
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dopamine-induced plasticity-related-protein, which exerted its action at activated 
synaptic inputs through processes of synaptic tagging. Further analysis and fine 
mapping of the PRKCZ gene in other samples is needed. In the future, DNA 
sequencing of PRKCZ may identify aetiological base pair changes affecting the 
expression or function of PRKCZ. 
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Chapter 5  
Mutation screening of the GRM7 
glutamate receptor gene in Bipolar 
disorder 
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5.1. Introduction 
Metabotropic glutamate receptors are emerging novel targets for the disorders of 
brain associated with the dysfunction of the prefrontal cortex, a region critical for 
cognitive and emotional processes. The mGluRs are involved in LTP and LTD, two 
prominent forms of long-term synaptic plasticity in the hippocampus which play an 
important role in learning and memory as well as in disease development (Sanderson 
and Dell'Acqua 2011). mGluR7, encoded by GRM7, is a highly conserved group III 
mGluR and is highly expressed in the cingulate cortex, frontal cortex, amygdala, 
hippocampus and locus coeruleus, the brain regions associated with emotional 
learning (Shigemoto et al. 1997; O'Connor et al. 2010). Presynaptic mGluR7 
modulates the release of L-glutamate and GABA and may also be involved in 
excitability levels in specific neuronal circuits, thereby, influencing different 
emotional states such as anxiety and depression as well as cognitive dysfunction 
associated with such disorders (Swanson et al. 2005).  
 GRM7 is located on 3p26.1 and previous linkage studies have implicated 
chromosomal region 3p in bipolar disorder (Kelsoe et al. 2001; Fallin et al. 2005; 
Etain et al. 2006). A recent comparative linkage meta-analysis of bipolar disorder 
genome-wide linkage datasets using GSMA and MSP methods also found evidence 
of association at 3p25.3-3p22.1 under GSMA narrow (P = 0.0099) and broad (P = 
0.0060) models (Tang et al. 2011). Independent studies by Breen et al. (2011b) and 
Pergadia et al. (2011) reported evidence for genetic linkage between MDD and the 
choromosome 3p26-p25 locus, the region containing GRM7, with LOD scores of 4.0 
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and 4.14 respectively. However, both the studies failed to replicate their initial 
findings in their respective replication samples. 
Genome-wide significant associations have not been reported for GRM7 in any 
bipolar GWAS. However, some of these studies have reported modest support for 
association with GRM7 (WTCCC 2007; Sklar et al. 2008; Sklar et al. 2011). In the 
Psychiatric GWAS Consortium (PGC) bipolar study (Figure 5.1), the most 
associated GRM7 marker was rs11915371 (P = 1.13 x 10
-4
) (Sklar et al. 2011) 
(Figure 5.1). A recent GWAS of personality traits in bipolar patients found 
association for a GRM7 SNP with the neuroticism-anxiety scale of the Zuckerman-
Kuhlman Personality Questionnaire (rs13080594, P = 7.68 x 10
-7
). Scott et al. (2009) 
performed a meta-analysis of non-overlapping samples from three bipolar disorder 
GWAS (NIMH/Pritzker, GSK and WTCCC) and found significant association at 
3p21, which was one of the three regions showing association at the level of P ≈ 10-7. 
GWAS of major depression along with meta-analyses have also demonstrated 
association with GRM7 (Sullivan et al. 2009; Muglia et al. 2010; Shi et al. 2011; 
Shyn et al. 2011). A meta-analysis of major mood disorders, including bipolar 
disorder and MDD samples from GAIN-MDD, NIMH- BP, WTCCC, Step-BD and 
an unpublished German bipolar disorder study found genome-wide significant 
evidence for SNPs in 3p21.1 region (rs2251219, P = 3.63 x 10
-8
) (McMahon et al. 
2010). Breen et al. (2011a) reanalysed the data from the McMahon et al. (2010) 
study and performed further replication in additional MDD samples from three 
studies: the RADIANT (Recurrent depressive disorder and treatment study), 
deCODE Genetics, and the MDD2000+ community sample (Breen et al. 2011a).
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Figure 5.1 Association of GRM7 SNPs in the PGC-Bipolar GWAS generated using Ricopili. 
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Random-effect meta-analysis of the McMahon et al. (2010) study showed that the 
SNP rs2251219 was a genome-wide significant locus for bipolar disorder and not 
MDD whereas the replication study failed to find any association between rs2251219 
and MDD (P = 0.14) (Breen et al. 2011a). 
The contribution of CNVs in the psychiatric disorders has been appreciated only 
recently with the implementation of array technologies that enable genome-wide 
determination of CNVs. In a systematic study of CNVs in bipolar disorder, although 
an increase in overall CNV load was not reported, a nominally significant increase in 
singleton CNVs in bipolar disorder cases compared to controls was found (Zhang et 
al. 2009). GRM7 was one of the genes affected by singleton deletions in this study 
and the results have been discussed in detail in section 1.2.7. Deletions and 
duplications in GRM7 were found in UCL1 bipolar sample as well (McQuillin et al. 
2011). Rare CNVs occurring within GRM7 have been documented in patients with 
other psychiatric disorder patients such as mood disorder (Saus et al. 2010) and 
schizophrenia (Walsh et al. 2008). 
Structurally, mGluR7 is composed of a large N-terminal extracellular domain of 
approximately 590 amino acids, a 7 transmembrane (TM) domain of around 260 
amino acids and an intracellular C-terminus consisting of 30-80 amino acids similar 
to the other group III mGluRs (Figure 5.2). The VFT domain is responsible for the 
binding of L-glutamate and also contains a highly evolutionarily conserved 
orthosteric binding site. On binding to L-glutamate or an orthosteric agonist, the 
VFT domain undergoes a conformational change which is then propagated via an 
extracellular cysteine rich region to the 7 TM and cytoplasmic domains resulting in 
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G-protein activation, second messenger formation and ion channel modulations 
(Niswender and Conn 2010). L-AP4 was the first prototypic group III agonist used 
for defining the physiological functions of these receptors in vivo, although it was 
not subtype specific. AMN082 is the first selective allosteric agonist for mGluR7 
that does not require the presence of any orthosteric ligand and has been extensively 
used in the pharmacological studies. Interestingly, AMN082 activates mGluR7 in a 
pathway-selective manner such that only a subset of the receptor's signal 
transduction pathways is activated (Flor and Acher 2012). 
 
Figure 5.2 Schematic representation of a group III GluR homodimer with 
orthosteric and allosteric drug binding sites indicated 
[Taken from (Flor and Acher 2012)] 
A growing body of evidence suggests a strong relationship between mGluR7 
function and the action of antidepressants and mood-stabilizers. mGluR7 mRNA was 
upregulated in the dentate gyrus of Wistar Kyoto (WKY) rats, animal models of 
depression (O'Mahony et al. 2010). In animal models, AMN082 decreased 
Third party copyright material removed 
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immobility in standard experimental paradigms like forced swim test and tail 
suspension tests whereas these antidepressant-like effects were blocked when 
GRM7-deficient mice were used (Palucha et al. 2007). Furthermore, chronic 
treatment with citalopram decreased mGluR7 immunoreactivity in rat hippocampus 
and frontal cortex (Wieronska et al. 2007). Fabbri et al. (2012) investigated the 
modulation of early antidepressant efficacy by glutamatergic gene variants in the 
STAR*D sample and found that a GRM7 SNP rs1083801 was associated with an 
early response to treatment under a recessive model (GG genotype observed in 
14.34% of early responders vs 5.25% of late responders). Also the effect of the 
rs1083801 variant was more pronounced in their female subsample, confirming 
previous results which suggested that a gender-specific effect may be not infrequent 
in antidepressant pharmacogenetics (Pitychoutis et al. 2010)  
In summary, good evidence from genetic, pharmacological and animal studies 
suggests a connection between GRM7 and bipolar disorder and other 
neuropsychiatric disorders.  
5.2. Hypothesis 
GRM7 was significantly associated in the UCL1 bipolar GWAS. Analysis of 
deletions and duplications in the GWAS data revealed the presence of CNVs in 
GRM7, thereby strengthening the connection between GRM7 and bipolar disorder in 
the UCL1 sample. I hypothesised on the basis of these results and results from 
previous published linkage, GWA, CNV and expression studies that GRM7 is a 
strong susceptibility gene for bipolar disorder. 
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5.3. Aims  
The aim of this study was to identify novel variants in GRM7 associated with bipolar 
disorder by resequencing GRM7 in bipolar cases selected for inheriting a disease 
haplotype in the UCL1 GWAS. On the detection of novel associated functional 
variants, further characterisation of the variant would be undertaken to understand 
the mechanism of action of the mutation in the disorder. Also, the CNVs identified 
in the UCL1 sample would be validated using QRT-PCR. 
5.4. Results 
5.4.1. Association analysis 
In the UCL1 GWAS (Sklar et al. 2008), eight SNPs in GRM7 showed allelic 
association with bipolar disorder and the most significant SNP associated at this 
locus was rs1508724 (P = 0.0014) (Appendix V). Also, GRM7 has been found to be 
associated in other bipolar disorder samples. In the WTCCC sample, 35 SNP 
markers within GRM7 were found to be associated with bipolar disorder and in the 
STEP-BD sample a further 10 SNPs were associated. Furthermore, only one SNP, 
rs13070476, was associated with bipolar disorder in the UCL and WTCCC sample 
suggesting the presence of heterogeneity even within populations of similar ancestry. 
I failed to replicate the association of the three most significantly associated UCL1 
GWAS SNPs, rs1508724, rs11710946, and rs6769814 in the UCL2 sample (Table 
5.1). On combining the UCL1 and UCL2 genotype data for the three SNPs using 
PLINK, two SNPs, rs1508724 and rs6769814, remained significant (Table 5.2). I 
also performed a meta-analysis to assess the association of these SNPs in the 
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combined sample keeping account of the heterogeneity. Only one SNP rs6769814 
remained significant as a result of meta-analysis (Cochrane Q-statistic P-value of 
0.2166, Fixed effects model; P-value= 0.03506 and OR= 1.1544) (Table 5.2). The 
heterogeneity index for the other two SNPs rs1508724 and rs11710946 was 
significantly high at 76.83 and 81.67 respectively. This suggested that the UCL1 and 
UCL2 samples are not completely homogeneous although both were selected based 
on strict ancestry-based questionnaires. 
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Table 5.1 SNP association results with GRM7 in the UCL bipolar samples 
SNP 
Position 
(NCBI35/hg19) 
UCL1 UCL2 
Allele counts (MAF) P-value OR Alleles counts (MAF) 
P-value OR 
BP CON   BP CON 
rs1508724 7241745 
A 344 (0.34)  A 280 (0.28)  
0.001 1.36 
A 297 (0.29) A 270 (0.29) 
0.979 1.00 
G 668 (0.66) G 740 (0.72) G 723 (0.71) G 652 (0.71) 
rs11710946 7246241 
A 359 (0.36) A 430 (0.42) 
0.002 0.75 
A 399 (0.40) A 351 (0.38) 
0.634 1.05 
G 653 (0.64) G 590 (0.58) G 615 (0.60) G 567 (0.62) 
rs6769814 7251433 
G 349 (0.35) G 297 (0.29) 
0.008 1.29 
G 324(0.31) G 275 (0.30) 
0.571 1.06 
A 657 (0.65) A 721 (0.71) A 716 (0.69) A 639 (0.70) 
MAF, minor allele frequency; BP, bipolar; CON, control; OR, odds-ratio 
Table 5.2 Combined analysis of GRM7 SNPs in UCL1 and UCL2 samples 
SNP Position Combined analysis Meta-analysis 
(NCBI35/hg19) Allele counts (MAF) Fixed effects model Random effects model Q I
2
 
 BP CON P-value OR P Value OR P-value OR 
rs1508724 7241745 
A 623 (0.31) A 550 (0.28) 
0.043 1.15 0.032 1.16 0.32 1.15 0.038 76.83 
G 1373 (0.69) G 1392 (0.72) 
rs11710946 7246241 
A 751 (0.38) A 781 (0.40) 
0.092 0.90 0.080 0.89 0.477 0.90 0.020 81.67 
G 1241 (0.62) G 1157 (0.60) 
rs6769814 7251433 
G 652 (0.33) G 572 (0.30) 
0.045 1.15 0.035 1.15 0.091 1.15 0.217 34.5 
A 1354 (0.67) A 1360 (0.70) 
MAF, minor allele frequency; BP, bipolar; CON, control; OR, odds ratio; Q, p-value for Cochrane's Q statistic; I2, I^2 heterogeneity index (0-100) 
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5.4.2. Sequencing 
Detection of novel variants in GRM7 associated with bipolar disorder was pursued 
by resequencing all the exons in all the GRM7 isoforms (Figure 5.3), exon/intron 
boundaries, ~3 kb of the promoter region of the isoforms ENST00000486284 and 
ENST00000463676, and 1 kb of the promoter region of the isoform 
ENST00000458641, 5'-UTR and 3′-UTR of the GRM7 gene in 32 haplotype 
selected cases and 32 random controls. In total, I found 71 previously published and 
10 novel mutations in GRM7 (Table 5.3). Most of the published SNPs were of 
similar frequency in the sequenced cases and controls (Table 5.3), and therefore, 
these were not genotyped. Also, SNPs that were in complete LD with the UCL1 
bipolar GWAS SNPs were not genotyped in the complete sample. Of the novel 
mutations, three were single base substitutions, two STRs, and five insertion 
deletions (Table 5.3). Bioinformatic analysis was carried out for the novel SNPs to 
determine their effect on the structure and/or function of GRM7. Finally, based on an 
increased frequency in cases compared to controls in the sequencing panel, 18 SNPs 
were further genotyped in the complete UCL sample (UCL1 and UCL2). Among 
these, only rs56173829 was significantly associated with bipolar disorder in the UCL 
sample (P = 0.035; OR = 0.4829) (Table 5.4), although the minor allele was less 
common in cases than controls. The rare allele of the SNP rs56173829 was present 
in 25/1821 alleles (1.4%) in control subjects versus 12/1810 (0.66%) in bipolar cases 
(Table 5.4). The SNP rs56173829 is present in the 3′-UTR of the long isoform of 
GRM7 and may play an important role in microRNA binding. 
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Figure 5.3 Isoforms of GRM7 
(Generated using UCSC genome browser Feb. 2006 assembly). The main isoform of GRM7 is shown 
by the red arrow and the other two shorter isoforms are shown by black arrows. 
Additionally, some SNPs were present only in cases, rs138571076 (P = 0.0826) in 
three bipolar disorder patients, GRM7_3f_7313045 in two bipolar disorder patients 
and GRM7_nPb_7467774 in only one bipolar disorder patient. One of the novel 
SNPs, GRM7_9c_7698252 was found in only one control. All these SNPs are 
intronic in the GRM7 gene. The SNP rs712774 was predicted to introduce a splice 
acceptor site using the Splice Site Prediction by Neural Network 
(http://www.fruitfly.org/seq_tools/splice.html) but was not associated with bipolar 
disorder in the UCL sample (P=0.853). Imputation using European sample data for 
the GRM7 exonic SNPs and SNPs in the intron/exon boundary in the 1000 genomes 
sequencing panel did not reveal any synonymous or functional SNPs that were 
associated with bipolar disorder (Table 5.5).  
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Table 5.3. SNPs found by resequencing GRM7 
Region  
Coding/non
-coding 
SNP ID Position (NCBI35/hg19) Alleles MAF 
Promoter promoter 3_6900524_1000G 6900524 CT/C 0.18* 
Promoter promoter rs183111337 6900527 T/C 0.01* 
Promoter promoter rs62237226 6900528 C/T 0.19* 
Promoter promoter rs115717493 6900573 G/A 0.01* 
Promoter promoter rs340653 6900663 C/T 0.3* 
Promoter promoter rs163422 6900744 C/T 0.08* 
Promoter promoter rs371097 6900910 C/A 0.1* 
Promoter promoter rs371841 6900912 C/T 0.29* 
Promoter promoter rs62237227 6901071 C/T 0.19* 
Promoter promoter rs339807 6901090 G/A 0.26 
Promoter promoter rs63470962 6901176 C/CAAG 0.09* 
Promoter promoter rs114774914 6901783 A/T 0.03* 
Promoter promoter 3_6901914_1000G 6901976 AAGA/- NA  
Promoter promoter rs62237228 6902167 A/G 0.19* 
Promoter promoter 3_6902624_1000G 6902624 T/TC 0.25* 
Exon 1 
coding-
synonymous 
rs3749380 6903297 C/T 0.45 
Intron  intronic rs342034 6903601 A/G 0.04 
Intron  intronic rs3828472 7188006 G/T 0.33 
Intron  intronic rs9868134 7188033 T/C 0.22 
Intron  intronic rs3749450 7188063 G/A 0.33 
Intron  intronic rs3749449 7188072 A/G 0.18 
Intron  intronic rs3749448 7188116 G/A 0.18 
Exon 2 
coding-
synonymous 
rs35106713 7188180 T/C 0.02 
Intron  intronic rs140139253 7188396 T/C 0.001* 
Promoter of ENST00000463676 isoform intronic rs6768211 7337515 G/T NA 
Promoter of ENST00000463676 isoform intronic rs185220306 7337786 T/G 0.01* 
Promoter of ENST00000463676 isoform intronic rs9850091 7337788 G/T 0.44* 
Promoter of ENST00000463676 isoform intronic rs116361217 7337904 C/T 0.07* 
Promoter of ENST00000463676 isoform intronic GRM7_3f_7313045 7338045 G/A NA 
Promoter of ENST00000463676 isoform intronic rs7638548 7338112 G/A 0.37* 
Promoter of ENST00000463676 isoform intronic rs78210196 7338179 C/A 0.01* 
Promoter of ENST00000463676 isoform intronic rs7640834 7338353 G/A 0.37* 
Promoter of ENST00000463676 isoform intronic rs61060115 7338521 -/A NA * 
Promoter of ENST00000463676 isoform intronic rs75618003 7338776 C/T 0.18* 
Promoter of ENST00000463676 isoform intronic rs138571076 7338985 A/G 0.01* 
Promoter of ENST00000463676 isoform intronic rs138761134 7339328 ATGTT/A 0.01* 
Promoter of ENST00000463676 isoform intronic rs78677232 7339409 C/T 0.18* 
Promoter of ENST00000463676 isoform intronic rs192193072 7339471 A/G 0.002* 
Promoter of ENST00000463676 isoform intronic rs2291867 7340164 C/T 0.39 
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Region  
Coding/non
-coding 
SNP ID Position (NCBI35/hg19) Alleles MAF 
Intron  
affects 
splicing 
rs712774 7456675 C/T 0.26 
Promoter of ENST00000458641 isoform 
intronic GRM7_nPb_74677
74 
7492774 C/T NA 
Promoter of ENST00000458641 isoform intronic rs712792 7492779 C/T 0.26 
Promoter of ENST00000458641 isoform intronic nPa_7493030 7493030 -/C indel NA 
Promoter of ENST00000458641 isoform intronic rs73015547 7493347 C/T 0.13* 
Promoter of ENST00000458641 isoform intronic rs712793 7493351 A/G 0.34 
Exon 6 
coding-non-
synonymous 
rs2229902 7494417 A/T 0.44 
Exon 8 
coding-
synonymous 
rs1485174 7595828 A/G 0.29 
Intron  intronic nex4_7600830 7600830 T indel NA 
Intron  intronic rs1143739 7601039 G/T 0.26 
Exon of ENST00000458641 isoform 3' UTR rs1965222 7603194 C/T 0.13 
Exon of ENST00000458641 isoform 3' UTR rs3828429 7603367 C/G 0.01* 
Exon 8 
coding 
synonymous 
rs34373930 7620168 A/G 0.3* 
Exon 8 
coding 
synonymous 
rs7614915 7620382 C/T 0.26 
Exon 8 
coding 
synonymous 
rs1485175 7620789 C/T 0.43 
Intron  intronic rs1485173 7621093 A/T 0.3* 
Intron  intronic rs1485172 7621158 C/T 0.43 
Intron intronic rs2139187 7649591 G/T 0.34* 
Exon of ENST00000458641 isoform frameshift nex7_7649745 7649745 Insertion of T NA 
Intron intronic rs114582026 7649815 G/T 0.16* 
Intron intronic rs115155482 7649819 C/T 0.3* 
Exon of ENST00000458641 isoform 3' UTR rs7611935 7678010 A/G 0.34* 
Exon of ENST00000458641 isoform 3' UTR rs7612048 7678090 A/G 0.3 
Intron intronic rs17047754 7678134 C/T 0.3 
Intron intronic nex8_7678357 7678357 G/T NA 
Intron intronic rs162802 7721613 T/C 0.5 
Exon 9 3' UTR rs2280739 7721997 G/A 0.06 
Exon 9 3′-UTR 3' UTR rs10514663 7723179 G/A 0.08 
Exon 9 3′-UTR 
3' UTR GRM7_9c_769825
2 
7723252 G/A NA 
Exon 9 3′-UTR 3' UTR rs162801 7723744 G/A 0.5* 
Exon 9 3′-UTR 3' UTR rs140995942 7723896 G/A 0.01* 
Intron 
intronic 
STR 7724024 
Simple T 
repeat  
Exons 11 and 12 3' UTR rs5846531 7732725 -/T 0.02* 
Intron intronic rs2279840 7735770 A/G 0.2 
Intron intronic Ex14_Indel 7736114 18 bp insertion NA 
Intron intronic rs162777 7736246 C/T 0.26 
Exon 15, 3′-UTR 3' UTR rs75721571 7782367 C/G 0.07* 
Exon 15, 3′-UTR 3' UTR rs9826579 7782371 C/T 0.24* 
Exon 15, 3′-UTR 3' UTR rs56173829 7782494 A/T 0.01* 
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Region  
Coding/non
-coding 
SNP ID Position (NCBI35/hg19) Alleles MAF 
Exon 15, 3′-UTR 3' UTR rs17726576 7782551 C/T 0.02 
Exon 15, 3′-UTR 3' UTR rs60445645 7782703 -/T NA 
Outside the gene, 3′ end 
outside the 
gene 
rs150288969 7783347 G/A 0.01* 
MAF, minor allele frequency; NA, not available; *MAF in European samples derived from the 1000 genomes project 
 
  
210 
 
Table 5.4 Tests of allelic association of GRM7 SNPs, found by resequencing, in 
the UCL sample 
SNP Position 
(NCBI35/ 
hg19) 
Min/Maj 
Allele 
MAF  Genotype 
counts 
Allele 
counts 
P-
value 
OR (95% CI) 
rs114774914 6901783             
Cases   A/T 0.014 0/26/897 26/1820 0.268 0.75 (0.45-1.25) 
Controls     0.019 0/35/901 35/1837     
3_6901914 6901914             
Cases   C/CTCTT 0.022 1/39/885 41/1809 0.766 1.07 (0.69-1.67) 
Controls     0.021 0/38/878 38/1794     
rs62237228 6902167             
Cases   C/A 0.190 30/290/601 350/1492 0.228 1.11 (0.94-1.31) 
Controls     0.175 27/267/625 321/1517     
rs342034 6903601             
Cases   A/G 0.040 4/64/837 72/1738 0.351 1.18 (0.83-1.67) 
Controls     0.034  1/60/852 62/1764     
rs35106713 7188180             
Cases   C/T 0.008 0/14/915 14/1844 0.188 0.64 (0.33-1.25) 
Controls     0.012  0/22/914 22/1850     
rs140139253 7188396             
Cases   T/C 0.004 0/7/927 7/1861 0.787 1.16 (0.39-3.47) 
Controls     0.003  0/6/924 6/1854     
GRM7_3f_7313045 7338045             
Cases   G/A 0.001 0/2/927 2/1856 0.157 NA  
Controls     0.000  0/0/932 0/1864     
rs138571076 7338986             
Cases   G/A 0.002 0/3/926 3/1855 0.083 NA 
Controls     0.000  0/0/932 0/1864     
rs192193072 7339471             
Cases   A/G 0.001 0/2/926 2/1854 0.156 0.33 (0.07-1.65) 
Controls     0.003  0/6/919 6/1844     
rs712774 7456675             
Cases   C/T 0.263 81/392/580 554/1552 0.853 0.99 (0.86-1.14) 
Controls     0.266  65/353/491 483/1335     
GRM7_nPb_7467774 7492774             
Cases   T/C 0.001 0/1/923 1/1847 0.321 NA 
Controls     0.000  0/0/909 0/1818     
rs2229902 7494417             
Cases   T/A 0.447 185/445/282 815/1009 0.227 0.92 (0.81-1.05) 
Controls     0.467 213/442/275 868/992     
rs1965222 7603194             
Cases   T/C 0.128 18/235/805 271/1845 0.713 1.04 (0.86-1.25) 
Controls     0.124 11/210/713 232/1636     
GRM7_9c_7698252 7723252             
Cases   A/G 0.000 0/0/924 0/1848 0.319 NA 
Controls     0.001 0/1/928 1/1857     
rs140995942 7723896             
Cases   A/G 0.013 0/24/909 24/1842 0.371 0.78 (0.46-1.34) 
Controls     0.016 0/30/885 30/1800     
rs56173829 7782494             
Cases   A/T 0.007 0/12/899 12/1810 0.035 0.48 (0.24-0.96) 
Controls     0.014 0/25/898 25/1821     
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SNP Position 
(NCBI35/ 
hg19) 
Min/Maj 
Allele 
MAF  Genotype 
counts 
Allele 
counts 
P-
value 
OR (95% CI) 
rs17726576 7782551             
Cases   T/C 0.027 1/47/874 49/1795 0.763 1.07 (0.71-1.6) 
Controls     0.025 0/46/874 46/1794     
rs150288969 7783347             
Cases   A/G 0.008 0/14/910 14/1834 0.682 1.18 (0.54-2.55) 
Controls     0.006 0/12/918 12/1848     
Min, minor; Maj, major; MAF, minor allele frequency; OR, odds-ratio; CI, confidence interva
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Table 5.5 Significantly associated GRM7 SNPs (P ≤ 0.05) using imputation from 
1000G GRM7 SNPs 
SNP Position  A1 A2 GENO NPRX INFO F_A F_U OR P 
rs10510354 7252190 C G 0.408 2 0.479 0.375 0.408 0.87 0.003 
rs1352411 7799831 A G 0.389 2 0.423 0.079 0.092 0.839 0.017 
rs340659 6906622 C T 0.408 2 0.54 0.065 0.052 1.27 0.021 
rs11708019 7229619 G A 0.408 2 0.441 0.343 0.365 0.908 0.027 
rs9823996 7244509 G C 0.408 2 0.475 0.316 0.294 1.11 0.028 
rs9820417 7104786 G A 0.387 2 0.438 0.238 0.258 0.899 0.033 
rs17288442 6866379 A C 0.407 2 0.479 0.302 0.324 0.903 0.034 
rs13070476 7259313 C T 0.403 2 0.45 0.226 0.245 0.901 0.034 
rs1508724 7241745 A G 0.763 2 0.82 0.311 0.284 1.14 0.035 
rs6769814 7251433 G A 0.763 2 0.802 0.324 0.297 1.13 0.035 
rs17047149 7380288 G A 0.407 2 0.353 0.007 0.011 0.623 0.052 
rs11717750 7464013 T C 0.408 2 0.846 0.507 0.479 1.12 0.053 
A1, Allele 1; A2, Allele 2; GENO, Genotyping for the reference SNP; NPRX, Number of proxy SNPs used to tag reference 
SNP; INFO, Information metric for each reference SNP; F_A; Reference SNP allele frequency in cases; F_U; Reference SNP 
allele frequency in controls; OR, odds-ratio; P, Asymptotic p-value for test of association. All the positions are correct 
according to NCBI35/hg19 assembly 
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5.4.3. Haplotype analysis 
I performed haplotype analysis on the combined data including all the SNPs 
genotyped in GRM7 (UCL1 GWAS SNPs, the three GWAS SNPs in UCL2, and 
SNPs found by mutation screening in GRM7) in the present study using Haploview 
(Figure 5.4) (Barrett et al. 2005). The most significant haplotype (HAP_GRM7) was 
associated with normal controls comprising SNPs rs1400166, rs2875257, 
rs10510353, rs11708019, rs1963265, rs1508724, rs9823996, rs11710946 and 
rs6769814 (P = 0.007) (2.2% and 4.3% in cases and controls respectively). 
Particularly, the SNPs driving the association of this haplotype were the three most 
significantly associated SNPs in UCL1 GWAS, rs1508724, rs11710946 and 
rs6769814. All the other associated haplotypes, including HAP_GRM7, did not 
survive permutation testing.
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Figure 5.4 LD structure between GRM7 SNPs genotyped in the UCL research sample 
The most significantly associated haplotype that also contains the significant GWAS SNPS is marked with a a three sided arrow.
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5.4.4. CNV validation 
McQuillin et al. (2011) performed an analysis of the deletions and the duplications in 
the UCL1 bipolar research sample and found that the overall rate of CNVs was 
significantly lower in the cases compared to controls. Both deletions and 
duplications of size >100 kb were detected in GRM7 in the UCL1 sample (Table 
5.6). Singleton deletions were present in two cases and one control whereas 
duplication was present in only one case but not in any controls (Figure 5.5). 
Table 5.6 CNVs in GRM7 detected in UCL1 samples 
Location CNV Sample 
Chr3:7347535 - 7733108 Duplication Case 
Chr3:7277350 - 7558603 Deletion Case 
Chr3:7001273 - 7107443 Deletion Case 
Chr3:7040496 - 7208936 Deletion Control 
 
 
  
 
Figure 5.5 CNVs occurring in GRM7 in UCL1 GWAS sample 
Figure generated using data from (McQuillin et al. 2011). UCSC genome browser March 2009 
assembly 
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I selected a deletion and a duplication involving a common genomic region for the 
validation using QRT-PCR assay. TaqMan® RNase P Copy Number Reference 
(CNR) Assay, Human (Applied Biosystems, UK) was used for the CNV validation. 
In the RNase P CNR assay, four individuals, one each with a deletion and a 
duplication, and two CNV negative control individuals were tested using primer 
pairs designed to detect duplication and deletion in the same assay. Replicable 
results were obtained with all the four primer pairs tested and the CNVs were 
confirmed in the respective UCL samples (Table 5.7) (Figure 5.6 and Figure 5.7).  
Table 5.7 CNV validation using RNaseP copy number reference assay 
Sample  Target Referenc
e 
Mean 
Cp 
Cp 
Error 
Mean 
Cp 
Cp 
Error 
Target/Ref Target/Ref 
Error 
Duplication GRM7 RNaseP 26.65 0.121 28.10 0.205 2.729 0.4022 
Control GRM7 RNaseP 27.41 0.046 28.47 0.118 2.083 0.1613 
Control GRM7 RNaseP 27.24 0.177 28.37 0.071 2.192 0.2593 
Deletion GRM7 RNaseP 27.39 0.165 27.89 0.079 1.415 0.1674 
 
 
Figure 5.6 CNV validation with one primer pair using TaqMan® RNase P copy 
number reference assay  
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Figure 5.7 CNV validation with four different primer pairs using TaqMan® 
RNase P copy number reference assay  
5.5. Discussion 
The association of GRM7 in the UCL1 sample with bipolar disorder was not 
replicated in the UCL2 sample. This might be explained by the presence of 
heterogeneity even within a single ancestrally selected group of bipolar cases. The 
population based case-control samples are useful in detecting the sporadic cases 
containing common risk variants conferring susceptibility to a complex disorder like 
bipolar disorder, thereby sometimes failing to identify the rare variants associated 
with the disorder. Another limitation may be that the replication sample was not 
large enough to detect the expected level of association with GRM7, having less than 
80% power to detect the association for all the three SNPs (refer to the graph in 
Appendix VI). Furthermore, the presence and the proportion of several other disease 
haplotypes in GRM7 causing bipolar disorder in different populations makes it more 
difficult to replicate findings. Another possibility is that the previous association 
results are false positives. Nonetheless, two of the previously associated SNPs, 
rs1508724 and rs6769814, in UCL1 remained significant when I combined genotype 
data of the UCL1 and UCL2 samples using PLINK. Resequencing of GRM7 in the 
haplotype selected cases detected a 3′-UTR variant, rs56173829, with the minor 
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allele significantly more common in controls compared to cases. Variants in the 3′-
UTR play an important role in the regulation of translation by means of microRNA 
(miRNA) binding sites. Additionally, I found two novel and one previously 
published case-only base-pair changes in the UCL sample, however, their 
frequencies were extremely low. 
Alternative splicing in GRM7 results in five isoforms characterised by different C-
terminals. The rs56173829 variant is located in the 3′-UTR of the long isoform of 
GRM7 (NM_181874; ENST00000486284). RNA webserver was used to predict the 
secondary structure of the wild-type and mutant 3′-UTR containing SNP 
rs56173829. The RNA webserver (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi) 
produces two structures - MFE and centroid secondary structure. The MFE structure 
of an RNA sequence is the secondary structure that contributes a minimum of free 
energy (MFE) whereas the centroid structure of the same is the secondary structure 
with minimal base pair distance to all other secondary structures in the Boltzmann 
ensemble. The predicted centroid secondary structures for the wild-type 3′-UTR was 
altered by the introduction of the SNP rs56173829, however, the MFE structures for 
both were not dissimilar (Figure 5.8 and Figure 5.9). The cis-regulatory elements in 
the 3′-UTR of mRNAs have been reported to influence translation and cause genetic 
diseases. Translation de-regulation and disorders resulting from mutations affecting 
the termination codon, polyadenylation signal and secondary structure of 3′-UTR of 
mRNA have also been documented (Chatterjee and Pal 2009). A correlation between 
the functionality of 3′-UTR variants and alterations in the predicted mRNA 
secondary structure was reported in a study by Chen et al. (2006) on 83 disease 
associated 3′-UTR variants of various human mRNAs.  
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(a) 
 
(b) 
 
Figure 5.8 Centroid secondary structure for the wild-type (a) and mutant (b) 3'-
UTR containing SNP rs56173829 predicted using RNAfold webserver 
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(a) 
 
(b) 
 
Figure 5.9 MFE secondary structure for the wild-type (a) and mutant (b) 3'-
UTR containing SNP rs56173829 predicted using RNAfold webserver  
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miRNas are 21-22 nucleotides long, single-stranded and bind to 3′-UTRs of 
particular mRNAs through partially complementary sequences and prevent the 
mRNAs from being translated into proteins. Multiple types of miRNAs can 
cooperate to suppress translation of a single mRNA, and a single miRNA can 
interact with multiple types of miRNAs, thereby regulating the protein expression of 
different genes (Filipowicz et al. 2008). RegRNA 
(http://regrna.mbc.nctu.edu.tw/html/prediction.html) is a web server that designs a 
variety of interface to facilitate the analysis for the homologs of the regulatory RNA 
motifs. This software predicted that the wild-type and mutant 3′-UTR were bound to 
different miRNAs (Appendix VII). However, target scan and UCSC genome browser 
did not predict any miRNA binding site involving the nucleotide and the sequence 
around it. In a study by Zhou et al. (2009) chronic treatment of primary cultures with 
the mood stabilizers, VPA or lithium, elevated levels of GRM7 and lowered levels of 
miR-34a. Incubation of primary hippocampal culture with miR-34a precursor 
significantly reduced GRM7 protein levels whereas, with anti-miR miRNA-34a 
inhibitor significantly increased GRM7 protein levels. These results suggested that 
the mood stabilizers produce a part of their behavioural effects through mechanisms 
including modulation of protein levels through miRNAs such as miR-34a (Zhou et 
al. 2009). 
CNVs have been implicated in the pathogenesis of psychiatric disorders such as 
autism (Sebat et al. 2007; Christian et al. 2008; Glessner et al. 2009), schizophrenia 
(Bergen et al. 2012), bipolar disorder (Zhang et al. 2009)and ADHD (Elia et al. 
2011). I confirmed the presence of previously reported singleton deletion and 
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duplication in the UCL1 sample. Functional studies investigating the possible role of 
these CNVs are required to shed more light on their involvement in the disorder. 
In conclusion, I found a 3′-UTR variant in GRM7 that was significantly associated 
with bipolar disorder in the UCL sample but with increased representation in 
controls compared to cases. Bioinformatic analyses predicted that the rs56173829 
variant influenced the centroid secondary structure of the RNA and also altered the 
binding site of microRNAs. However, results from these in silico analyses should be 
interpreted with caution as these are based on mathematical algorithms instead of 
expression studies. Thus, functional assays need to be carried out to assess the role of 
the 3′-UTR variant on GRM7 gene expression. The case-only novel mutations 
reported in the current study also warrant further investigation in other populations to 
understand their distribution and involvement in the aetiology of bipolar disorder.  
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Chapter 6  
Mutation screening of the GRM3 
glutamate receptor gene in Bipolar 
disorder 
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6.1. Introduction 
The GRM3 gene encodes the mGluR3 protein which is a group II metabotropic 
glutamate receptor similar to mGluR2. mGluR3 is a G protein-coupled receptor 
which acts by inhibition of adenylate cyclase and reducing cyclic AMP production 
(Cartmell and Schoepp 2000). The group II mGluRs are involved in learning, 
memory, anxiety and perception of pain. mGluR3 is found on pre- and postsynaptic 
neurons in synapses of the hippocampus, cerebellum, cerebral cortex as well as other 
parts of the brain and in peripheral tissues. The mGluR3 receptors modulate 
glutamate concentrations by sensing excess synaptic glutamate release and providing 
a negative feedback mechanism which downregulates glutamate transmitter release. 
The activation of postsynaptic mGluR2/3 receptors can reduce neuronal excitability 
and plasticity through intracellular mechanisms such as modulation of ion channels 
and induction of long-term synaptic depression (Anwyl 1999). Studies have also 
suggested that mGluR2/3 receptors may function as heteroreceptors controlling the 
release of GABA and other neurotransmitters (Feyissa et al. 2010). 
GRM3 is located on 7q21. Several bipolar linkage studies provide support for 
linkage on 7q (Baron 2002; Liu et al. 2003; Cassidy et al. 2007). Two meta-analyses 
of genome scans were also supportive under some models (Segurado et al. 2003; 
Tang et al. 2011). A recent study following up previously reported linkage signals 
with enlarged samples and enhanced marker density demonstrated strong linkage for 
bipolar disorder on 7q34 with a LOD of 3.53 (Xu et al. 2011). The linkage studies 
and GWAS are discussed in detail in sections 1.2.4 and 1.2.6. 
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The GRM3 gene has been investigated in BPAD as part of several GWAS, but failed 
to reach genome-wide significance in any of these studies. In a collaborative study 
(Ferreira et al. 2008; Sklar et al. 2008) fifteen single nucleotide polymorphism (SNP) 
markers within 50 kb of GRM3 gene showed allelic association with bipolar 
disorder. The SNP rs2237563 was the most significantly associated marker (P = 3.85 
x 10
-5
) in the UCL1 sub-sample. Fourteen other markers within 125 kb of the gene 
also showed nominally significant associations with bipolar disorder in the UCL1 
sub-sample. In the WTCCC sample (WTCCC 2007), thirteen SNP markers within 
125 kb of GRM3 were found to be associated with bipolar disorder and in the STEP-
BD sample, a further four SNPs were associated. Of these, three markers, 
rs10258008, rs11974622 and rs1557665 were consistently found to be associated 
with bipolar disorder in the UCL and WTCCC sample, whereas only one marker, 
rs12704286, was associated with bipolar disorder in both the STEP-BD and UCL 
samples. In the PGC bipolar study, the most associated GRM3 marker was 
rs17161018 (P = 9.32 x 10
-4
) (Figure 6.1) (Sklar et al. 2011). A total of 32 different 
SNP markers within 125 kb of GRM3 were nominally associated with bipolar 
disorder. Several other association studies in different populations also provide 
evidence of association between GRM3 markers and bipolar disorder. In a study of 
Ashkenazi bipolar trios, GRM3 was ranked as showing “highly suggestive” 
transmission disequilibrium between a four SNP marker haplotype and bipolar 
disorder (Fallin et al. 2005). A study of bipolar disorder in South Africa found that 
heterozygotes for the GRM3 SNP rs6465084 had a four-fold increased risk of 
lifetime history of psychotic symptoms (Dalvie et al. 2010). However, a German 
study found no evidence of association between GRM3  
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Figure 6.1 Association of GRM3 SNPs in the PGC-BP GWAS generated using Ricopili 
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and bipolar disorder (Marti et al. 2002). A study of MDD revealed an allelic 
association between the SNP rs6465084 in GRM3 and depression (P = 0.037) 
(Tsunoka et al. 2009). 
The human GRM3 gene consists of six exons that give rise to four transcript 
variants, the main transcript being NM_000840. Four alternatively spliced transcripts 
of GRM3 have been previously reported in human brain, including a full length 
transcript, a transcript with exon 2 deleted, a transcript with exons 2 and 3 deleted 
and a transcript with exon 4 deleted (Sartorius et al. 2006) (Figure 6.2). Molecular 
characterization of the promoter of GRM3 (Corti et al. 2001) provided evidence of a 
silencing element being present in exon 1. Clinical studies of the effect of receptor 
agonists and antagonists of mGluR2/mGluR3 have been carried out for the treatment 
of anxiety, schizophrenia, depression and withdrawal from morphine and nicotine 
(Schoepp et al. 2003; Patil et al. 2007; Dunayevich et al. 2008). 
 
Figure 6.2 Alternatively spliced GRM3 isoforms. 
The transcripts are shown with their Ensemble database transcript numbers. Numbered exons are 
shown as boxes. Translated regions are shown in black and untranslated regions are shown in gray 
(adapted from Sartorius et al. (2006)) 
Third party copyright material removed 
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6.2. Hypothesis 
A positive association was observed for GRM3 in the UCL1 bipolar GWAS and 
several other bipolar GWAS have also reported nominal associations for the gene. 
On the basis of the results of GWAS and linkage studies, I hypothesised that GRM3 
is a strong susceptibility candidate gene for bipolar disorder. 
6.3. Aims 
The aim of this study was to identify novel variants in GRM3 associated with bipolar 
disorder by resequencing GRM3 in bipolar cases selected for inheriting a disease 
haplotype in the GWAS. Further functional characterisation of the novel variants 
would be undertaken to understand the mechanism of action of the mutation in the 
disorder. 
6.4. Results 
6.4.1. GRM3 association analysis 
GRM3 was associated with bipolar disorder in the UCL1 GWAS (Appendix V). I 
tested association of the three most significantly associated GRM3 SNPs, rs2237563, 
rs274621 and rs2158786 from the UCL1 bipolar sample in the UCL2 case-control 
sample. None of these SNPs showed association with bipolar disorder in the UCL2 
case-control sample (Table 6.1). When the genotyping data of the three SNPs in 
UCL1 and UCL2 was combined using PLINK (Purcell et al. 2007), two of the three 
SNPs remained significantly associated (rs2237563: P=0.0099, OR=1.222 and 
rs2158786: P= 0.025, OR=0.852) with bipolar disorder (Table 6.2).
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Table 6.1 SNP association results with GRM3 in the UCL bipolar sample 
SNP Position (NCBI35/hg19) 
UCL1
1
  UCL2
2
  
Allele counts (freq) P Value OR  Allele counts (freq) P Value OR  
BP CON    BP CON    
rs2237563 86443168 G 264 (0.27) G 190 (0.19) 3.85 x 10
-5
 1.56  G 217 (0.21) G 195 (0.21) 0.95 1.01  
  A 734 (0.73) A 822 (0.81)    A 813 (0.79) A 729 (0.79)    
rs274621 86272799 C 388 (0.38) C 332 (0.33) 0.007 1.29  C 365 (0.35) C 329 (0.36) 0.82 0.98  
  T 622 (0.62) T 688 (0.67)    T 677 (0.65) T 599 (0.64)    
rs2158786 86406018 G 764 (0.76) G 723 (0.71) 0.01 0.78  G 757 (0.72) G 661 (0.72) 0.67 0.96  
  A 242 (0.24) A 295 (0.29)    A 285 (0.28) A 263 (0.28)    
SNP, single nucleotide polymorphism; OR, odds ratio;1 UCL1 data from our GWA study (Sklar et al. 2008); 2 UCL2 is a replication sample; Additional genotyping performed in UCL1 after the 
GWAS has been added to UCL1&2; BP, bipolar cases, and CON, controls; Significant P values are in bold P < 0.05 
 
Table 6.2 Combined analysis of GRM3 SNPs in UCL1 and UCL2 samples 
SNP 
Position Combined analysis Meta-analysis 
(NCBI35/hg19) Allele counts (MAF) Fixed effects model Random effects model 
Q I
2
 
 BP CON P-value OR P Value OR P-value OR 
rs2237563 7251433 
G 465 (0.23) G 385 (0.20) 
0.01 1.22 0.00323 1.2536 0.2989 1.2439 0.0062 86.64 
A 1547 (0.77) A 1551 (0.80) 
rs274621 7241745 
C 728 (0.36) C 662 (0.34) 
0.18 1.09 0.07854 
1.1225 0.3981 1.119 
0.0428 75.62 
T 1296 (0.64) T 1288 (0.66) 
rs2158786 7246241 
G 1453 (0.64) G 1440 (0.71) 
0.03 0.85 0.02134 
0.8498 0.1715 0.8504 
0.0938 64.38 
A 517 (0.26) A 558 (0.29) 
MAF, minor allele frequency; BP, bipolar; CON, control; OR, odds ratio; Q, p-value for Cochrane's Q statistic; I2, I^2 heterogeneity index (0-100) 
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To assess the effect of heterogeneity on the association of these SNPs in the 
combined sample, I performed a meta-analysis of these SNPs using PLINK. 
Interestingly, only one of the SNPs, rs2158786 remained significant in the meta-
analysis (Cochrane Q-statistic P-value of 0.1405, Fixed effects model; P-value= 
0.021 and OR= 0.850) (Table 6.2). The heterogeneity index for the two other SNPs, 
rs2237563 and rs274621 was very high at 86.64 and 75.62 respectively, suggesting 
that UCL1 and UCL2 are heterogeneous even though they were selected using the 
same ancestry-based methods (Table 6.2). Of note is the impact of heterogeneity on 
replication of allelic associations even within well-defined ancestral populations, but 
the meta-analysis in this case is underpowered with only two studies being analysed. 
Therefore, there is support for the association between the GWAS associated SNP 
rs2237563 in GRM3 and bipolar disorder in the UCL2 samples despite evidence of 
heterogeneity. 
6.4.2. Detection and evaluation of new variants 
A total of 11 SNPs including a putative Kozak sequence variant (rs148754219) were 
detected by sequence analysis across the promoter region, 5'-UTR, exons, 
intron/exon junctions and the 3′-UTR of GRM3 (Table 6.3). These included the 
synonymous and non-synonymous coding base pair changes, rs2228595 and 
rs17161026; a SNP in intron 2, rs139639092; three SNPs in the exon 1 5′-UTR, 
rs184681725, rs2073549 and rs148754219; and five promoter SNPs, rs274617, 
rs274618, rs166677, rs274619, and rs274622. Bioinformatic analysis of the promoter 
region SNPs for altered transcription factor binding indicated that the mutant alleles 
of rs148754219 and rs166677 were likely to bind to an increased range of 
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Table 6.3 SNPs found by sequencing GRM3 
GRM3 Gene 
region 
SNP 
Predicted effect on GRM3 structure/function for 
novel SNPs 
Chr 7 position 
(NCBI37/hg19) 
BP MAF  CON MAF  HapMap 
MAF 
1000 genome 
MAF (Mar 2012) 
Promoter rs274617  86271830 0.42 0.57 0.32 0.26 
Promoter rs274618  86272016 0.42 0.60 0.32 0.24 
Promoter rs166677 Alters binding of two transcription factors (TESS) 86272294 0.29 0.47 0.40 0.35 
Promoter rs274619  86272487 0.46 0.34 0.25 0.26 
Promoter rs274622  86272940 0.42 0.60 0.32 0.27 
Exon 1 5′-UTR rs184681725  86273267 0.02 0.03 na 0.003 
Exon 1 5′-UTR rs2073549  86273584 0.07 0.05 0.01 0.02 
Exon 1 5′-UTR rs148754219  86274087 0.03 0 na 0.01 
Intron 2 rs139639092  86395015 0.03 0 na 0.01 
Exon 3 rs2228595 Coding synonymous (A293A) 86415987 0.05 0.02 0.06 0.06 
Exon 4 rs17161026 Coding non-synonymous (G475D) 86468254 0.02 0 0.02 0.01 
Chr, Chromosome; MAF, minor allele frequency; BP, bipolar cases; CON, Controls; UTR, untranslated region; na, not available. 
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transcription factors compared to their respective common alleles. Prediction of the 
5′-UTR secondary structure of GRM3 mRNA by the Mfold program showed that the 
rs148754219 base pair change was not likely to alter the mRNA structure (Figure 
6.3). The variant rs148754219 is located two bases upstream of the ATG start codon 
of the GRM3 isoform GRM3∆2∆3 (ENST00000546348) encoding 
ENSP00000441407, and is therefore in the Kozak sequence for this isoform (Figure 
6.2).  
Ten of these SNPs were selected for genotyping in the complete sample (UCL1 and 
UCL2) on the basis of increased frequency in the sequenced cases compared to 
sequenced controls or on predicted functional effects (Table 6.3). Of these, the 
Kozak sequence variant rs148754219 was found to be significantly associated with 
bipolar disorder (P = 0.005; OR, 4.20; 95% CI, 1.43-12.37) (Table 6.4) after 
correction for multiple markers (P = 0.047). In the UCL research sample, 19 bipolar 
cases and only four controls were found to be heterozygous for the variant. The 
association of the rs148754219 variant in the UCL research sample remained 
significant when only Bipolar I cases were included in the analysis (P = 0.006). 
None of the other new SNPs were associated with bipolar disorder in the complete 
UCL sample (Table 6.4). Imputation using genotype data for GRM3 exonic SNPs 
and SNPs in the intron/exon boundary, of European samples in the 1000 genomes 
project did not find any functional SNPs associated with bipolar disorder (Table 6.5). 
All the variants showing proxy association as a result of imputation, excluding the 
rs148754219 variant, were intronic in GRM3 or outside the gene. 
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Table 6.4 Tests of association with potentially aetiological GRM3 SNPs in the UCL sample 
SNP ID 
Position 
(NCBI37/hg19) 
N Allele counts (MAF) Genotype counts P-value OR (95% CI) 
rs148754219       
Case 86274087 1062 A 19 (0.01); G 2105 AA 0; AG 19; GG 1043 0.005 4.20 (1.43-12.37) 
Control  932 A 4 (0.002) ; G 1860 AA 0; AG 4; GG 928   
rs166677       
Case 86272294 1048 G 960 (0.46); A 1136 GG 221; AG 518; AA 310 0.19 1.09 (0.96-1.23) 
Control  908 G 794 (0.44); A 1022  GG 176; AG 442; AA 290   
rs17161026       
Case 86415987 1056 T 30 (0.01); C 2082 TT 0; CT 30; CC 1026 0.51 1.21 (0.69-2.10) 
Control  931 T 22 (0.01); C 1840 TT 0; CT 22; CC 909   
rs139639092       
Case 86395015 1057 A 21 (0.01); G 2093 AA 0; AG 21; GG 1036 0.53 1.24 (0.64-2.41) 
Control  934 A 15 (0.01); G 1853 AA 0; AG 15; GG 919   
rs2228595       
Case 86468254 1053 T 118 (0.06); C1988 TT 1; CT 116; CC 936 0.68 0.94 (0.72-1.23) 
Control  931 T 110 (0.06); C 1752 TT 6; CT 98; CC 826   
rs2073549       
Case 86273584 1061 T 76 (0.04); A 2046 TT 1; AT 74; AA 986 0.85 0.97 (0.69-1.35) 
Control  932 T 69 (0.04); A 1795 TT 1; AT 67; AA 865   
rs184681725       
Case 86273267 1056 A 25 (0.01); C 2087 AA 0; AC 25; CC 1031 0.87 0.96 (0.54-1.69) 
Control  927 A 23 (0.01); C 1831 AA 0; AC 23; CC 904   
 SNP, single nucleotide polymorphism; N, number of samples; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval; NA, not applicable  
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Table 6.5 Tests of association with GRM3 SNPs in the UCL sample using imputation from 1000 genomes European samples  
SNP BP A1 A2 GENO NPRX INFO F_A F_U OR P 
rs2237563 86443168 G A 0.752 2 0.816 0.231 0.2 1.2 0.00627 
rs148754219 86274087 A G 0.908 2 0.988 0.0089 0.00216 4.14 0.00672 
rs2299231 86489625 G A 0.403 2 0.403 0.117 0.103 1.16 0.0164 
rs2158786 86406018 A G 0.757 2 0.784 0.258 0.285 0.869 0.0194 
rs12704286 86374941 A G 0.398 2 0.494 0.253 0.275 0.893 0.0217 
rs2237554 86378896 G T 0.402 2 0.499 0.253 0.275 0.894 0.0227 
rs10236047 86512637 G A 0.402 2 0.403 0.115 0.102 1.15 0.0251 
rs10258008 86535446 A C 0.403 2 0.417 0.115 0.101 1.16 0.0251 
rs723631 86401592 C G 0.403 2 0.469 0.251 0.271 0.901 0.0273 
rs2519713 86544667 C A 0.402 2 0.445 0.428 0.45 0.913 0.0292 
rs11974622 86536377 A G 0.402 2 0.416 0.115 0.102 1.15 0.0295 
rs7804907 86428208 T C 0.403 2 0.48 0.25 0.268 0.911 0.0507 
A1, Allele 1; A2, Allele 2; GENO, Genotyping for the reference SNP; NPRX, Number of proxy SNPs used to tag reference SNP; INFO, Information metric for each reference SNP; F_A; 
Reference SNP allele frequency in cases; F_U; Reference SNP allele frequency in controls; OR, odds-ratio; P, Asymptotic p-value for test of association. All the positions are correct according 
to NCBI35/hg19 assembly 
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      (a)       (b) 
Figure 6.3 Secondary structures of mRNA predicted using mFold webserver for wild-type and mutant 5′-UTR of GRM3 containing 
rs148754219 variant
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I combined data from all the SNPs genotyped in the GRM3 gene in the present study 
(UCL1 GWAS SNPs, the three GWAS SNPs in UCL2, and ten SNPs found by 
mutation screening) and performed haplotype analysis using Haploview (Barrett et 
al. 2005). The haplotype block comprising seven SNPs rs2299221, rs12704289, 
rs7804907, rs2237563, rs7806785, rs2299224 and rs17697609 showed the strongest 
association with bipolar disorder, which survived permutation testing (P = 7.11 x  
10
-5
, empirical P = 0.0009) (Figure 6.4) (Table 6.6). The haplotype driving this 
association was the same haplotype identified by SNP rs2237563 in the UCL1 
GWAS study (Sklar et al. 2008). No other haplotypes were significantly associated 
with bipolar disorder. The Kozak sequence variant rs148754219 was located outside 
this haplotype block and showed negligible LD with SNP rs2237563 (D′= 0.57, r2 = 
0.001). The SNPs that were of similar frequency in the case and control sequencing 
panel samples and those that were in complete LD with the UCL1 bipolar GWAS 
SNPs were not genotyped in the whole sample
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Table 6.6 GRM3 haplotypes associated with bipolar disorder 
Haplotype Alleles 
Frequency 
of the 
haplotype 
Frequency 
Chi-square P-value 
Case Control 
rs1405881-rs1405880-rs274637-rs274621-
rs802437-rs802439-rs802441-rs802459 
TGCCAGCT 0.349 0.375 0.321 6.86 0.0088 
rs802467-rs2189812-rs10238436-rs16888204 ACGA 0.297 0.323 0.270 7.095 0.0077 
rs2237553-rs12704286-rs2237554-SNP_A-
2126810-rs2888551-rs723631-rs17160978-
rs17697445-rs2158786-rs16888210-rs2237559 
CGTAAGCGGCG 0.702 0.727 0.677 6.299 0.0121 
TAGAACCGACG 0.133 0.117 0.150 4.993 0.0255 
rs2299221-rs12704289-rs7804907-rs2237563-
rs7806785-rs2299224-rs17697609 
ATCGCAA 0.222 0.257 0.185 15.782 7.11E-05 
ATTAGAA 0.143 0.126 0.161 5.133 0.0235 
rs17161024-rs166677-rs184681725-rs2073549-
rs10952891-rs148754219 
GACACG 0.467 0.436 0.501 8.075 0.0045 
rs7788115-rs6955452-rs6955917-rs2299231-
rs10236047-rs10258008-rs7781178-
rs11974622-rs2519713 
TCGAACAGA 0.287 0.311 0.265 5.339 0.0209 
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Figure 6.4 Linkage disequilibrium between all the GRM3 SNPs genotyped in UCL research sample 
The figure was generated using Haploview. The most significantly associated GWAS SNP, rs2237563 is marked with a black arrow; the 5′-UTR variant, rs148754219 is 
marked with a red arrow and the associated haplotype is marked using a box. 
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6.4.3. Genotyping of the rs148754219 variant in a 
bipolar family, and unrelated alcohol 
dependence and schizophrenia cohorts 
 
I sequenced the DNA of the family members available for one of the bipolar patients 
who was heterozygous for the rs148754219 variant to examine if the mutation 
segregated with psychiatric illness in the family. DNA samples available from a 
family containing members with unipolar disorder included that of a same-sex 
sibling (F076004) and, one alternate sex (F076002) and two same-sex third-degree 
relatives (F076001 and F076003), all of whom have a unipolar disorder diagnosis 
except F076002 (Figure 6.5). Sequencing analysis revealed that none of the family 
members of the proband (heterozygous for rs148754219 variant) carried the 
mutation. 
I further genotyped the rs148754219 variant in the alcohol dependence and 
schizophrenia samples to detect the frequency of this variant in other psychiatric 
disorder samples available in the Molecular Psychiatry Laboratory, UCL. The 
variant showed significant association with schizophrenia and a trend towards 
association with alcoholism (P = 0.024 and 0.0869 respectively) (Table 6.7). When 
the genotype data from all the bipolar disorder, alcohol dependence and 
schizophrenia samples was combined and compared to that of the UCL controls, the 
SNP remained significant at P = 0.012 [OR (95%CI) = 3.47 (1.24-9.73)]. 
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Figure 6.5 Pedigree of the bipolar case heterozygous for the rs148754219 
variant  
Solid shapes represent bipolar disorder diagnosis, half-filled shapes represent unipolar disorder 
diagnosis and clear shapes represent normal individual. 
 
Table 6.7 Association results of rs148754219 variant in psychiatric disorder 
samples 
Sample 
Allele counts  Genotype counts 
P-value OR (95% CI) 
A G  AA AG GG 
CON 4 1860  0 4 928 NA NA 
ALC 11 1941  1 9 966 0.085 2.64 (0.84-8.30) 
BP 19 2105  0 19 1043 0.005 4.20 (1.43-12.37) 
SCZ 9 1175  0 9 583 0.024 3.56 (1.09-11.59) 
ALC+BP+SCZ/CON 39 5221  1 37 2592 0.012 3.47 (1.24-9.73) 
CON, controls; ALC, alcohol dependence; BP bipolar; SCZ, schizophrenia; OR, odds ratio; CI, confidence 
interval.  
Bipolar case 
(rs148754219 carrier) 
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6.4.4. DNA-Protein complex formation by 
rs148754219 variant 
TESS analysis predicted that the rare allele of rs148754219 variant created 
transcription factor binding sites recognised by transcription factors including AP-1, 
NF-X3, RFX2, E12 and myogenin and the wild-type allele created binding sites for 
RAF-1 and GCR1 (Figure 6.6). Electrophoretic mobility shift assays (EMSAs) of the 
allelic variants of rs148754219 on transcription factor binding showed that under the 
experimental conditions used the mutant A allele caused gel shifts compared to the 
wild-type G base sequence. This effect could be completely abolished by the 
addition of a 200-fold excess of unlabelled A probe but not by unlabelled competitor 
wild-type G probe, indicating that the DNA-protein binding was exclusive to the 
mutant allele (Figure 6.7). Similar results were obtained in three independent 
experiments. Supporting the TESS prediction results, the rare A allele of 
rs148754219 appears to bind more strongly to transcription factors within the 
nuclear lysate than the wild-type G allele, suggesting that this variant creates a 
transcription factor binding site likely to change GRM3 mRNA expression compared 
to the wild-type sequence.
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GRM3_rs148754219_wt 
00001  GCCAGTAAGC TACCTCTTTT GTGTCGGATG AGGAGGACCA ACCATGAGCC  00050 
       ====(8.00) NF-1 R01681 
                       ====(8.00) Dof2,Dof3,MNB1a,PBF 
R08443,R08440,R08441,R08442 
                       =====(8.00) LEF-1,TCF-1(P),TCF-1,TCF-1A,TCF-1B,TCF-
1C,TCF-1E,TCF-1F,TCF-1G,TCF-2alpha 
R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248 
                           = =====(12.00) GR R03537 
                                ====(8.00) RAF R00256 
                                  =====(10.00) GCR1 R03806 
                                      = ====(10.00) GAL4 R00492 
                                          ======(8.9089) H-2RIIBP I00178 
                                            =====(10.00) H4TF-2 R00681 
                                            =====(7.9248) H4TF2 I00180 
 
GRM3_rs148754219_mut 
00001  GCCAGTAAGC TACCTCTTTT GTGTCAGATG AGGAGGACCA ACCATGAGCC  00050 
       ====(8.00) NF-1 R01681 
                       ====(8.00) Dof2,Dof3,MNB1a,PBF 
R08443,R08440,R08441,R08442 
                       =====(8.00) LEF-1,TCF-1(P),TCF-1,TCF-1A,TCF-1B,TCF-
1C,TCF-1E,TCF-1F,TCF-1G,TCF-2alpha 
R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248,R02248 
                           = ======(14.00) Zta R00299 
                           = ======(9.3987) v-Jun I00417 
                           = ======(14.00) AP-1,c-Jun,v-Jun,YAP1 
R01412,R01412,R01412,R01412 
                           = =====(12.00) GR R03537 
                                 ======(9.6721) NF-X3 I00397 
                                 ======(9.6721) RFX2 I00406 
                                 ======(12.00) E12,myogenin R08512,R08512 
                                      = ====(10.00) GAL4 R00492 
                                          ======(8.9089) H-2RIIBP I00178 
                                            =====(10.00) H4TF-2 R00681 
                                            =====(7.9248) H4TF2 I00180 
 
 
 
Figure 6.6 TESS results for rs148754219 wild-type and mutant alleles 
The alleles are shown in red and the transcription factors predicted to bind the alleles are highlighted.
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Figure 6.7 Electrophoretic mobility shift assay for the rs148754219 variant 
EMSAs performed with G (1-3) or A allele probes (4-15) and SH-SY5Y cell nuclear extract. DNA-protein complex (band) formed with A-allele was 
competed in a concentration-dependent manner by unlabelled A-allele (5-10), but not by unlabelled G-allele (11-15). 
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6.4.5. Effect of the rs148754219 variant on GRM3 
promoter activity and its function as a 
transcriptional silencer 
The ability of the rs148754219 variant to modulate transcription was tested using 
luciferase reporter gene constructs (Figure 6.8). Clone A tested the effect of 
rs148754219 on the ability of GRM3 exon 1 to act as a promoter for luciferase 
reporter gene activity. In HEK293 cells there was no difference in the relative 
luciferase expression levels of wild-type and mutant Clone A and B constructs 
(Figure 6.9 and 6.10). I observed significant reductions of 61% (Student’s t-test, 
P<0.001) (Figure 6.10) in the level of luciferase expression with the mutant Clone A 
construct compared to the wild-type Clone A construct, whereas, there was no 
difference in the expression levels of wild-type and mutant Clone B constructs in 
SH-SY5Y cells (Figure 6.10). Clone B tested whether similar effects on promoter 
activity with the rs148754219 alleles could be observed when the GRM3 putative 
minimal promoter was combined with exon 1. Since the difference in expression 
levels between wild-type and mutant Clone A constructs is not apparent in the 
presence of the minimal promoter in the Clone B constructs, minimal GRM3 
promoter activity appears to mask any effect the mutation would have on the 
expression of GRM3. Therefore, given the considerable loss in Clone A construct 
promoter activity with the mutant compared to the wild-type allele in SH-SY5Y 
cells, I further tested the ability of the rs148754219 mutation to negatively regulate 
expression of GRM3. 
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Clone C with GRM3 exon 1 cloned upstream of the SV-40 promoter followed by the 
luciferase gene was used to test whether rs148754219 alleles affected the silencing 
element present in exon 1 (Corti et al. 2001). After 48 hours of transfection, the 
mutant Clone C construct reduced the expression of luciferase by 37% (Mann-
Whitney U test, P < .0001) compared to the wild-type construct in HEK293 cells 
(Figure 6.9). In contrast, this effect was reversed in SH-SY5Y cells with an increase 
in luciferase expression in the mutant construct of 11% (Student’s t-test, P-value = 
0.04) compared to the wild-type construct (Figure 6.10). Together, these findings 
indicate that the rs148754219 variant exhibits characteristics of a tissue-specific 
transcription enhancer element binding site in SH-SY5Y cells and a silencer element 
in HEK293 cells. 
 
Figure 6.8 Luciferase (Luc+) reporter gene constructs designed to assess the 
impact of rs148754219 on transcription and/or translation 
In clone E the native luciferase start codon is mutated so that translation can only begin at the start 
codon in GRM3 exon 1. 
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6.4.6. Elimination of luciferase expression driven 
by post-transcriptional/translational activity 
of the rs148754219 variant 
In order to investigate whether the rs148754219 variant regulated GRM3 gene 
expression at the translational level, I cloned the GRM3 Exon 1 upstream of the 
firefly luciferase gene and just downstream of the SV-40 promoter, making the insert 
the 5′-UTR of the firefly luciferase gene. The wild-type and mutant constructs 
(Clone D) were transfected in HEK293 and SH-SY5Y cells. In both cell-lines, the 
wild-type rs148754219 variant in the pGL3-promoter backbone of Clone D resulted 
in a decrease in luciferase reporter activity while the mutant led to total elimination 
of luciferase activity (Figure 6.9 and 6.10). To elucidate that the nullifying effect of 
the mutant allele of rs148754219 on protein production was related to the in-frame 
ATG 2 bp downstream of the mutation in the GRM3 5′-UTR insert and not the ATG 
of the firefly luciferase gene, I created Clone E. In Clone E, the A base of the start 
codon of luciferase gene was mutated to G to give GTG, leaving the ATG 
immediately downstream of the GRM3 5′-UTR insert as the only in-frame start 
codon for initiating the translation of firefly luciferase. Again, following the 
transfection of wild-type and mutant Clone E constructs, the mutant Clone E 
construct did not produce any reporter activity in either HEK293 or SH-SY5Y cells 
as observed with Clone D (Figures 6.8 and 6.9). These results suggest that the 
mutant A allele of rs148754219 polymorphism abolishes upstream post- 
transcriptional/translational activity. 
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Figure 6.9 Relative luciferase activity of reporter gene assays for the 
experimental constructs in HEK293 cells 
Data expressed as mean ± SEM of three independent experiments performed in triplicate (n = 9). 
*P < 0.05; ***P < 0.001.  
 
 
 
Figure 6.10 Relative luciferase activity of reporter gene assays for the 
experimental constructs in SH-SY5Y cells 
Data expressed as mean ± SEM of three independent experiments performed in triplicate (n = 9). 
*P < 0.05; ***P < 0.001.  
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To gain further insight into the molecular impact of the rs148754219 variant on gene 
regulation, I quantified the luciferase mRNA levels of the wild-type and mutant 
Clone D constructs and compared the results to that of the gene reporter 
luminescence assays described above. There was no significant difference in the 
relative mRNA levels of the wild-type and mutant clones in the HEK293 cell-line 
(wild-type; mean [SEM], 0.8517 [0.0274]; mutant, 0.8543 [0.0513]) (n=3) and the 
SH-SY5Y cell-line (wild-type, 0.8303 [0.0087]; mutant, 0.7889 [0.0291]) (n=3) 
(Figure 6.11). Therefore, the abundance of luciferase mRNA produced by the Clone 
D construct with the mutant allele suggests that the luciferase gene is being 
transcribed. However, this did not correlate with the relative reporter activity of this 
clone whereby luciferase luminescence was absent, indicating that the luciferase 
protein was not translated. Thus, these results suggest that the bipolar associated 
GRM3 5′-UTR variant rs148754219 can be functionally distinguished from the wild-
type in different gene reporter assays and has an effect at the post-transcriptional 
and/or translational level. 
 
Figure 6.11 Relative luciferase mRNA quantification of wild-type and mutant 
Clone D constructs using QRT-PCR 
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6.5. Discussion 
The failure to find genetic association in the UCL2 cohort for the markers most 
strongly associated in the UCL1 sample (Sklar et al. 2008) is typical in the field of 
complex disease genetics. The difficulty in obtaining clear cut replications is due to 
the presence of low frequency disease alleles and high degree of aetiological genetic 
heterogeneity. The UCL2 replication sample was under powered for detecting the 
association between the SNPs rs274621 and rs2158786 and bipolar disorder but had 
95% power for detecting that of SNP rs2237563 (Appendix VI). Therefore, it is 
possible that the initial association signals were chance findings. Significant 
association was observed for the rs148754219 variant with BP I disorder in the 
combined UCL1 and UCL2 sample. The small number of BP II cases did not permit 
a test of association with this variant in the UCL sample. The rs148754219 variant 
has not been previously reported in any other sample other than the 1000 genomes 
sample (www.1000genomes.org). The rs148754219 variant did not segregate in 
unipolar affective disorder family members of one of the heterozygous bipolar 
patients for the variant. One explanation may be that this variant is a pure bipolar 
disorder susceptibility variant and thus could not be detected in the unipolar family 
members. Also this variant was significantly associated with schizophrenia and was 
present at a higher frequency in the alcohol dependence syndrome samples compared 
to the control samples. It should be noted that the same controls samples were used 
for testing allelic association in the bipolar disorder, alcohol dependence and 
schizophrenia samples. Thus, caution needs to be excercised while interpreting the 
results of the association analyses of the Kozak sequence variant with other 
psychiatric disorders. 
  
250 
 
The rs148754219 variant is located in the first exon of GRM3, which is transcribed 
and not translated in the main isoform of the gene (NM_000840). Bioinformatic 
analysis predicted that the mutant allele of rs148754219 bound to several more 
transcription factors than the wild-type allele. The results from the EMSA assays 
provided experimental evidence for this as shown by the protein/DNA band shifts 
with the mutant allele. In this study, I did not use super-gel shift assays to verify the 
composition of the DNA-protein complex because antibodies specific for all the 
transcription factors altered by the mutant allele were not available commercially. 
Based on the bioinformatic analysis and the EMSA results I provide evidence that 
the rs148754219 variant affects gene expression via the basal transcription apparatus 
that contains partial sequence downstream of the transcription start site as reported 
for several other genes (Minet et al. 1999; Singh et al. 2002; Berardi et al. 2003; 
Coppotelli et al. 2006). I also showed that the mutant A allele could cause 
upregulation of reporter activity in neuroblastoma cells and downregulation in 
kidney derived cells. These differences are likely due to the variation in the presence 
of different transcription factors expressed in the two cell types. 
To further elucidate the mechanism of action of this variant on the transcriptional 
regulation of the gene, I generated three constructs using two different reporter 
vectors – pGL3-Basic and pGL3-promoter vector. The resultant clones were 
transfected into two different cell-lines, one that does not express GRM3 
endogenously and another expressing GRM3 endogenously, HEK293 and SH-SY5Y 
respectively. With the introduction of new transcription factor binding sites specific 
to the mutant allele as predicted by TESS analysis, I expected to see a change in 
expression in the promoter assays with the mutant allele. As the differences observed 
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with the two clones (Clones A and B) are inconsistent and vary by cell-type, it adds 
to the complexity of the role this variant has in controlling mRNA transcription. One 
explanation for the inconsistency between the expression level results of Clone A 
and Clone B constructs is that the minimal GRM3 promoter activity in Clone B 
constructs masks any effect the mutation has on the expression of GRM3, implying 
an interaction between the promoter and the 5′-UTR. 
Experimental evidence suggests that exon 1 of GRM3 contains a silencer binding 
sequence resulting in a negative regulation of transcriptional activity (Corti et al. 
2001). Interestingly, contrasting results in the two cell-lines were obtained with these 
constructs designed to assess the effect of rs148754219 variant on the silencing 
effect of exon 1. In accordance with these results, it is apparent that this mutation 
might affect the transcriptional regulation of GRM3 in a cell-specific manner by 
creating a transcription enhancer element binding site in the SH-SY5Y 
neuroblastoma cells and a transcription silencer element binding site in HEK293 
cells. Together, the results from all the three constructs (Clone A, Clone B, and 
Clone C) designed for investigating the in vitro effect of rs148754219 polymorphism 
on the transcriptional regulation of GRM3 gene suggest that the variant may regulate 
gene expression by altering the binding affinity of the 5′-UTR towards transcription 
factors, in turn affecting the promoter activity.  
Four alternatively spliced transcripts of GRM3 have been previously reported in 
human brain corresponding to full-length GRM3, transcripts with a deletion of exon 
2, exons 2 and 3 deleted or with exon 4 deleted (Figure 6.1) (Sartorius et al. 2006). 
In GRM3∆2∆3 isoform, the SNP rs148754219 is at -2 position from the translation 
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initiation codon ATG forming part of the Kozak consensus motif, which is a 
consensus sequence found in eukaryotic mRNA regulating protein translation 
(Kozak 1999). Based on its location in the GRM3 5′-UTR, I hypothesised that 
rs148754219 variant might influence the translation efficiency of an alternatively 
spliced isoform, GRM3∆2∆3 and levels of the truncated form of protein for GRM3. 
Luciferase assays with the mutant 5′-UTR cloned downstream of a strong SV-40 
promoter and upstream of the firefly luciferase cDNA (Clone D) showed that the 
mutant allele caused a total suppression of luciferase expression in both the cell-lines 
suggesting that the mutation might be harmful. Confirmation that the null reporter 
activity caused by the mutant allele resulted from the effect on translation initiation 
from the ATG codon immediately following the rs148754219 variant was found by 
mutating the luciferase gene start codon in Clone E. Thus, the AUG codon 2 bp 
downstream of the rs148754219 allele was the only in-frame AUG present in the 
Clone E construct that could result in the translation of a full-length, functional 
luciferase protein. Similar to the Clone D constructs, the mutant Clone E construct 
did not produce any luciferase expression compared to the wild-type clone. 
Prediction of the 5′-UTR secondary structure of GRM3 mRNA by Mfold program 
showed that the rs148754219 polymorphism does not alter the mRNA structure. The 
mRNA levels of the mutant and wild-type alleles of Clone D were consistent 
suggesting that the variant was acting at the post-transcriptional / translational level 
and not at the level of transcription.  
GRM3 has previously been reported to be genetically associated with schizophrenia 
(Harrison and Weinberger 2005; Straub and Weinberger 2006; Mossner et al. 2008). 
Altered levels of dimeric forms of GRM3 with no change in total GRM3 was 
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reported in the prefrontal cortex in schizophrenia patients (Corti et al. 2007). The 
GRM3 splice isoform GRM3∆4 encodes a truncated variant of the receptor lacking 
the trans-membrane domain and has been detected in the human brain (Sartorius et 
al. 2006). Sartorius et al. (2008) hypothesised that the truncated form of the receptor 
encoded by GRM3∆4 might interact with the full-length receptor by forming hetero-
dimers or act as a ‘decoy receptor’ soaking up glutamate in active competition with 
the full-length receptor. Expression data results of GRM3 and GRM3∆4 transcripts 
in the dorsolateral prefrontal cortex (DLPFC) and hippocampus of two case-control 
cohorts of schizophrenia patients and controls, CBDB/NIMH collection and Stanley 
Array Collection, were inconclusive as they found that the GRM3 expression was 
increased in schizophrenia patients only in the CBDB/NIMH collection (Sartorius et 
al. 2008).  
Multiple proteins can be synthesized from one mRNA by alternative splicing or by 
the choice of a translation initiation codon. The choice as well as efficiency of 
translation is controlled by mRNA-specific elements such as the GC content of the 
5′-UTR, the size of the 5′-UTR and the location of potentially active upstream 
initiation codons (Meijer and Thomas 2002). Mutations in the 5′-UTR of genes 
affecting translation efficiency have been extensively documented (Signori et al. 
2001; Bisio et al. 2010; Lukowski et al. 2011). According to Kozak, the optimal 
context around an initiation codon required for efficient translation in higher 
eukaryotes is CCRCCAUGG, with the most conserved nucleotides at -3 position (R) 
being A or G, and the G at +4 considering the A of the AUG as +1 (Kozak 1999). 
The nucleotides at positions -6, -5, -4, -2, -1 could also influence translation 
efficiency when the transcripts contain a weak Kozak motif (Kozak 1986). Kozak 
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SNPs at positions -1 and -5 of genes, CD40 and GP1BA (glycoprotein Ib, α 
polypeptide) and +4 position of CHAT (choline acetyl transferase) and SCARB1 
(scavenger receptor class B, member 1) have been reported to be associated with 
Grave’s disease (Jacobson et al. 2005), ischemic stroke (Baker et al. 2001; Maguire 
et al. 2008), Alzheimer’s disease (Ozturk et al. 2006) and Type 2 diabetes (Osgood 
et al. 2003) respectively. The 148754219 polymorphism in exon 1 is located 
upstream of the initiation codons of two alternatively spliced transcripts of GRM3 
gene, GRM3∆2 and GRM3∆2∆3. I propose that this mutation might affect GRM3 
expression by altering the expression level(s) of either or both these transcripts. 
Firstly, the GRM3∆2∆3 transcript does not have a strong Kozak sequence as the 
triplet sequence preceding the initiation codon is CGG that lacks a purine at the -3 
position. It is possible that the substitution of G allele with the A allele in the 
rs148754219 polymorphism at -2 position alters the strength of its Kozak sequence 
leading to altered expression levels of this transcript in bipolar disorder patients. 
Luciferase activity by the wild-type Clones D and E demonstrates that the in-frame 
ATG of the GRM3∆2∆3 isoform is efficiently recognised by scanning ribosomes, 
which might then initiate translation of this transcript to produce a truncated protein. 
Furthermore, evidence from the bioinformatic analysis and EMSA results suggests 
that it is likely that the mutant allele in these constructs binds to a translational 
repressor, thereby, suppressing reporter activity. These results provide preliminary 
experimental evidence that GRM3∆2∆3 isoform is translatable in vivo. Existence of 
a truncated form of GRM3 protein resulting from the translation of GRM3∆2∆3 
isoform can only be confirmed by carrying out further in vivo localization and 
expression experiments.  
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Secondly, in the luciferase assays with Clone D constructs, the mutant allele had a 
debilitating impact on the reporter activity, whereby, the mRNA was being 
transcribed at a similar level for the wild-type and mutant constructs. Again, this 
might be explained by ribosomal scanning process, which is involved in the IRES 
(internal ribosomal entry site) -mediated cap-independent translational control of 
mRNA (Kozak 1978). During the scanning process, it is plausible that the 
rs148754219 mutation in the 5′-UTR of GRM3 gene causes the ribosomes to ignore 
the ATG of the GRM3∆2∆3 transcript, a process called ‘leaky-scanning’, and 
recognise the downstream ATG of the GRM3∆2 transcript and initiate translation of 
this transcript. In the Clone E constructs, the downstream ATG of the GRM3∆2 
transcript was out-of-frame and the ATG of GRM3∆2∆3 transcript was the only in-
frame codon to initiate translation of the full-length luciferase protein. Perhaps, this 
mutation causes a switch in the usage of the alternative initiation codon on exon 1 
resulting in the translation to start at the downstream and out-of-frame ATG of 
GRM3∆2 transcript in the mutant clone, thereby, failing to produce a functional 
protein. This switching of the initiation codons might be applicable to the other two 
downstream AUGs located in exon 2 of GRM3 corresponding to that of full-length 
GRM3 and GRM3∆4 as well. Because in the present study I did not incorporate the 
downstream sequence from exon 2 in the plasmid constructs (to prevent 
complications in the methodology and interpretation of the results), it is rather 
difficult to comment on the impact of this mutation on the translation efficiency of 
full-length GRM3 and GRM3∆4. A significant regional variation in the mRNA 
expression and splicing of the MAPT (microtubule-associated protein tau) gene 
within the human brain has been reported in a study including brain samples from 
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439 normal individuals (Trabzuni et al. 2012). The Trabzuni et al. (2012) study 
found that the H1/H2 haplotypes were associated with the expression of exon 3 
containing isoforms in human brain. Thus, evidence is emerging suggesting that 
genetic factors contributing to neurodegenerative diseases may operate by changing 
mRNA splicing in different brain regions as opposed to the overall expression of the 
MAPT gene. Therefore it is possible that altered transcript regulation caused by 
rs148754219 might be one of the potential molecular mechanisms behind the genetic 
association of this variant in GRM3 with bipolar disorder.  
The modulation of excitatory neurotransmission via mGluRs in treating anxiety and 
stress-related disorders has been increasingly recognised in the last decade (Spooren 
et al. 2001; Schoepp et al. 2003; Linden et al. 2005). Altered expression levels of 
mGluR3 are well described in the pathology of several psychiatric disorders such as 
depression, anxiety and schizophrenia. Preliminary expression data in animals 
suggest that mGluR2/3 is reduced in the hippocampus in animal models of 
depression such as the olfactory bulbectomy in mice (Wieronska et al. 2008), and in 
spontaneously depressed flinders sensitive line rats when compared to controls 
(Matrisciano et al. 2008). In a recent study by Feyissa et al. (2011), significantly 
increased levels of mGluR2/3 protein was observed in the prefrontal cortex of MDD 
subjects compared to controls. Additionally, reports on elevated (Gupta et al. 2005) 
and reduced expression (Gonzalez-Maeso et al. 2008; Ghose et al. 2009) levels of 
mGluR2/mGluR3 in the frontal cortex of schizophrenia patients have previously 
been reported. Using a systematic approach combining exon capture and massive 
parallel sequencing of GPCR family genes in melanoma, Prickett et al. (2011) 
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identified mutations in GRM3 activating MEK, leading to increased anchorage-
independent growth and migration of melanoma cells. 
Several mGluR2/3 agonists and antagonists have been reported. Clinical studies on 
mGLuR2/3 agonist LY354740 in the treatment of anxiety (Schoepp et al. 2003; 
Dunayevich et al. 2008) and its LY404309 pro-drug LY2140023 in the treatment of 
schizophrenia (Patil et al. 2007) have been conducted with positive outcomes. 
MGS0039 is a selective group II mGluR antagonist that has antidepressant-like 
activity in rat models (Chaki et al. 2004). In the UCL sample, the Kozak sequence 
variant was convincingly over-represented in bipolar disorder cases compared to 
controls with an odds ratio above 4, suggestive of moderate to high risk to bipolar 
disorder. Further screening of normal comparison subjects in the general population 
is needed to establish the distribution of the mutation. This is the first study to date 
which reports a possible, though unconfirmed, rare and functional base pair change 
that is significantly associated with bipolar disorder. The finding needs confirmation 
in additional samples of both unipolar and BPAD as well as in alcoholism where 
unipolar affective disorder is known to be a primary aetiological factor. The 
knowledge of expression of the alternatively spliced transcripts of GRM3 and their 
respective protein products in bipolar disorder, schizophrenia, alcohol dependent and 
normal individuals may provide more insight into the regulation of this gene under 
these pathological conditions. Thus, further expression and immunochemical studies 
on bipolar disorder, schizophrenia and alcohol dependence should be designed to 
quantify and localize the alternative transcripts of GRM3 gene, which might be 
altered in these patients.  
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Chapter 7  
General Discussion 
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Bipolar disorder is a highly heritable disorder of the brain with increasing evidence 
pointing towards the involvement of multiple risk variants in the aetiology of the 
disease. Even with ever advancing technology, the underlying genetic and 
pathophysiological components of the disorder remain elusive. Intensive research in 
the field of bipolar disorder, including numerous family linkage studies, association 
studies and GWAS, has implicated genes on almost all the chromosomes in the 
pathogenicity of bipolar disorder. In this thesis, I aimed to investigate the genetic 
basis of bipolar disorder by examining a susceptibility locus based on linkage results 
and two metabotropic glutamate receptor genes based on GWAS results. In reference 
to the aims of this thesis, the following findings are presented: 
1. The fine mapping study showed positive association with the microsatellite 
marker D1S243 (P=0.037) leading us to further investigate the most proximal 
gene to this marker, PRKCZ, with increased marker density. Marker 
rs3128396 in PRKCZ was significantly associated with bipolar disorder in 
the UCL1 sample and the association improved further in bipolar disorder 
females for the two SNPs, rs3128296 and rs3128309 on gender-specific 
association analysis. However, a different marker rs2503706, which was not 
associated in the female-only analysis showed association in the male-only 
analysis. Haplotype association analysis also revealed significantly associated 
disease haplotypes in the gene. 
2. The replication of the three most significantly associated GRM7 SNPs in the 
UCL1 GWAS, rs1508724, rs11710946, and rs6769814, was not successful in 
the UCL2 sample. Analysis of the combined genotype data along with a 
meta-analysis of the two study samples found that two of the SNPs, 
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rs1508724 and rs6769814, remained significant in the combination analysis 
whereas only rs6769814 reached significance under the fixed-effects model. 
3. Resequencing of the GRM7 gene in the haplotype selected cases and random 
controls identified a 3'-UTR variant rs56173829 which was significantly 
associated with bipolar disorder in the complete sample (UCL1 and UCL2), 
however, it was more common in controls compared to cases. Bioinformatic 
analyses suggested that the variant altered the centroid secondary structure of 
the RNA and also changed the miRNA binding sites. Three bipolar-only 
mutations (2 novel and one previously published) and one novel control-only 
mutation in GRM7 with extremely low frequency were also identified in this 
study. 
4. The CNVs identified in the UCL1 bipolar GWAS were successfully 
validated using QRT-PCR. 
5. The replication of the three most significantly associated GRM3 SNPs in the 
UCL1 bipolar GWAS, rs2237563, rs274621 and rs2158786, was not 
successful in the UCL2 sample. Genotype data from both the studies was 
subjected to a combined analysis and a meta-analysis resulting in SNPs 
rs2237563 and rs2158786, whereas only SNP rs2158786 becoming 
significantly associated with bipolar disorder respectively. 
6. Resequencing GRM3 gene in haplotype selected cases and random controls 
identified a 5′-UTR variant rs148754219, which on genotyping in the 
complete sample was found to be significantly associated with bipolar. 
Bioinformatic analysis of the variant suggested that the rare allele of the 
rs148754219 variant altered the binding of transcription factors. 
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7. Electromobility shift assays and luciferase reporter assays were employed to 
investigate the mechanism underlying the effect of rs148754219 variant on 
GRM3 gene expression. A specific DNA-protein complex was observed for 
the mutant allele of the variant and not for the common allele in the EMSA 
experiments confirming the predictions of the bioinformatic analysis that the 
rare allele of the variant introduced new transcription factor binding sites. 
Further characterisation of the rs148754219 variant using luciferase reporter 
assays suggested that, though the mutation affected gene expression via both 
transcriptional and post-translational mechanisms, it affected more evidently 
via a post-translational mechanism. 
The most promising finding of this thesis is the identification of a possible functional 
variant in GRM3, rs148754219 that is significantly associated with bipolar disorder. 
Apart from the current study, the rs148754219 variant has only been reported in the 
1000 genomes data suggestive of its low frequency. This reinforces the theory of 
multiple rare variants in the causation of complex disorders like bipolar disorder. It is 
plausible that owing to its low frequency and its absence in the microarray chips 
used in GWAS the discovery of this mutation was not possible in other studies. The 
location of this variant in the GRM3 gene is of particular interest, being present in 
the 5′-UTR (Exon 1) of the gene that has been previously reported to contain a 
silencing element and also forming part of the promoter region. Additionally, this 
mutation is present in the Kozak sequence of a GRM3 isoform suggesting that it 
might play an important role in the translation of this particular transcript. 
On the basis of EMSA and reporter assays, I predict that the rare allele of the 
rs148754219 variant binds to a repressor protein/transcription factor causing 
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downregulation or complete abolishment of gene expression. However, it is also 
possible that this variant alters the translation efficiency of the isoforms of GRM3 
gene causing changes in the relative expression of these isoforms in vivo. The results 
from these in vitro studies need to be supported by primary culture and animal 
studies before arriving at a firm conclusion. 
Alternative splicing resulting in four isoforms of GRM3 gene has been documented 
in human brain. Previously, altered expression of a GRM3 isoform GRM3Δ4 has 
been observed in schizophrenic patients. However, the relative expression of all the 
GRM3 isoforms in a normal individual and in an individual with bipolar disorder is 
yet to be investigated. Interestingly, the rs148754219 variant showed association 
with schizophrenia and trend towards association with alcoholism (P = 0.024 and 
0.087 respectively) in this study. It is known that bipolar disorder is highly comorbid 
with alcohol dependence and schizophrenia, making a possible association with 
these disorders not unexpected. Confirmation of the association of the rs148754219 
variant in other bipolar disorder samples as well as in schizophrenia and alcohol 
dependence syndrome is required. Further expression and immunochemical studies 
on bipolar disorder and schizophrenia ought to be designed to quantify and localize 
the alternative transcripts of GRM3 gene, which might be altered in these patients. In 
future, lymphoblastoid, fibroblast, genome-edited and iPS cell-lines from affected 
patients can be cultured and used for the study of the neurobiology of mGluR3 and 
targeted treatments for mutation carriers. Additionally, the findings in PRKCZ and 
GRM7 also warrant further investigation in other samples. Functional assays aimed 
at understanding the role of the 3'-UTR variant in GRM7, rs56173829, in the 
pathology of bipolar disorder also need to be undertaken. 
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Recent GWAS in bipolar disorder have identified common non-coding 
polymorphisms in some genes, such as ANK3 and CACNA1C that have been 
replicated in several samples. However, bipolar disorder being a complex disorder, 
allelic heterogeneity must play a strong role in the genetic aetiology of bipolar 
disorder and larger samples are needed. Lack of complete frequent replications in 
association is to be expected if disease allele frequencies of 1%-2% are the norm and 
in many samples they may not be detectable. Epigenetic mechanisms causing 
modifications in the genome also increase the complexity of the genomic variation 
and provide a mechanism for modification of the bipolar disorder phenotype.  
Combined efforts from different research groups involving collaborative GWAS and 
meta-analysis have aided the search for genetic variants contributing to bipolar 
disorder. New analytical approaches such as pathway analysis of the genes in related 
systems involved in the disorder are currently being employed to identify novel 
susceptibility genes. Furthermore, next-generation sequencing seems to be the way 
forward for tackling allelic heterogeneity underlying these disorders. With the 
discovery of susceptibility genes and their susceptibility base pair changes, the 
development of treatments better targeted towards individual patients is already a 
viable proposition. 
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APPENDIX I 
Buffers and solutions 
DNA Extraction from blood samples 
10 X Lysis buffer 
100 mM NaCl, 100 mM EDTA; 5.84 g of NaCl and 37.22 g EDTA was added to one 
litre of MilliQ water and autoclaved. 
 
Proteinase K enzyme (20 mg/ml) (Sigma-Aldrich, UK) 
Proteinase K buffer 
50mM Tris.HCl (pH8.0), 50mM EDTA, 100mM NaCl; 25ml 2M Tris, 100ml 0.5M 
EDTA, and 25ml 4M NaCl were added and made up to one litre using MilliQ water. 
10% SDS 
10g of SDS was dissolved in 100 ml of autoclaved water. 
Polyvinylpolypyrrolidine (PVPP) (Sigma-Aldrich, UK) 
Phenol (Sigma-Aldrich, UK) 
1:24 Isoamylalcohol:chloroform solution 
One part of Isoamylalcohol (Sigma-Aldrich, UK) was mixed with 24 parts of 
chloroform (Sigma-Aldrich, UK) and mixed well. 
3 M Sodium Acetate 
Absolute ethanol (Sigma-Aldrich, UK) 
Low EDTA TE 
10 mM Tris, 0.1 mM EDTA 
Purification of PCR products 
MicroCLEAN 
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0.5 M NaCl, 1 mM Tris HCl pH 8.0, 0.1 mM EDTA, 20 % w/v PEG8000, 1.75 mM 
MgCl2. All the contents were added to 50 ml of PCR water and the solution was 
heated gently for the contents to dissolve. The solution was filter sterilized using a 
0.45 µM filter. 
PAGE for microsatellite genotyping 
SequaGel XR (EC-842)(National Diagnostics, UK)  
Ammonium persulfate 10 %(w/v) 
Ammonium persulfate (APS) acts as a catalyst for the copolymerization of 
acrylamide and bisacrylamide gels by generating free radicals during an oxido-
recuction reaction with TEMED. Fresh 10 % APS solution was prepared by adding 
0.1 g APS to 1 ml of deionized water in an eppendorf tube. 
10X TBE electrophoresis buffer 
Cell culture 
Complete growth medium 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, UK) supplemented 
with 10% FBS (Sigma-Aldrich, UK) and 1% Penicllin – Streptomycin (Sigma-
Aldrich, UK). 
Trypsin-EDTA solution (Sigma-Aldrich, UK) 
1 X Phosphate buffered saline (PBS) (Sigma-Aldrich, UK) 
0.4% Trypan blue solution (Sigma-Aldrich, UK) 
Trypan blue is a vital stain that interacts with the cells only when the cell membrane 
is damaged as the chromophore is negatively charged. Non-viable cells absorb the 
dye and appear blue and asymetrical whereas viable cells are seen as bright round 
cells. 
Freezing medium 
DMEM supplemented with 20% FBS, 10% DMSO and 1% PenStrep 
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EMSA 
Cytoplasmic Lysis buffer 
10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.6, 1 mM 
EDTA (ethylene diamine tetraacetic acid), 0.1 mM EGTA (ethylene glycol 
tetraacetic acid), 10 nM KCl, 1 mM dithiothreitol (DTT), 1 mM vanadate, 1 tablet of 
'complete' protease inhibitor (Roche Diagnostics Ltd, UK). 
 
Nuclear Lysis buffer 
20mM HEPES pH 7.6, 0.2mM EDTA, 0.1mM EGTA, 25% glycerol, 0.42M NaCl, 
1mM DTT, 1mM vanadate and 1/2 tablet ‘complete’ protease inhibitor. 
Nonidet P-40 (NP-40, Sigma-Aldrich, UK) 
1X PBS 
The cytoplasmic and the nuclear lysis buffers were filter sterilized using 0.2 µm 
membrane filter and stored at 4
o
C. 
Polyacrylamide gel for EMSA 
40% Acrylamide/Bis-acrylamide solution (Mix Ratio 19:1) (Sigma-Aldrich, UK) 
10X TBE 
TEMED (Tetramethylethylenediamine) 
10 % APS (w/v) 
Binding buffer 
100 mM Tris, 500 mM NaCl, 10 mM DTT, (pH 7.5), 2.5 mM DTT, 50 ng/µl of Poly 
(dI.dC) (Sigma-Aldrich, UK) 5 mM MgCl2, and 0.05 % NP-40 
Transient transfection 
Lipofectamine 2000 (Invitrogen Life technologies, UK) 
DMEM supplemented with 10% FBS and with and without Penstrep 
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Opti-MEM® I Reduced Serum Medium 
Glycerol stocks 
80% glycerol 
In a glass bottle, 8 ml of 100% glycerol (Sigma-Aldrich, UK) was added to 2 ml of 
MilliQ water and the mixture was autoclaved on a liquid cycle (121
o
C for 30 
minutes). 
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Appendix II 
Primer sequences for screening GRM7 and GRM3 
Table A2.1 Primer sequences used for screening GRM7 
Primer ID Primer sequence 
GRM7_ExPa_F CAAAGAAAGGCATTCCCAATCAATG 
GRM7_ExPa_R TGCTGACTGCTCCCAAACCC 
GRM7_ExPb_F GCGTCTTTAAGTCAAGAATCAGGCTC 
GRM7_ExPb_R TGCTGCTCGCTCTCTCCAACA 
GRM7_Ex1a_F CTGGGCTTTCCCGGAGGAG 
GRM7_Ex1a_R GGCTACCATGATGGAGACCGAA 
GRM7_Ex1b_F GGAAGCGATGCTCTACGCCC 
GRM7_Ex1b_R TGTCAAGCCGGATGGAGTGG 
GRM7_Ex2_F TCCCATGCTAACCTCCTTCCC 
GRM7_Ex2_R CAGGTGTACTTCACAGGACTCTGGG 
GRM7_Ex3_F TCCTCGCTTAGCAACAGCATCA 
GRM7_Ex3_R CAAGCACAGACTTCGCCGCT 
GRM7_Ex4_F TTGCTCTTGTTTCTGAAGATGC  
GRM7_Ex4_R TTTGAAACAACCCCACATGA 
GRM7_Ex5_F TTTCGGTCGACACACAAGAGGA 
GRM7_Ex5_R CCTGGCTGGAACTGAACAAGAGG 
GRM7_Ex6_F TCGAAGCAGTGTTTTCTTTAAGC 
GRM7_Ex6_R CCAAACCATAACCCCCAAAT 
GRM7_Ex7_F GGGGACCTATTAAAGGGGATA 
GRM7_Ex7_R CCACAACAAATTGCATGCTC 
GRM7_Ex8a_F TCTTGCAAGCTGAGGGTAAA 
GRM7_Ex8a_R GATGCCCGTCAAAAGAACAT 
GRM7_Ex8c_F GGGATCATTGCCACCATCTTTG 
GRM7_Ex8c_R ATCCAATGGGCTTGGCTTCG 
GRM7_Ex8d_F GCCCAACATCACAACTGGCAA 
GRM7_Ex8d_R TCCAGTGGAATGAACGTGGCTC 
GRM7_Ex9_F GCATGTGCATGGATTGACCC 
GRM7_Ex9_R TGGCATTCACCAAGGCAACC 
GRM7_Ex10_F TGTTTGGGCTGGTTCCCTCA 
GRM7_Ex10_R GGCAGCTGCTGGCACTAAGC 
GRM7_Ex11_12_F CCAAGGTCAGTTAATCTCCAAAA 
GRM7_Ex11_12_R GGGACTCCCAGTCCAGTTT 
GRM7_Ex13_F GAAACTGGCCACCAGGGTCA 
GRM7_Ex13_R GGATGTTGCTGGCATGTGATGA 
GRM7_Ex14_F TGCAGGAAGAGTAGCATTCATGGG 
GRM7_Ex14_R GGCTTTAAGGCATCATTGCTCCA 
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Primer ID Primer sequence 
grm7_15a_F1 CTTAGAGTCAGAGGAATC 
grm7_15a_R1 GCTCTCAGTGGTCCATTC 
GRM7_Ex15c_F TCACTGACATCAGCACTGCCAA 
GRM7_Ex15c_R GGCATGCATTCCAAAGATCAAGA 
GRM7_Ex15d_F CCACTGCACATCATGTTTTT 
GRM7_Ex15d_R TCTTGGACAATATCACAGAATTGAA 
GRM7_Ex15e_F CGTTAATCTTGCTGCTTATGTGCCA 
GRM7_Ex15e_R CCTCTTCCCTTCCCACTTGCTG 
GRM7_Ex3a_F ATGGTCCTGTCTTTGCGTTC 
GRM7_Ex3a_R TTTAGTTTTATTCCACTTATTCCACTG 
GRM7_Ex3b_F CTTGGACGGCCATTAGGACT 
GRM7_Ex3b_R CCACAATAAAGAAACTTGAACAGG 
GRM7_Ex3c_F AAAAATGTTATTTGTATGGCTCAAAA 
GRM7_Ex3c_R CATCTTACTTCCCTGCTTCTTG 
GRM7_Ex3d_F TTTTCACAATCATGCTCTGCT 
GRM7_Ex3d_R TTCTTTAAAATATAAACACCCAACAA 
GRM7_Ex3e_F ACGACCAATTTGGCATTTTTA 
GRM7_Ex3e_R AAGAAACATCTAAAATCAGCAACG 
GRM7_Ex3f_F TTCAAATAATAAATTAGCCTTTTGTTC 
GRM7_Ex3f_R AAGATACAAAGTACCAAAACTGAATGC 
GRM7_Ex3g_F GCAACCTTGTTTAAGGCACT 
GRM7_Ex3g_R CAGGAAAAGATATTACCAAACAAAA 
grm7_9a_F1 GCATCAGGAAGCTCTAGAAG 
grm7_9a_R1 GATGCCGTTATCATGGTAGTG 
GRM7_Ex9b_F TTCCTCTAGCATGTGAATGTTGA 
GRM7_Ex9b_R AAATCCCTTCTGCCTTAAACAA 
GRM7_Ex9c_F TTGCATTTAGAATGAGGCAGA 
GRM7_Ex9c_R ACACTGAATGCCACAGCAAG 
GRM7_Ex9d_F ATTGTGGGCTCCAGTTTGAC 
GRM7_Ex9d_R ACGCCCAGCCATAAATTCTT 
GRM7_Ex9e_F TTCCTGAAGAGGCAAAAAGC 
GRM7_Ex9e_R TGCAAATTTGACAAGACAACC 
GRM7_Ex9f_F GGCAACAAGAGCAAAACTCC 
GRM7_Ex9f_R CACACAAAGCATTCCGCATA 
GRM7_Pd_F CCAGATGGGGAAACTAAAACC 
GRM7_Pd_R GAAAGAGGTGATGGCAGGAA 
GRM7_Pe_F TTATCCCTGAATGGCTCTGG 
GRM7_Pe_R TGGCAATGTAACGAAGAAACC 
GRM7_Pf_F TCATTCTTTATCTTTCTCTATCTCCA 
GRM7_Pf_R TGCCCCTCTTACTTGTTTCAA 
GRM7_Pg_F CGAGACATGTGCAGGTGAAA 
GRM7_Pg_R GTACCTGCTCCTTCCTGCAA 
GRM7_Ph_F TCCAGAAACTGTCTATAGCGACTAA 
  
292 
 
Primer ID Primer sequence 
GRM7_Ph_R AGCACCTCAGGCTGTCTTTG 
grm7_nPa_F2 GACAGTGCTATAAGCAAGATTTG 
GRM7_isonew_nPa_R1 CCAGATCCCTTTCACTGGTC 
grm7_nPb_F1 AGCACAGTGGCTGTCCGG 
grm7_nPb_R1 GCTCAGTCGCAATTCAAC 
GRM7_isonew_nex4_F GGTTGGCAAGAAAGATTGGA 
GRM7_isonew_nex4_R AATGCTCTTTTGGCCAGGAT 
GRM7_isonew_nex5_F AAGGATGCTTAAGGACCAACTG 
GRM7_isonew_nex5_R CCACAAAGCTAAGAGAGAAGTGG 
GRM7_isonew_nex7_F AGTTACCTTTCCTGCTCCTCTC 
GRM7_isonew_nex7_R AGTGGAAAGCGATTCCTCAA 
GRM7_isonew_nex8_F GCCTAAACTGTGTCCACTAGGC 
GRM7_isonew_nex8_R CCACTTGCTTTATGGGGAAG 
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Table A2.2 Primer sequences used for screening GRM3 
Primer ID Primer sequence 
GRM3_ExPa_F TGGCGTAACGTGGGAGAGGA 
GRM3_ExPa_R CCTTTCAACGTATTCTTTCTGGAATGC 
GRM3_ExPb_F1 GCATTCCAGAAAGAATACGTTGAAAGG   
GRM3_ExPb_R1 GGAACCTTAAATCGGTGACG  
GRM3_Ex1a_F CGTCACCGATTTAAGGTTCC    
GRM3_Ex1a_R CTAGAGCGCTTGGCTTTCAG   
GRM3_Ex1b_F GGCTCGCAGTGTGCAGTTGA 
GRM3_Ex1b_R AGCTCTTCCCAGCCGAGTCC 
GRM3_Ex1c_F ATTAGATGCGACGGCTTCAG 
GRM3_Ex1c_R TCCTCCTCTGGGACCCTTAC    
GRM3_Ex2a_F GAGTGCCTGGTGCTGTGGTG 
GRM3_Ex2a_R CCAATGCATAGGTATCCCTTGAACA 
GRM3_Ex2c_F TCAACGCCTGGAAGCCATGT 
GRM3_Ex2c_R CCCAGTGAAACCCAGCCTCC 
GRM3_Ex3a_F CCCTTTCCTGAAGCACACAC   
GRM3_Ex3a_R GACTTGCGGATGTTGGAG   
GRM3_Ex3b_F GCCATGGCTGAGATCTTGCG 
GRM3_Ex3b_R CGCCTGTGGTTGCGTTTGTT 
GRM3_Ex3c_F GTTCGACCGCTACTTCCAG  
GRM3_Ex3c_R GCCATGTCGTGTACCAGC   
GRM3_Ex4a_F TGGCACCCTTTGATACTCAGTAATGG 
GRM3_Ex4a_R CCTCAGGAAGGTCATAGCATCCA 
GRM3_Ex4b_F TCACTGGGCAGAAACCTTATCGC 
GRM3_Ex4b_R CATCGAAGATGCGGGCAATG 
GRM3_Ex4c_F CCCTTGGTCAAAGCATCGGG 
GRM3_Ex4c_R GGCCAACCAGATGATGCACG 
GRM3_Ex4d_F ACCCTTGCAGAGAAGCGGGA 
GRM3_Ex4d_R CAGGCTCATCATGGCATTTGAA 
GRM3_Ex5c_F GGCAAGCATTCAGAAGCACCC 
GRM3_Ex5c_R CCCAGCACTTAGCACAATACCTGAC 
GRM3_Ex6a_F TCCCTCACCTCCTTCCCACC 
GRM3_Ex6a_R CCCTGTCACCAATGCTCAGCTC 
GRM3_Ex6d_F GAGCTGAGCATTGGTGACAGGG 
GRM3_Ex6d_R CTGGGCAATTCTCGGCTTCC 
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APPENDIX III 
Primers for genotyping microsatellite and SNP markers 
Table A3.1 Primer sequences for genotyping novel microsatellite markers at 
chromosome 1p36 generated for fine mapping of a bipolar disorder 
susceptibility locus 
Marker Type Primer ID Primer sequence 
PRKCZ(GT)17 Dinucleotide 
repeat 
PRKCZ(GT)17F 
PRKCZ(GT)17R 
AAAATACGCCCATTCACTCG 
GGGCAGGTTTCAAAGCA 
PRKCZ(CA)13 Dinucleotide 
repeat 
PRKCZ(CA)13F 
PRKCZ(CA)13R 
AGCAAGAGCACACACACAGC 
TGGCTTTGTCTGAGGAA 
PRKCZ(AC)24 Dinucleotide 
repeat 
PRKCZ(AC)24F 
PRKCZ(AC)24R 
GGAGGCACAACACGGAC 
CCAAGATTTGGGCTTTGTGT 
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Table A3.2 Primers for genotyping GRM7 SNPs using Kaspar and HRM assay 
Primer ID Primer sequence 
rs114774914_F1 GAAGGTGACCAAGTTCATGCTCAGGATGCCAGTACAGGTTGC
A 
rs114774914_F2 GAAGGTCGGAGTCAACGGATTCAGGATGCCAGTACAGGTTGC
T 
rs114774914_R1 CAGGAGGAGACGCCGCTCATAA 
rs56173829_F1 GAAGGTGACCAAGTTCATGCTAGGTACGACATCAGATGGCAA
AGT 
rs56173829_F2 GAAGGTCGGAGTCAACGGATTAGGTACGACATCAGATGGCA
AAGA 
rs56173829_R2 CTAGGTTGCAAGGTTTTGAAATTTTCTGTA 
rs17726576_F1 GAAGGTGACCAAGTTCATGCTGTTTGTTTTCGAATGCCTTGTT
TTC 
rs17726576_F2 GAAGGTCGGAGTCAACGGATTCACTGTTTGTTTTCGAATGCCT
TGTTTTT 
rs17726576_R1 ATTCCACCGTCTGAGAGAATA 
rs342034_F1 GAAGGTGACCAAGTTCATGCTCCCCGGAGGGAGCGCAC 
rs342034_F2 GAAGGTCGGAGTCAACGGATTGCCCCGGAGGGAGCGCAT 
rs342034_R2 AACATCCTGAGGCTCTTCCAGGTA 
3_6901914_F1 GAAGGTGACCAAGTTCATGCTCCATCACCTCTTTCCTGCTCTT
T 
3_6901914_F2 GAAGGTCGGAGTCAACGGATTCCATCACCTCTTTCCTGCTCTT
A 
3_6901914_R2 CTGGTGCACCTGGTGGCAGTTT 
GRM7_Ex3f_7313045_F1 GAAGGTGACCAAGTTCATGCTAATACCTAAACCAGGAAAAG
ATATTACCA 
GRM7_Ex3f_7313045_F2 GAAGGTCGGAGTCAACGGATTACCTAAACCAGGAAAAGATA
TTACCG 
GRM7_Ex3f_7313045_R
2 
GCAAATATGTTCCAAGTAATATTGTCTATA 
GRM7_rs35106713_Ex2_
F1 
GAAGGTGACCAAGTTCATGCTGAAGTCATAGCGCCGGTCATC
A 
GRM7_rs35106713_Ex2_
F2 
GAAGGTCGGAGTCAACGGATTAAGTCATAGCGCCGGTCATCG 
GRM7_rs35106713_Ex2_
R2 
GCATCAACGGCACCCGAGCTAA 
rs140139253_F1 GAAGGTGACCAAGTTCATGCTGAGAACTCTACAAGCCACAGA
CG 
rs140139253_F2 GAAGGTCGGAGTCAACGGATTAAGAGAACTCTACAAGCCAC
AGACA 
rs140139253_R2 CTCTGATCAAGCTGGCTCTCTTCAA 
rs138571076_F1 GAAGGTGACCAAGTTCATGCTGTTGTTTAATTTCCAAGTGTTT
GGAGAT 
rs138571076_F2 GAAGGTCGGAGTCAACGGATTGTTGTTTAATTTCCAAGTGTTT
GGAGAC 
rs138571076_R4 CAAAGTAGAAATCAATGACAGAAAGATAAA 
rs192193072_F1 GAAGGTGACCAAGTTCATGCTATATTTGTAGAAAAGTCCTAA
TGGCCG 
rs192193072_F2 GAAGGTCGGAGTCAACGGATTAAATATTTGTAGAAAAGTCCT
AATGGCCA 
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Primer ID Primer sequence 
rs192193072_R2 CCCCTGGGTCTTGTGCCCCTT 
rs721774_F1 GAAGGTGACCAAGTTCATGCTGAATGTGCCAGCAGTGCCCC 
rs721774_F2 GAAGGTCGGAGTCAACGGATTGAATGTGCCAGCAGTGCCCT 
rs721774_R1 CCCTAAACAGAGTTAAATGAAAAGGTCATT 
nPb_7467774_F1 GAAGGTGACCAAGTTCATGCTCTTATTGTTTCTTCACTACACA
AATG 
nPb_7467774_F2 GAAGGTCGGAGTCAACGGATTCTCTTATTGTTTCTTCACTACA
CAAATA 
nPb_7467774_R2 CCAAATTGTTTCCTACGGCA 
rs1965222_F1 GAAGGTGACCAAGTTCATGCTGATGTTAGAAGGATGGGATAG
AGACT 
rs1965222_F2 GAAGGTCGGAGTCAACGGATTATGTTAGAAGGATGGGATAG
AGACC 
rs1965222_R1 CTGGAAGGACTTTCCATGCCAACAT 
GRM7_9c_7698252_F1 GAAGGTGACCAAGTTCATGCTACTTGTCCTAGGACTTCTGTCA
C 
GRM7_9c_7698252_F2 GAAGGTCGGAGTCAACGGATTAGACTTGTCCTAGGACTTCTG
TCAT 
GRM7_9c_7698252_R2 CAACATTGTGGGCTCCAGTTTGACTT 
GRM7_15e_7758348_F1 GAAGGTGACCAAGTTCATGCTGGTTTTTAATATGCCTTTCAGA
AATGGC 
GRM7_15e_7758348_F2 GAAGGTCGGAGTCAACGGATTGGGTTTTTAATATGCCTTTCA
GAAATGGT 
GRM7_15e_7758348_R2 CAAGTAACATGCTTTAGCTCACGACTA 
Pa_6877167_GRM7 Pre-designed assay from Kbiosciences, UK 
rs2229902 Pre-designed assay from Kbiosciences, UK 
rs140995942_F_HRM  GTTAGGAGTTGGTGACCAG 
rs140995942_R_HRM  TGGAGTTTTGCTCTTGTTGC 
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Table A3.3 Primers for genotyping GRM3 SNPs using KASPar assay 
Primer ID Primer sequence 
rs166677_F1 GAAGGTGACCAAGTTCATGCTGGAATGCAATAGCATTGACCACG 
rs166677_F2 GAAGGTCGGAGTCAACGGATTCTGGAATGCAATAGCATTGACCACA 
rs166677_R2 AAACACAAAGGAAGAGGAATTTTGCTTGTA 
rs17161026_F1 GAAGGTGACCAAGTTCATGCTCAACTTTCAAGTAGGAATACTTTCCAC 
rs17161026_F2 GAAGGTCGGAGTCAACGGATTCCAACTTTCAAGTAGGAATACTTTCC
AT 
rs17161026_R2 GGCGATACAACGTGTTCAATTTCCAAAAT 
rs2073549_F1 GAAGGTGACCAAGTTCATGCTCGTCTAGGTACCCTGGCTCA 
rs2073549_F2 GAAGGTCGGAGTCAACGGATTCGTCTAGGTACCCTGGCTCT 
rs2073549_R2 CTCTTATAAGGGTATATCTGCAGAGTCTT 
rs148754219_F1 GAAGGTGACCAAGTTCATGCTCATGGTTGGTCCTCCTCATCC 
rs148754219_F2 GAAGGTCGGAGTCAACGGATTCTCATGGTTGGTCCTCCTCATCT 
rs148754219_R2 GGACAAAGCCAGTAAGCTACCTCTT 
rs184681725_F1 GAAGGTGACCAAGTTCATGCTGTGAGAGCCAGGGAGGCC 
rs184681725_F2 GAAGGTCGGAGTCAACGGATTGTGTGAGAGCCAGGGAGGCA 
rs184681725_R1 CAGTGTGCAGTTGAGTCGCGAGTA 
rs139639092_F1 GAAGGTGACCAAGTTCATGCTATTGCATTGTTGATATAATCCGTTGAT
GAT 
rs139639092_F2 GAAGGTCGGAGTCAACGGATTGCATTGTTGATATAATCCGTTGATGA
C 
rs139639092_R2 GTGTTGGGGGAACAAAAGGAAAATATCAT 
rs2228595_F1 GAAGGTGACCAAGTTCATGCTGGCCACCCAGGTGAAGGAG 
rs2228595_F2 GAAGGTCGGAGTCAACGGATTCTGGCCACCCAGGTGAAGGAA 
rs2228595_R1 GACGACTCGCGGGAGCTCATT 
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Appendix IV 
Primers used for CNV validation and cloning 
Table A4.1 Primers for validating CNVs in GRM7 using RNase P CNR assay 
Primer ID Sequence Roche UPL probe 
GRM7_CNV_p19_F1 GCATAGCTGACAGAAGGAAGC 
19 
GRM7_CNV_p19_R1 TGTCCTGCAAGACGTATGCT 
GRM7_CNV_p19_F2 AGACAGAGTCCCACTCTCTTGG 
19 
GRM7_CNV_p19_R2 TGTGGTGAGCCAAAATTGC 
GRM7_CNV_p22_F1 AGTCGGCAGCCTTGTTAAAG 
22 
GRM7_CNV_p22_R1 TGTACCACCTTGGTTTCACACT 
GRM7_CNV_p38_F1 CGCTTATTTATCACCCGTTCC 
38 
GRM7_CNV_p38_R1 TTGAAGAGGCATCTACCTGGA 
 
Table A4.2 Primers used for sequence verification of pJet1.2 and pGL3 vector 
constructs 
Primer ID Primer sequence 
pJET1.2_F CGACTCACTATAGGGAGAGCGGC 
pJET1.2_R AAGAACATCGATTTTCCATGGCAG 
GLprimer2 CTTTATGTTTTTGGCGTCTTCCA 
RVprimer3 CTAGCAAAATAGGCTGTCCC 
RVprimer4 GACGATAGTCATGCCCCGCG 
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Table A4.3 Primers used for site-directed mutagenesis in the construction of 
reporter vector constructs 
Primer ID Primer sequence 
GRM3_rs148754219A_F_SDM GCTACCTCTTTTGTGTCAGATGAGGAGGACCAACC 
GRM3_ rs148754219A _R_SDM GGTTGGTCCTCCTCATCTGACACAAAAGAGGTAGC 
GRM3_SDM_5BPDEL_F GTTGTCGGTGCGAGCCATGGAAGACGCC 
GRM3_SDM_5BPDEL_R GGCGTCTTCCATGGCTCGCACCGACAAC 
GRM3_SDM_8BPDEL_F GAGTTGTCGGTGCGAGTGGAAGACGCCAAAAA 
GRM3_SDM_8BPDEL_R TTTTTGGCGTCTTCCACTCGCACCGACAACTC 
GRM3_SDM_3BPDEL_F GAGTTGTCGGTGCGAGTGGAAGACGCCAAAAA 
GRM3_SDM_3BPDEL_R TTTTTGGCGTCTTCCACTCGCACCGACAACTC 
PGL3PROM_SDM_a/g_F CTGTTGGTAAAGCCACCGTGGAAGACGCCAAAAAC 
PGL3PROM_SDM_a/g_R GTTTTTGGCGTCTTCCACGGTGGCTTTACCAACAG 
 
  
300 
 
Appendix V 
Association analysis of GRM7 and GRM3 in UCL1 bipolar 
GWAS data 
Table A5.1 Association of GRM7 SNPs in the UCL1 sample (SNP data from 
UCL1 bipolar GWAS (Sklar et al. 2008)) 
SNP ID BP A1 F_A F_U A2 CHISQ P OR 
rs1400286 6861715 A 0.0414 0.048 C 0.5522 0.4574 0.855 
rs17046124 6861866 C 0.0129 0.006 T 2.733 0.09827 2.203 
rs17288442 6866379 A 0.297 0.3323 C 3.129 0.0769 0.8467 
rs17046139 6869166 T 0.06434 0.07059 C 0.3273 0.5672 0.9054 
rs342045 6885895 C 0.1232 0.1363 T 0.8029 0.3702 0.8903 
rs342040 6891874 C 0.1185 0.133 T 0.9953 0.3184 0.8761 
rs3749380 6903297 T 0.3833 0.3961 C 0.3631 0.5468 0.9476 
rs340659 6906622 C 0.06814 0.04804 T 3.864 0.04932 1.449 
rs340657 6907600 G 0.443 0.4314 A 0.29 0.5902 1.048 
rs456835 6911400 T 0.414 0.419 C 0.05218 0.8193 0.9799 
rs17046231 6913374 T 0.05882 0.06961 C 1.021 0.3122 0.8354 
rs9870018 6927311 T 0.2523 0.2682 C 0.6859 0.4075 0.9209 
rs3846161 6939834 G 0.2151 0.2348 A 1.172 0.279 0.8931 
rs11915789 6950603 A 0.02091 0.02357 T 0.1642 0.6853 0.885 
rs17046322 6952739 A 0.04604 0.03543 G 1.505 0.2199 1.314 
rs10490857 6959982 G 0.1411 0.1441 A 0.03801 0.8454 0.976 
SNP_A-4194743 6962448 C 0.02033 0.01287 T 1.768 0.1836 1.592 
rs2116711 6968207 T 0.09982 0.1048 C 0.1403 0.7079 0.9473 
rs17694650 7001308 T 0.1112 0.1125 C 0.00929 0.9232 0.9867 
rs4686101 7006880 C 0.4575 0.4555 T 0.008035 0.9286 1.008 
rs4686102 7006960 T 0.02354 0.02705 C 0.2581 0.6114 0.867 
rs17751439 7010587 G 0.01845 0.01775 A 0.01438 0.9045 1.04 
rs781393 7011534 C 0.2519 0.245 T 0.1316 0.7168 1.038 
rs1356268 7021095 G 0.04638 0.04314 A 0.1289 0.7195 1.079 
rs6801970 7026273 C 0.295 0.2922 G 0.02105 0.8846 1.014 
rs576913 7026696 A 0.1388 0.1598 G 1.834 0.1756 0.8473 
rs6808554 7028319 A 0.08656 0.101 G 1.291 0.2559 0.8436 
rs2069062 7034549 C 0.1934 0.2078 G 0.6876 0.407 0.9137 
rs1499161 7045455 C 0.4724 0.4941 A 0.9957 0.3183 0.9166 
SNP_A-1937262 7046445 C 0.1971 0.2126 G 0.7795 0.3773 0.9089 
rs1532544 7052752 A 0.1679 0.1755 G 0.2032 0.6521 0.9482 
rs6781223 7065496 C 0.464 0.4863 T 1.044 0.307 0.9146 
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SNP ID BP A1 F_A F_U A2 CHISQ P OR 
rs11711367 7077524 T 0.4216 0.4436 A 1.018 0.3129 0.9145 
rs6771606 7085713 G 0.2072 0.1831 A 1.94 0.1637 1.166 
rs17234886 7092021 C 0.2177 0.2366 G 1.059 0.3034 0.898 
rs9820417 7104786 G 0.2303 0.2672 A 3.645 0.05622 0.8206 
rs17824866 7104822 C 0.2255 0.2475 T 1.392 0.2381 0.8853 
rs6803027 7110070 A 0.05515 0.05906 G 0.1492 0.6993 0.93 
rs6777970 7110108 A 0.05525 0.06004 G 0.2221 0.6375 0.9155 
rs6772333 7116696 G 0.2677 0.2959 A 2.04 0.1532 0.8701 
rs9311976 7122638 A 0.2421 0.2292 G 0.4824 0.4873 1.074 
rs9812630 7124872 A 0.4006 0.4069 G 0.08701 0.768 0.9741 
rs9875041 7125230 C 0.4061 0.4157 A 0.194 0.6596 0.9614 
rs9856068 7125486 A 0.05268 0.05588 C 0.105 0.746 0.9395 
rs6785425 7125901 C 0.05 0.05413 T 0.1815 0.6701 0.9196 
rs13072518 7131501 T 0.4476 0.4588 G 0.2671 0.6053 0.9558 
rs9826341 7132442 C 0.414 0.4239 G 0.2091 0.6475 0.9603 
SNP_A-2134151 7138976 G 0.05147 0.05392 A 0.0634 0.8012 0.9521 
rs1909397 7139094 A 0.4372 0.4518 T 0.4535 0.5007 0.9425 
rs9837834 7142227 G 0.3814 0.39 A 0.1622 0.6872 0.9646 
rs9837989 7142307 C 0.3801 0.3907 T 0.2441 0.6213 0.9565 
rs6764411 7143551 C 0.3824 0.3927 A 0.2378 0.6258 0.9573 
rs9876724 7152640 A 0.3665 0.4008 G 2.616 0.1058 0.8649 
rs6777701 7153339 C 0.4456 0.4702 T 1.28 0.2578 0.9054 
rs6778030 7153652 C 0.461 0.4862 T 1.335 0.248 0.9038 
rs11928865 7155702 A 0.2532 0.2701 T 0.7786 0.3776 0.9162 
rs6443090 7168009 G 0.1875 0.1873 C 0.000208 0.9885 1.002 
rs9814809 7170741 C 0.2546 0.2761 G 1.237 0.266 0.8956 
rs1878164 7173002 T 0.4328 0.4559 C 1.137 0.2863 0.9107 
rs4441639 7179682 T 0.2569 0.2805 C 1.484 0.2232 0.8869 
rs3828472 7188006 G 0.2994 0.3051 T 0.07996 0.7774 0.9735 
rs3749448 7188116 T 0.1957 0.2006 C 0.07762 0.7806 0.9699 
rs7650218 7191923 A 0.1951 0.1944 G 0.001767 0.9665 1.005 
rs9814881 7198602 G 0.1895 0.1905 A 0.003252 0.9545 0.9936 
rs12497688 7201316 C 0.1859 0.1887 T 0.02806 0.867 0.9814 
rs17235018 7212512 G 0.3208 0.3327 C 0.3386 0.5606 0.9473 
rs17288561 7212607 T 0.3686 0.3703 C 0.007056 0.9331 0.9924 
rs11131064 7214945 T 0.3787 0.3477 C 2.175 0.1403 1.143 
rs1400166 7218175 T 0.3056 0.321 C 0.5695 0.4505 0.9309 
rs2875257 7221090 A 0.3088 0.3353 G 1.691 0.1935 0.8858 
rs10510353 7221165 C 0.3051 0.3343 T 2.061 0.1511 0.8744 
rs11708019 7229619 G 0.3327 0.3755 A 4.214 0.04009 0.8293 
rs1963265 7233935 T 0.3404 0.3089 G 2.363 0.1242 1.155 
rs1508724 7241745 A 0.3346 0.2745 G 8.947 0.002779 1.329 
rs9823996 7244509 G 0.329 0.2863 C 4.515 0.03359 1.223 
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SNP ID BP A1 F_A F_U A2 CHISQ P OR 
rs11710946 7246241 A 0.3603 0.4216 G 8.309 0.003945 0.7728 
rs6769814 7251433 G 0.3401 0.2917 A 5.669 0.01726 1.251 
rs10510354 7252190 C 0.3631 0.4216 G 7.568 0.005941 0.7821 
rs13070476 7259313 C 0.2197 0.254 T 3.376 0.06616 0.8273 
rs951557 7269035 T 0.443 0.4451 C 0.009256 0.9234 0.9916 
rs2136152 7282402 T 0.1562 0.1745 G 1.274 0.2591 0.876 
rs4686119 7282739 T 0.1645 0.1804 C 0.9302 0.3348 0.8947 
rs908465 7283715 T 0.1633 0.1812 G 1.177 0.2781 0.8818 
rs1605705 7290044 G 0.1562 0.1725 A 1.019 0.3127 0.888 
rs4095095 7309658 T 0.3139 0.3139 C 1.83E-06 0.9989 1 
rs6443099 7320514 C 0.4006 0.4059 T 0.0621 0.8032 0.9781 
rs1876614 7321289 A 0.1596 0.1729 G 0.6701 0.413 0.9085 
SNP_A-4250891 7321712 G 0.009242 0.00789 A 0.1125 0.7373 1.173 
rs12637466 7321909 T 0.4292 0.4127 C 0.5867 0.4437 1.07 
rs7635212 7328063 G 0.3803 0.3931 A 0.3659 0.5453 0.9473 
rs6443100 7333382 T 0.3759 0.3947 G 0.7814 0.3767 0.9238 
rs7632044 7335947 C 0.1621 0.1722 G 0.3912 0.5317 0.9295 
rs2133450 7336452 C 0.4524 0.42 A 2.211 0.137 1.141 
rs2291867 7340164 G 0.3696 0.3894 A 0.8638 0.3527 0.9194 
SNP_A-1971589 7341024 G 0.4594 0.4222 A 2.938 0.08652 1.163 
SNP_A-1971590 7341994 A 0.3759 0.399 G 1.184 0.2765 0.9072 
rs17047073 7349612 A 0.381 0.3996 G 0.7635 0.3822 0.9248 
rs9849147 7350358 A 0.3704 0.3902 T 0.8753 0.3495 0.9194 
rs10510356 7350877 C 0.3824 0.3988 G 0.5994 0.4388 0.9331 
rs17697853 7366195 A 0.4375 0.402 G 2.729 0.09854 1.157 
rs9990013 7366352 A 0.4384 0.4006 C 3.086 0.07897 1.168 
rs7621537 7372535 C 0.3419 0.3745 G 2.435 0.1187 0.8677 
rs17047149 7380288 G 0.005515 0.01282 A 3.127 0.07698 0.427 
rs10510364 7381271 T 0.1155 0.1258 C 0.5008 0.4792 0.9079 
rs6810141 7383890 A 0.4314 0.4266 G 0.04832 0.826 1.02 
rs1508720 7384636 A 0.1206 0.122 C 0.009945 0.9206 0.9868 
rs1499199 7386444 C 0.4072 0.3951 A 0.3193 0.572 1.052 
rs11131069 7386487 G 0.1654 0.1798 C 0.7608 0.3831 0.904 
rs9836538 7387400 G 0.3969 0.3842 C 0.3552 0.5512 1.055 
rs9837019 7387710 T 0.3971 0.3843 C 0.3592 0.549 1.055 
rs17047183 7389204 T 0.09444 0.1069 C 0.8951 0.3441 0.8717 
rs989126 7389526 C 0.3137 0.3089 A 0.05339 0.8173 1.022 
rs7628504 7390577 G 0.2143 0.1962 A 1.038 0.3082 1.117 
rs17047199 7392719 T 0.09375 0.1088 A 1.317 0.2512 0.8472 
rs7622749 7397946 T 0.1232 0.1375 C 0.9586 0.3275 0.8809 
rs7340751 7414354 G 0.4705 0.4706 T 6.19E-06 0.998 0.9998 
rs2324122 7414789 G 0.4162 0.4081 A 0.142 0.7063 1.034 
rs10510366 7415452 T 0.1447 0.1591 C 0.8463 0.3576 0.894 
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SNP ID BP A1 F_A F_U A2 CHISQ P OR 
rs1499079 7433728 A 0.05463 0.04635 C 0.7458 0.3878 1.189 
rs1499204 7437037 C 0.4553 0.4802 G 1.301 0.2541 0.9047 
rs12489041 7437599 G 0.4594 0.4882 A 1.752 0.1857 0.8908 
rs712767 7443688 T 0.3854 0.3703 C 0.5061 0.4768 1.066 
rs1066658 7445630 G 0.384 0.3696 A 0.4651 0.4953 1.063 
rs6775424 7448339 A 0.5138 0.4833 G 1.953 0.1623 1.13 
rs712775 7458710 G 0.2486 0.248 A 0.000951 0.9754 1.003 
rs712777 7463958 C 0.2518 0.2436 T 0.1915 0.6616 1.045 
rs11717750 7464013 T 0.5 0.4617 C 3.089 0.07882 1.166 
rs17655560 7466155 G 0.4559 0.4863 C 1.952 0.1624 0.8851 
rs712779 7476597 T 0.1575 0.1412 C 1.096 0.2951 1.137 
rs712782 7481801 G 0.1593 0.1402 A 1.505 0.2199 1.162 
rs17717959 7481854 T 0.5084 0.4743 C 2.42 0.1198 1.146 
rs712785 7485714 C 0.1507 0.1343 G 1.16 0.2815 1.144 
rs779701 7518772 G 0.2902 0.3078 A 0.7798 0.3772 0.9193 
rs779699 7519647 C 0.2745 0.2967 G 1.264 0.2608 0.897 
rs752300 7520084 T 0.2677 0.296 C 2.062 0.151 0.8694 
rs779694 7521741 G 0.2878 0.3084 C 1.068 0.3014 0.9061 
rs1083801 7523498 G 0.2831 0.2588 A 1.568 0.2105 1.131 
rs779706 7524042 G 0.2895 0.3098 C 1.033 0.3096 0.9079 
rs779705 7524103 G 0.2831 0.3078 A 1.551 0.213 0.8878 
rs779733 7527372 A 0.2405 0.2454 C 0.06846 0.7936 0.9733 
rs9870680 7529555 A 0.4596 0.4569 G 0.01541 0.9012 1.011 
rs12494654 7533393 T 0.4329 0.4382 C 0.06086 0.8051 0.9785 
rs10222587 7533618 T 0.1271 0.1257 C 0.008426 0.9269 1.012 
rs3804945 7539974 T 0.3505 0.3517 C 0.003312 0.9541 0.9947 
rs11131078 7548067 T 0.3217 0.3127 C 0.1945 0.6592 1.042 
rs756084 7561149 C 0.454 0.4283 A 1.404 0.236 1.11 
rs1106486 7562364 C 0.3336 0.35 T 0.6247 0.4293 0.9299 
rs1121606 7564242 G 0.4677 0.4454 A 1.038 0.3083 1.094 
rs9819987 7567664 G 0.4678 0.4461 T 1.004 0.3164 1.092 
rs3804928 7576514 A 0.203 0.2269 G 1.789 0.1811 0.8675 
rs779749 7576541 T 0.3633 0.3865 C 1.185 0.2764 0.9059 
rs779742 7583058 G 0.4733 0.4539 A 0.7939 0.3729 1.081 
rs17664833 7583314 C 0.09835 0.102 G 0.07639 0.7823 0.9607 
rs779741 7583602 C 0.4133 0.4333 A 0.8655 0.3522 0.9211 
rs1351938 7598417 A 0.4458 0.4637 G 0.6844 0.4081 0.9301 
rs17665113 7598811 C 0.1094 0.1061 T 0.059 0.8081 1.035 
rs1143740 7602077 C 0.3722 0.3833 T 0.2755 0.5996 0.9539 
rs1531939 7617025 C 0.2865 0.2958 G 0.2169 0.6414 0.9559 
rs1485174 7620828 T 0.2831 0.277 C 0.09623 0.7564 1.031 
rs1485172 7621158 A 0.4288 0.4283 G 0.000636 0.9799 1.002 
rs9826424 7621512 A 0.2887 0.2959 G 0.1282 0.7204 0.9662 
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SNP ID BP A1 F_A F_U A2 CHISQ P OR 
rs3804906 7621654 A 0.2877 0.2922 C 0.05117 0.821 0.9785 
rs3804904 7621977 A 0.286 0.2947 C 0.1937 0.6599 0.9586 
rs3792460 7622270 C 0.284 0.2879 T 0.03846 0.8445 0.981 
rs11716647 7624410 A 0.4256 0.4224 G 0.02143 0.8836 1.013 
rs11717471 7624469 G 0.2831 0.2804 A 0.01891 0.8906 1.013 
rs4143516 7624941 C 0.2848 0.2824 T 0.01413 0.9054 1.012 
rs1872400 7624974 A 0.427 0.4245 G 0.01318 0.9086 1.01 
rs3792457 7631222 A 0.08333 0.0789 G 0.1381 0.7102 1.061 
rs3804886 7636612 C 0.1939 0.2108 G 0.927 0.3356 0.9008 
rs3804883 7639708 G 0.2969 0.2971 A 8.52E-05 0.9926 0.9991 
rs11713266 7645217 G 0.1498 0.1451 T 0.09318 0.7602 1.038 
rs1485171 7651185 A 0.1596 0.1542 C 0.1144 0.7352 1.041 
rs17047734 7662963 A 0.07721 0.06287 G 1.655 0.1983 1.247 
rs1485167 7664334 C 0.1765 0.1939 T 1.059 0.3035 0.8909 
rs6799329 7666694 T 0.4118 0.399 C 0.3547 0.5515 1.054 
rs3792452 7666784 A 0.1753 0.1931 G 1.117 0.2906 0.8879 
rs17723289 7666994 G 0.1685 0.1781 C 0.3408 0.5594 0.9349 
rs10510370 7667672 T 0.1682 0.1775 A 0.3155 0.5743 0.9373 
rs3804867 7667909 T 0.1682 0.1775 C 0.3155 0.5743 0.9373 
rs9860274 7673242 T 0.3833 0.3863 G 0.02005 0.8874 0.9874 
rs3804859 7678340 C 0.1471 0.1368 A 0.4526 0.5011 1.088 
rs3804857 7678617 C 0.1876 0.1947 T 0.1681 0.6818 0.9554 
rs1872397 7680410 T 0.1472 0.1396 C 0.2409 0.6236 1.064 
rs1872394 7680566 A 0.3318 0.334 G 0.01132 0.9153 0.9902 
rs9819314 7681695 T 0.3309 0.332 G 0.003091 0.9557 0.9949 
rs11918634 7683434 C 0.2924 0.2853 T 0.1259 0.7227 1.035 
rs17673467 7685663 C 0.4426 0.4526 T 0.2103 0.6465 0.9605 
rs4686145 7686392 A 0.06342 0.07549 C 1.19 0.2753 0.8293 
rs4686146 7688564 G 0.3315 0.3471 T 0.5688 0.4507 0.9329 
rs4686148 7688662 A 0.3093 0.3248 C 0.5844 0.4446 0.9307 
rs3804850 7688702 T 0.2243 0.2264 C 0.01344 0.9077 0.988 
rs3864076 7708008 G 0.5046 0.4652 A 3.24 0.07185 1.171 
rs11706732 7710584 A 0.431 0.4095 T 0.9762 0.3231 1.092 
rs2324209 7710841 G 0.06066 0.04804 C 1.626 0.2022 1.28 
rs9870241 7710922 A 0.05985 0.04536 G 2.199 0.1381 1.34 
SNP_A-2274307 7712944 T 0.06019 0.04519 C 2.353 0.1251 1.353 
rs3804843 7715397 T 0.05545 0.04331 G 1.641 0.2002 1.297 
rs9860395 7718570 C 0.06461 0.0507 T 1.839 0.1751 1.293 
rs6782528 7721032 A 0.43 0.4479 T 0.6851 0.4078 0.9298 
rs162802 7721613 G 0.5018 0.4931 A 0.1594 0.6897 1.035 
rs162785 7727101 T 0.4788 0.4676 C 0.2641 0.6073 1.046 
rs329044 7748565 G 0.03676 0.02353 T 3.133 0.07674 1.584 
rs9860560 7748736 C 0.4393 0.4422 A 0.01697 0.8964 0.9886 
  
305 
 
SNP ID BP A1 F_A F_U A2 CHISQ P OR 
rs1504047 7748843 G 0.4393 0.4422 T 0.01697 0.8964 0.9886 
rs332938 7753230 A 0.4384 0.4402 G 0.006749 0.9345 0.9928 
rs1155966 7757788 G 0.04926 0.05894 A 0.9606 0.327 0.8272 
rs1857697 7758107 C 0.4476 0.4549 T 0.113 0.7367 0.971 
rs1352411 7799831 A 0.07486 0.1023 G 4.697 0.03021 0.7102 
rs1027527 7805160 G 0.1527 0.16 A 0.2093 0.6473 0.9462 
rs6443124 7813180 T 0.1866 0.1853 A 0.005758 0.9395 1.009 
rs6443125 7816412 A 0.1847 0.1853 G 0.001062 0.974 0.9963 
rs9841316 7820659 T 0.3408 0.3274 G 0.4196 0.5171 1.062 
BP, Position in base pairs of SNP based on NCBI build 37 (hg19); A1, Allele 1;F_A, Frequency of 
A1 in cases; F_U, Frequency of A1 in controls; A2, Allele 2; CHISQ, Basic allelic test chi-square 
(1df); P, Asymptotic p-value for this test; OR, Estimated odds ratio (for A1, i.e. A2 is reference). 
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Table A5.2 Association of GRM3 SNPs in the UCL1 sample (SNP data from 
UCL1 bipolar GWAS (Sklar et al. 2008)) 
SNP BP A1 F_A F_U A2 CHISQ P  OR 
rs1405881 85897433 C 0.10 0.11 T 0.13 0.72 0.95 
rs1405880 85897732 C 0.10 0.10 G 0.00 0.96 0.99 
rs274637 85898289 C 0.39 0.34 T 5.95 0.01 1.25 
rs274621 85917450 C 0.38 0.33 T 7.63 0.01 1.29 
rs802437 85930852 A 0.41 0.36 G 5.13 0.02 1.23 
rs802439 85931065 A 0.29 0.31 G 1.01 0.32 0.91 
rs802441 85931754 T 0.29 0.31 C 1.17 0.28 0.90 
rs802459 85952689 T 0.40 0.35 C 5.47 0.02 1.24 
rs802467 85973261 G 0.40 0.42 A 0.83 0.36 0.92 
rs2189812 85993650 C 0.32 0.28 G 5.22 0.02 1.25 
rs10238436 86014795 C 0.22 0.24 G 2.05 0.15 0.86 
rs16888204 86014885 G 0.03 0.04 A 1.59 0.21 0.74 
rs2237553 86019184 T 0.25 0.29 C 3.60 0.06 0.83 
rs12704286 86019592 A 0.25 0.29 G 3.93 0.05 0.82 
rs2237554 86023547 G 0.25 0.29 T 3.81 0.05 0.82 
SNP_A-2126810 86031330 C 0.07 0.08 A 1.49 0.22 0.81 
rs2888551 86032662 G 0.03 0.03 A 0.00 1.00 1.00 
rs723631 86046243 C 0.24 0.29 G 6.18 0.01 0.78 
rs17160978 86049959 T 0.04 0.04 C 0.00 0.97 1.01 
rs17697445 86050097 A 0.03 0.03 G 0.00 0.97 1.01 
rs2158786 86050669 A 0.24 0.29 G 6.29 0.01 0.78 
rs16888210 86050734 T 0.04 0.04 C 0.00 0.97 1.01 
rs2237559 86051267 A 0.04 0.04 G 0.00 0.97 1.01 
rs2299221 86063065 T 0.04 0.04 A 0.56 0.45 0.85 
rs12704289 86066792 C 0.07 0.08 T 0.98 0.32 0.85 
rs7804907 86072859 T 0.24 0.28 C 5.61 0.02 0.79 
rs2237563 86087819 G 0.26 0.19 A 16.94 3.85 x 
10-5 
1.56 
rs7806785 86090967 G 0.24 0.28 C 5.41 0.02 0.79 
rs2299224 86092054 G 0.04 0.04 A 0.28 0.60 0.89 
rs17697609 86097034 G 0.04 0.04 A 0.42 0.52 0.86 
rs17161024 86105481 A 0.12 0.11 G 0.17 0.68 1.06 
rs10952891 86111902 T 0.12 0.11 C 0.07 0.79 1.04 
rs7788115 86116982 A 0.15 0.17 T 1.34 0.25 0.87 
rs6955452 86117235 G 0.06 0.05 C 2.15 0.14 1.33 
rs6955917 86117414 A 0.07 0.05 G 2.48 0.12 1.35 
rs2299231 86134276 G 0.13 0.10 A 4.40 0.04 1.35 
rs10236047 86157288 G 0.12 0.10 A 3.54 0.06 1.31 
rs10258008 86180097 A 0.12 0.09 C 4.19 0.04 1.34 
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SNP BP A1 F_A F_U A2 CHISQ P  OR 
rs7781178 86180995 G 0.28 0.27 A 0.09 0.76 1.03 
rs11974622 86181028 A 0.12 0.10 G 3.95 0.05 1.33 
rs2519713 86189318 C 0.41 0.47 A 5.93 0.01 0.80 
CHR, Chromosome; SNP, SNP ID; BP, Position in base pairs of SNP based on NCBI build 36 
(hg18); A1, Allele 1;F_A, Frequency of this allele in cases; F_U, Frequency of this allele in controls; 
A2, Allele 2; CHISQ, Basic allelic test chi-square (1df); P, Asymptotic p-value for this test; OR, 
Estimated odds ratio (for A1, i.e. A2 is reference). 
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Appendix VI 
Power calculation 
A graphical representation of power calculation for different odds ratios and minor 
allele frequencies for UCL2 sample. Genetic power calculator 
(http://pngu.mgh.harvard.edu/~purcell/gpc/) was used for generating the table A6.1 
and the graph (Figure A6.1). 
 
Figure A6.1 Power calculation for UCL2 replication sample 
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Table A6.1 Power calculation for UCL2 replication sample 
 
Minor allele frequency 
 
0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 0.5 
2 0.9676 0.9973 0.9992 0.9994 0.9991 0.9982 0.9954 0.9878 0.9688 0.9272 
1.9 0.94 0.99 1 1 1 1 0.99 0.98 0.95 0.89 
1.8 0.89 0.98 0.99 0.99 0.99 0.99 0.98 0.96 0.92 0.85 
1.7 0.81 0.95 0.97 0.98 0.98 0.97 0.95 0.92 0.86 0.78 
1.6 0.71 0.89 0.93 0.95 0.94 0.93 0.9 0.85 0.78 0.69 
1.5 0.57 0.78 0.85 0.87 0.87 0.84 0.8 0.75 0.67 0.58 
1.4 0.42 0.61 0.7 0.73 0.72 0.7 0.66 0.6 0.53 0.45 
1.3 0.27 0.41 0.49 0.52 0.52 0.5 0.46 0.42 0.36 0.31 
1.2 0.15 0.22 0.27 0.29 0.29 0.28 0.26 0.24 0.21 0.18 
1.1 0.08 0.1 0.11 0.11 0.11 0.11 0.11 0.1 0.09 0.09 
 
POWER 
 
Odds ratio 
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Appendix VII 
miRNA binding site prediction for rs56173829 using 
RegRNA 
Input sequences for GRM7 3' UTR 
>Wild type GRM7 
GGCTGACCTGTCTTATTACGTATGTACTTCTAGGTTGCAAGGTTTTGAAA
TTTTCTGTACAGTTTGTGAGGACCTTTGCACTTTGCCATCTGATGTCGTAC
CTCGGTTCACTGTTTGTTTTCGAATGCCTTGTTTTCATAGAGCCCTATTCT
CTCAGACGGTGGAATATTTGGAAAAATTTTAAAACAATTAAAATTTTAAA
GCAATCTTGGCAGACTAAAACAAGTACATCTGTACATGACTGTATAATTA
CGATTATAGTACCACTGCACATCATGTTTTTTTTTTTAAGACAAAAAA 
 
>Mutant GRM7 
GGCTGACCTGTCTTATTACGTATGTACTTCTAGGTTGCAAGGTTTTGAAA
TTTTCTGTACAGTTTGTGAGGACCTTTGCTCTTTGCCATCTGATGTCGTAC
CTCGGTTCACTGTTTGTTTTCGAATGCCTTGTTTTCATAGAGCCCTATTCT
CTCAGACGGTGGAATATTTGGAAAAATTTTAAAACAATTAAAATTTTAAA
GCAATCTTGGCAGACTAAAACAAGTACATCTGTACATGACTGTATAATTA
CGATTATAGTACCACTGCACATCATGTTTTTTTTTTTAAGACAAAAAA 
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Table A7.1 mi-RNAs predicted to bind to GRM7 3' UTR sequence containing 
wild-type rs56173829-A allele 
miRNA 
ID 
Location Len Hybridization MFE Score 
hsa-miR-
106a 51~85 35 
miRNA: 3' gauGGACGUG----ACAUU--------CGUGAAAa 5' 
-13.7 152 
             :|||:||    |||:|        |||||||  
-Target:5' tttTCTGTACAGTTTGTGAGGACCTTTGCACTTTg 
3' 
  
hsa-miR-
106b 53~85 33 
miRNA: 3' uaGACGUG----ACAGU--------CGUGAAAu 5' 
-
14.84 
147 
            |||:||    ||| |        |||||||  
Target:5' ttCTGTACAGTTTGTGAGGACCTTTGCACTTTg 3' 
  
hsa-miR-
130a 58~83 26 
miRNA: 3' uacggGAAAAUU----GUAACGUGAc 5' 
-8.31 147 
               :|| |:|    | |||||||  
Target:5' tacagTTTGTGAGGACCTTTGCACTt 3' 
  
hsa-miR-
130b 62~83 22 
miRNA: 3' uacgggaaagUAGUAACGUGAc 5' 
-8.31 144 
                    | | |||||||  
Target:5' gtttgtgaggACCTTTGCACTt 3' 
  
hsa-miR-
17 51~85 35 
miRNA: 3' gauGGACGUG----ACAUU--------CGUGAAAc 5' 
-17.7 152 
             :|||:||    |||:|        |||||||  
Target:5' tttTCTGTACAGTTTGTGAGGACCTTTGCACTTTg 3' 
  
hsa-miR-
182 63~90 28 
miRNA: 3' ucACACUC---AAGAUG-GUAACGGUuu 5' 
-16.7 146 
            ||||||    |:|:| | ||||||   
Target:5' ttTGTGAGGACCTTTGCACTTTGCCAtc 3' 
  
hsa-miR-
19a 59~82 24 
miRNA: 3' agUCAAAACGUAUCU--AAACGUGu 5' 
-14.5 162 
            || ||||:: :||  |||||||  
Target:5' acAG-TTTGTGAGGACCTTTGCACt 3' 
  
hsa-miR-
19b 
59~82 24 
miRNA: 3' agUCAAAACGUACCU--AAACGUGu 5' 
-16.9 166 
            || ||||:: |||  |||||||  
Target:5' acAG-TTTGTGAGGACCTTTGCACt 3' 
  
59~82 24 
miRNA: 3' agUCAAAACGUACCU--AAACGUGu 5' 
-16.9 166 
            || ||||:: |||  |||||||  
Target:5' acAG-TTTGTGAGGACCTTTGCACt 3' 
  
MFE, minimum free energy  
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Table A7.1 mi-RNAs predicted to bind to GRM7 3' UTR sequence containing 
wild-type rs56173829-A allele contd. 
miRNA 
ID 
Location Len Hybridization MFE Score 
hsa-
miR-
20a 
51~85 35 
miRNA: 3' gauGGACGUG----AUAUU--------CGUGAAAu 5' 
-14.6 148 
             :|||:||    |:|:|        |||||||  
Target:5' tttTCTGTACAGTTTGTGAGGACCTTTGCACTTTg 3' 
  
hsa-
miR-
20b 
51~85 35 
miRNA: 3' gauGGACGUG----AUACU--------CGUGAAAc 5' 
-18.1 152 
             :|||:||    |:|||        |||||||  
Target:5' tttTCTGTACAGTTTGTGAGGACCTTTGCACTTTg 3' 
  
hsa-
miR-
301a 
61~83 23 
miRNA: 3' cgAAACUGUUAUGAUAACGUGAc 5' 
-10.3 161 
            ||||  |: ||  |||||||  
Target:5' agTTTGTGAGGACCTTTGCACTt 3' 
  
hsa-
miR-
301b 
61~83 23 
miRNA: 3' cgAAACUGUUAUAGUAACGUGAc 5' 
-9.1 161 
            ||||  |: | | |||||||  
Target:5' agTTTGTGAGGACCTTTGCACTt 3' 
  
hsa-
miR-
3666 
63~83 21 
miRNA: 3' agccguagaUGUGAACGUGAc 5' 
-9.72 148 
                   || :|||||||  
Target:5' tttgtgaggACCTTTGCACTt 3' 
  
hsa-
miR-
3678-
3p 
59~81 23 
miRNA: 3' ggcCAGGCA-UGUUUGAGACGUc 5' 
-13.1 143 
             ||::|| | :| ||:||||  
Target:5' acaGTTTGTGAGGACCTTTGCAc 3' 
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Table A7.2 mi-RNAs predicted to bind to GRM7 3' UTR sequence containing 
mutant rs56173829-T allele 
miRNA 
ID 
Location Len Hybridization MFE Score 
hsa-miR-
1276 66~85 20 
miRNA: 3' acagagguguccCGAGAAAu 5' 
-9.5 140 
                      |||||||  
Target:5' gtgaggacctttGCTCTTTg 3' 
  
hsa-miR-
182 63~90 28 
miRNA: 3' ucACACUC---AAGAUG-GUAACGGUuu 5' 
-16.3 146 
            ||||||    |:|:| | ||||||   
Target:5' ttTGTGAGGACCTTTGCTCTTTGCCAtc 3' 
  
hsa-miR-
3683 74~100 27 
miRNA: 3' acuAUGAUGAA-GGU----UACAGCGu 5' 
-13.8 141 
             |:|| :|| |||    ||||||:  
Target:5' cttTGCTCTTTGCCATCTGATGTCGTa 3' 
  
hsa-miR-
489 75~99 25 
miRNA: 3' cgACGGCAUA---UACACUACAGUg 5' 
-13.4 144 
            |||: | |   || |||||||:  
Target:5' ttTGCTCTTTGCCATCTGATGTCGt 3' 
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Appendix VIII 
Publication 
